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ABSTRACT 
Modulating Gold Nanoparticle in vivo Delivery for 
Photothermal Therapy Applications Using aT Cell Delivery System 
by 
Laura Carpin Kennedy 
This thesis reports new gold nanoparticle-based methods to treat chemotherapy-
resistant and metastatic tumors that frequently evade conventional cancer therapies. Gold 
nanoparticles represent an innovative generation of diagnostic and treatment agents due 
to the ease with which they can be tuned to scatter or absorb a chosen wavelength of 
light. One area of intensive investigation in recent years is gold nanoparticle 
photothermal therapy (PTT), in which gold nanoparticles are used to heat and destroy 
cancer. This work demonstrates the utility of gold nanoparticle PTT against two 
categories of cancer that are currently a clinical challenge: trastuzumab-resistant breast 
cancer and metastatic cancer. In addition, this thesis presents a new method of gold 
nanoparticle delivery using T cells that increases gold nanoparticle tumor accumulation 
efficiency, a current challenge in the field of PTT. I ablated trastuzumab-resistant breast 
cancer in vitro for the first time using anti-HER2 labeled silica-gold nanoshells, 
demonstrating the potential utility of PTT against chemotherapy-resistant cancers. I next 
established for the first time the use of T cells as gold nanoparticle vehicles in vivo. 
When incubated with gold nanoparticles in culture, T cells can internalize up to 15000 
nanoparticles per cell with no detrimental effects to T cell viability or function (e.g. 
migration and cytokine secretion). These AuNP-T cells can be systemically administered 
to tumor-bearing mice and deliver gold nanoparticles four times more efficiently than by 
injecting free nanoparticles. In addition, the biodistribution of AuNP-T cells correlates 
with the normal biodistribution of T cell carrier, suggesting the gold nanoparticle 
biodistribution can be modulated through the choice of nanoparticle vehicle. Finally, I 
apply gold nanoparticle PTT as an adjuvant treatment for T cell adoptive transfer 
immunotherapy (Hyperthermia-Enhanced Immunotherapy or HIT) of distant tumors in a 
melanoma mouse model. The results presented in this thesis expand the potential of gold 
nanoparticle PTT from only chemotherapy-sensitive or localized cancers to 
chemotherapy-resistant non-localized cancers that currently defy conventional therapies. 
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CHAPTER! 
INTRODUCTION 
This thesis combines the use of immunotherapy and gold nanoparticle 
photothermal therapy (PTT) for the treatment of cancer. First, we ablate trastuzumab-
resistant breast cancer cells with gold nanoparticle PTT, showing for the first time that 
gold nanoparticle PTT is applicable to chemotherapy-resistant cancers. We next 
demonstrate for the first time increased gold nanoparticle delivery efficiency to a tumor 
by using T cells as gold nanoparticle delivery vehicles instead of depending on the 
enhanced permeability and retention (EPR) effect. Finally, we mitigate distant tumor 
progression in mice with bilateral tumors by using gold nanoparticle PTT as an adjuvant 
for T cell adoptive transfer immunotherapy. By combining gold nanoparticle PTT with 
immunotherapy, we extend the treatment limits of gold nanoparticle PTT from localized, 
conventional treatment responsive cancers to widespread, conventional-treatment 
resistant cancers. 
Motivation for CombininK Immunotherapy with Gold Nanoparticle PTT 
In 201 0, the NIH estimates that more than 1.5 million new cases of cancer are 
expected to be diagnosed in the United States, with an overall cost of $263.8 billion.[ I] 
Cancer is the second highest cause of death in the United States behind heart disease.[2] 
Improvements in early diagnosis and cancer treatment have increased the 5 year survival 
rate of a patient diagnosed with cancer in the United States from 50% in 1975 to 68% in 
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1999. [I] Although this is an improvement, it is a small increase compared to the billons 
of dollars that have been spent on research and the millions of lives that continue to be 
affected. 
One reason that overall survival remains below 80% is the lack of effective 
treatments against advanced cancers. There are several cancers that have very subtle or 
symptomless beginnings that allow the cancer to progress unnoticed until it is fairly 
widespread. Ovarian and pancreatic cancer are good examples of two cancers that lack 
prominent symptoms until advanced disease. The 5-year survival rates for these two 
cancers between 1975 and 2005 have remained below 50% for ovarian cancer and at less 
than 10% for pancreatic cancer (Table 1-1).[1] In the case of pancreatic cancer, even 
with early detection, the 5 year survival rate is only 22%.[1] These statistics highlight the 
need for effective treatments of metastatic disease. 
Conventional treatments for cancer include surgery, chemotherapy, and radiation 
Table 1-1. Relative Survival Rates for Common Cancers in the United States Based on Stage of Diagnosis 
(adapted from SEER Stat Fact Sheets [3] 
Cancer 5-Year Relative Survival 5-Year Relative Survival 
for Regional Spread Distant Spread (Metastatic) 
(Positive Lymph Nodes) 
Breast 83.8% 23.4% 
Prostate 100% 28.8% 
Colon and Rectal 69.2% 11.7% 
Lung and Bronchus 24.2% 3.6% 
Melanoma 61.4% 15.3% 
Ovarian 71.7% 27.2% 
Pancreatic 8.6% 1.8% 
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that are used alone or in combination depending on the type and stage of cancer. Surgery 
is generally performed to completely remove a localized cancer or to debulk a large 
tumor to improve patient quality of life and to improve the efficacy of chemotherapy. 
This is generally effective, particularly in localized cancers such as breast or prostate. 
However, this is a macroscopic method of treatment for a microscopic disease. Removal 
of all the diseased tissue is important, and cancers like pancreatic highlight the dangers of 
leaving microscopic disease behind in the patient. This is also an invasive method of 
treatment and has potential risks, such as infection and blood loss. Patients that have 
lymph nodes that are positive for cancer or tumors that are too large or complicated to 
remove surgically typically receive chemotherapy. 
Chemotherapy is a cancer treatment regimen that uses a drug or combination of 
drugs to target rapidly proliferating cells in the patient. This is a systemic treatment, and 
it is generally administered intravenously or intrathecally depending on the tumor 
location. While the general adminstration makes chemotherapy ideal for treating 
advanced or metastatic cancers, it does result in systemic side effects. Malignant or 
tumor cells are not the only cells in the body that proliferate quickly; in fact, many 
healthy tissues such as skin and the intestines replace cells on a daily basis. Symptoms 
such as nausea, mucositis, alopecia, and myelosuppression can all be caused by the 
untargeted nature of chemotherapy.[4] These side effects are often distressing and 
uncomfortable for the patient, and in some cases they can be life-threatening. The side 
effects of treatment must be carefully weighed by the clinician against potential risks of 
having cancer. In addition, it is not uncommon for the cancer undergoing treatment to 
develop resistance to the chosen therapy. 
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Radiation therapy is another untargeted conventional therapy that is used for the 
debulking of tumor and treatment of metastases. Radiation targets rapidly prolierating 
cells using high energy x-rays, gamma rays, or other charged particles to cause breaks in 
the tumor cell DNA or to generate free radicals that will kill the tumor cells.[5] Like 
chemotherapy, radiation therapy has side effects due to its non-specific nature. 
Rationale for Hyperthermia-Enhanced Immunotherapy (HIT) 
Gold nanoparticle photothermal therapy has advantages over conventional 
treatments because of its ability to target cancerous cells and minimize its effects on 
healthy tissue. However, this technology has been limited to localized cancers because of 
limitations in the penetration of near-infrared (NIR) light, discussed in more detail in 
Chapter 2, and concerns about shielding organs that receive very high doses of gold after 
nanoparticle intravenous injection. The combination of immunotherapy with gold 
nanoparticle PTT could mitigate these concerns. 
Immunotherapy covers several different categories of pharmaceuticals and cell 
vaccines. For the purposes of this thesis, we will focus on two particular therapies: 
trastuzumab (Herceptin®) or anti-HER2, a humanised antibody that targets the ErbB2 
tyrosine kinase commonly overexpressed in breast cancer, and adoptive T cell transfer 
therapy. Immunotherapy could benefit gold nanoparticle PTT in several ways. For one, 
immunotherapy agents such as trastuzumab could potentially increase the specificity of 
gold nanoparticles for the tumor cells, potentially increasing gold nanoparticle delivery 
and retention by the tumor in vivo. Although this semi-passive technique has been tried 
by several groups with modest success,[6, 7] a more active targeting technique could be 
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using T cells as gold nanoparticle delivery vehicles. T cells often accumulate within the 
tumor site naturally, and are able to migrate actively through tissue. This could certainly 
improve gold nanoparticle delivery into the tumor over more passive accumulation via 
the enhanced permeability and retention (EPR) effect, which is dependent on the sieve-
like angiogenic tumor vasculature to allow gold nanoparticles to diffuse into the tumor. 
Immunotherapies have also demonstrated clinical success against metastatic 
cancer, particularly melanoma.[8-10] One disadvantage to the current methods with 
adoptive T cell transfer is the use of systemic interleukin-2 (IL-2) and/or 
lymphodepletion chemotherapy regtmens to bolster T cell response. Both of these 
treatments have significant and potentially serious side effects that limit the 
administration of adoptive T cell transfer. However, there have been studies showing 
that hyperthermia may augment dendritic cell activation, which ultimately leads to 
improved T cell activation. This is discussed in detail in the introduction of Chapter 7. 
Gold nanoparticle PTT may be able to serve as an adjuvant treatment for adoptive T cell 
transfer, decreasing the need for the addition of systemic IL-2 and lympodepletion 
regimens during therapy. The ability of gold nanoparticle PTT to debulk the tumor via 
ablation may also be valuable when combined with adoptive T cell transfer because the T 
cells will be more effective against smaller lesions. The combination of PTT and T cell 
adoptive transfer, or hyperthermia-enhanced immunotherapy (HIT), may create a more 
effective treatment for metastatic cancers. 
This thesis will illustrate the benefits of combining immunotherapy with gold 
nanoparticle PTT. Chapter 2 will discuss gold nanoparticle photothermal therapy, the 
types of gold nanoparticles that have been developed for therapy, the different irradiation 
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modalities and their strengths and limitations, and the strategies that have been devised 
and studied to date for improving gold nanoparticle tumor delivery and biodistribution. 
Next, we will introduce in Chapter 3 some basic concepts of T cell immunology, the 
tumor microenvironment and its defense mechanisms against the immune system, and the 
clinical accomplishments of adoptive T cell transfer to date. In Chapter 4, we will ablate 
trastuzumab- and lapatinib-resistant HER2+ breast cancer cells using anti-HER2 targeted 
gold-silica nanoshells. We will then transition to Chapter 5, which will use T cells to 
deliver gold nanoparticles to tumors more efficiently than the EPR effect-driven delivery 
of freely injected gold nanoparticles. Chapter 6 will extend on Chapter S's work by 
transitioning this technology to antigen-specific murine T cells bearing NIR-resonant 
hollow gold nanoshells to melanoma tumors. Finally, we will slow the progression of 
distant non-ablated secondary tumors using a combination of gold nanoparticle PTT and 
adoptively transferred pmel T cells. 
CHAPTER2a 
GOLD NANOPARTICLE PHOTOTHERMAL THERAPY FOR THE 
TREATMENT OF MALIGNANCY 
Introduction 
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In 2010, the National Institutes ofHealth estimates that more than 1.5 million new 
cases of cancer will be diagnosed in the United States, with an overall projected cost of 
$263.8 billion.[!] Development of new approaches to improve screening, diagnosis, and 
treatment of cancer is an area of intensive research spending and has generated numerous 
innovations that have enhanced the 5-year survival rates of cancer patients.[ I] However, 
these new and innovative treatments can also contribute to the rising costs of 
healthcare.[ll] To justify these increasing expenses, new cancer treatments should have 
enhanced efficacy, decreased invasiveness, and fewer side effects than current cancer 
therapies. Gold nanoparticle photothermal therapies meet these criteria: a single 
intravenous injection of gold nanoparticles followed by laser irradiation of the tumor is 
able to induce full tumor regression with a minimum of side effects in mice. The ability 
of this therapy to provide localized and tumor-specific treatment is because of the special 
properties of the gold nanoparticles used to convert light to heat. 
The wide-ranging utility of gold nanoparticles for biomedical applications is 
based on the unique and highly tunable optical resonance of gold nanomaterials. When 
a Adapted from: Kennedy LC, Bickford LR, Lewinski NA, Coughlin AJ, Hu Y, Day ES, West JL, Drezek 
RA, "A New Era in Cancer Treatment: Gold Nanoparticle-Mediated Thermal Therapies"; Small (Weinheim 
an der Bergstrasse, Germany), 7(2):169-183 (2011). 
NIR laser 
.A= 808 nm 
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Figure 2-1. Scheme for gold nanoparticle photothermal therapy. The tumor-bearing mouse is intravenously 
injected with gold nanoparticles tuned to the near-infrared reg ion of light. The gold nanoparticles passively 
accumulate within the tumor over the course of 6-48 hours. The tumor is then treated with a near-infrared 
laser. The gold nanoparticles absorb the light energy and convert it to heat, resulting in tumor ablation. 
metallic nanoparticles are exposed to light at their resonant wavelength, the conduction 
band electrons of the nanoparticle generate a synchronized oscillation that ultimately 
terminates in either light scattering or light absorption. By carefully designing the size, 
shape, and composition of gold nanoparticles, the proportion of light scattering relative to 
light absorption can be optimized for the intended application. Gold nanoparticles are 
currently being studied for use as imaging contrast agents,[l2, 13] absorptive heating 
agents,[l4] and as dual imaging and therapeutic agents.[15, 16] 
Of these potential applications, gold nanoparticle-mediated hyperthermia has been 
extensively developed and is currently being studied in early clinical trials.[17] To treat a 
tumor, gold nanoparticles are systemically administered to the subject and allowed to 
passively localize to the tumor via the sieve-like tumor vasculature.[ 18] The tumor is 
then exposed to an exciting energy source, such as near-infrared (NIR) laser light,[14] 
radiowaves,[l9] or an alternating magnetic field.[20] The gold nanoparticles absorb the 
incident energy and convert it to heat, which raises the temperature of the tissue and 
disrupts the cell membrane of the cancerous cells.[21] The most common form of these 
hyperthermia therapies is gold nanoparticle photothermal therapy (PTT), which uses a 
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NIR laser as the energy source. Figure 2-1 depicts the basic process of gold nanoparticle 
PTT. At the molecular level, hyperthermic effects can be seen as changes in cytoskeletal 
structure, cell membrane rupture, protein denaturation, impairment of DNA and RNA 
synthesis, and programmed apoptosis.[22, 23] The long term success of the tumor 
ablation is dependent on all of the tumor cells being destroyed during treatment. 
The first step in performing gold nanoparticle PTT is selecting the gold 
nanoparticle variant. A diverse range of gold nanoparticles have been explored for use in 
ablation-based therapies. In the following section, we will discuss the development of 
the gold nanoparticle variants used for therapy, including gold-silica nanoshells, gold 
nanorods, and gold colloidal nanospheres. We will also discuss gold nanoparticle options 
that have a smaller diameter while still being tunable to the near-infrared (NIR); these 
options include gold nanocages, gold-gold sulfide nanoparticles, and hollow gold 
nanoshells. 
Gold Nanoparticle Variants Used in Photothermal Therapy 
Gold-Silica Nanoshells 
In 2003, Hirsch et a/. were the first to demonstrate photothermal therapy using 
gold-silica nanoshells.[l4] Gold-silica nanoshells, composed of silica cores with a thin 
overlay of gold, were the first gold nanoparticles easily tunable to the NIR. Gold-silica 
nanoshell fabrication is based on seed-mediated growth, where 'seeds' of gold colloid are 
attached to the silica cores, and additional gold is added for completion of the shell. By 
varying the size of the silica core and the thickness of the gold shell, the resonance of 
catter-based 
imaging 
Therapy 
Silver stain 
No nanoshells Non-specific 
antibody 
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Figure 2-2. In vitro therapy of HER2+ breast cancer cells using anti-HER2-conjugated silica-gold (Si02) 
nanoshells. The top row is darkfield imaging of each group, the middle row is a calcein stain of the cells 
after irradiation with NIR light, and the bottom row is silver staining to show nanoshell binding. Surface 
modification with a tumor marker-specific antibody increases the specificity of the nanoshell binding in 
vitro .[24] 
these nanoshells can span from the visible to the near infrared. 
The flexibility of gold-silica nanoshell tuning permits nanoshell use as an imaging 
contrast agent for darkfield microscopy,[13, 19] two-photon microscopy,[25, 26] 
reflectance confocal microscopy,[27] and optical coherence tomography (OCT).[15] 
Additionally, by fabricating nanoshells that are strong absorbers, these particles can be 
used for photothermal therapy (Figure 2-2), and have been tested in vitro against human 
breast, [13 , 28, 29] prostate,[30, 31] brain,[32] and liver[33] cancer cell lines. Further 
studies extended the use of nanoshell-mediated photothermal therapy to in vivo use 
against xenografted subcutaneous colon carcinoma in mice and allografted brain tumors 
in dogs.[34, 35] The combination of gold-silica nanoshells' ability to scatter and absorb 
light presents the possibility of both imaging and treating a tumor with the same particles. 
However, the large size of gold-silica nanoshells presents a challenge to in vivo delivery. 
An alternative gold nanoparticle, gold nanorods, were developed during the same period 
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as gold-silica nanoshells. They are generally smaller than nanoshells, which may give an 
advantage for delivery in vivo, and they present a slightly enhanced absorption profile 
per particle, an advantage for therapy. 
Gold Nanorods 
Like gold-silica nanoparticles, gold nanorods are also easily tuned to the NIR 
region by simple manipulation of their aspect ratio (length/width) and have been 
extensively studied for cancer therapy applications. Nanorods have the advantage of 
small size (on the order of 10 x 50 nm2), high absorption coefficients, and narrow spectral 
bandwidths. Owing to their distinctive rod shape, gold nanorods have two absorption 
peaks corresponding to the longitudinal and transverse resonance. The transverse 
resonance occurs at around 520 nm, while longitudinal resonance can span from the 
visible to the NIR wavelengths. Like gold-silica nanoshells, nanorods can also be 
designed to function as imaging probes, and have been used to enhance imaging contrast 
in clarkfield microscopy[36] and two-photon microscopy.[37] Nanorods have also 
demonstrated success as photothermal therapy agents in vivo against subcutaneous oral 
squamous cell carcinoma and colon cancer xenografts in mice.[38, 39] 
A major concern about the use of gold nanorods for photothermal therapy is their 
susceptibility to reshaping into gold nanospheres under intense laser illumination, 
resulting in a loss of the longitudinal NIR resonance (Figure 2-3). Without the 
longitudinal NIR resonance, there would be insufficient heating to ensure an adequate 
tumor ablation. However, an in vitro study by Didychuk and colleagues evaluated the 
impact of nanorod reshaping on photothermal therapy by embedding polyethylene glycol 
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Figure 2-3. Nanorod reshaping under laser illumination. Top box depicts gold nanorods in its native 
conformation, and the bottom boxes depict nanorod shape after exposure to different laser powers. At the 
highest power, the nanorod becomes spherical. All SEM images are 200 x 150 nm.[40] 
(PEG)-coated nanorods in a tissue phantom gel and irradiating with an 800 nm laser. [ 41] 
Their results indicated that at the laser fluence threshold for gold nanorod conversion, 
photothermal therapy would still be effective for tumors within 10 mm of the illuminated 
region. This correlates with the in vivo limitations of NIR laser penetration, and suggests 
that photothermal reshaping will not impair tumor ablation. 
Additional studies by other groups also suggest that nanorod reshaping can be 
mitigated by the choice of nanorod surface coating. Chon et al. implemented a simple 
heat-diffusion model to estimate the heat relaxation time of gold nanorods encased in 
silica shells, and found that heat dissipation in the silica shell was much faster than the 
gold nanorod reshaping process, resulting in inhibition of nanorod reshaping.[ 40, 42] In 
contrast, Horiguchi et al. reported an opposite effect on cetyl trimethylammonium 
bromide (CT AB) bilayer-coated gold nanorods, as CT AB enhanced heat isolation and 
caused the nanorods to reshape.[ 43] Based on these results, photothermal therapy is not 
likely to be impaired by nanorod reshaping within the limitations of NfR laser 
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penetration, and any concerns about reshaping could be alleviated by coating the 
nanorods with silica or another coating that rapidly dissipates heat. 
Recent studies have compared the photothermal heating efficiencies among NIR-
absorbing gold nanoparticles such as gold-silica nanoshells, gold nanorods, and gold-gold 
sulfide nanoparticles. Both theoretical and experimental results have shown that 
nanorods offer a superior absorption cross-section versus gold-silica nanoshells when 
normalizing for particle size differences. In addition, gold nanorods heat at least 6 times 
faster than gold-silica nanoshells on a per gram of gold basis.[ 44-46] However, gold-
silica nanoshells have a significantly larger photothermal transduction cross-section when 
compared to gold nanorods on a per particle basis.[44] Despite superior conversion of 
light to heat, the advantage of gold-silica nanoshells may be lost in vivo due to the low 
delivery yield of these nanoparticles to the tumor. Both gold-silica nanoshells and gold 
nanorods have poor in vivo delivery, with only a small percentage of the injected dose 
typically accumulating in the tumor. In the case of the gold-silica nanoshells, this is 
likely due to the large dimensions ofthe nanoparticle (>100 nm diameter). In the case of 
the nanorods, the poor delivery could partially be due to the shape of the nanoparticle. 
To address this problem, smaller particles that are tunable to the NIR region are being 
applied to photothermal therapy applications. In the next subsection, we discuss the 
development of gold-gold sulfide nanoshells, gold nanocages, and hollow gold nanoshells 
as an improved second generation of therapeutic nanoparticles. 
Small NIR-Tunable Gold Nanoparticles 
The smaller size of gold-gold sulfide (GGS) nanoparticles, gold nanocages, and 
hollow gold nanoshells (HAuNS) gives a perceived delivery advantage for in vivo 
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photothermal ablation over larger gold nanoparticles. The first example of these smaller 
gold nanoparticles is gold-gold sulfide nanoparticles that have a total diameter as small as 
25 nm (Figure 2-4). In addition to their smaller size, which may give a delivery 
advantage, Gobin et al. calculated that gold-gold sulfide nanoparticles have a predicted 
absorption efficiency that is nearly 30% greater than that seen with gold-silica 
nanoshells,[ 4 7] potentially giving these nanoparticles a heating advantage. To synthesize 
gold-gold sulfide particles, a reduction of chloroauric acid using sodium sulfide or 
sodium thiosulfate is used. After this single step fabrication, extensive washing is 
required to remove contaminating gold colloid from the product. There is some 
controversy over the exact structure of these particles;[ 48-50] some groups describe the 
nanoparticle as a gold sulfide core coated with a thin gold outer shell, while other groups 
describe these nanoparticles as aggregates of gold. Despite this controversy, these gold 
nanoparticles have NTR absorbance that has been utilized for ablative therapy. 
Gobin et al. applied gold-gold sulfide nanoparticles as a photothermal therapy 
mediating agent against prostate cancer in vitro and in vivo.[ 4 7] Using gold-gold sulfide 
particles with a core diameter ranging from 30-40 nm and a shell thickness of 3-6 nm, 
Figure 2-4. TEM image of gold-gold sulfide nanoparticles. Adapted from [47]. 
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cancer cells and tumors were successfully ablated. Gobin and colleagues compared the 
survival of mice treated with gold-gold sulfide nanoparticles to the survival of mice 
treated with gold-silica nanoshells. When nanoparticles were allowed to accumulate in 
the tumors for 24 hours post injection prior to laser treatment, approximately 71% of the 
mice in the gold-gold sulfide group survived for the duration of the study (8 weeks post-
injection), while ~82% of mice from the gold-silica nanoshell group survived for the 
duration of the study. However, if gold-gold sulfide nanoparticles were allowed to 
accumulate in tumors for 48 hours prior to laser treatment, the survival of the mice in the 
gold-gold sulfide treatment group increased to 82% for the duration of the study. This 
suggests that gold-gold sulfide nanoparticles have longer circulation times than gold-
silica nanoshells, resulting in gold-gold sulfide nanoparticles having an optimal timepoint 
of 48 hours while gold-silica nanoshells have an optimal tumor accumulation time of 24 
hours. Quantification of the gold content in the tumor using neutron activation analysis 
showed that the amount of gold that accumulated in the tumor at 24 hours was 
approximately the same between the gold-gold sulfide nanoparticle and gold-silica 
nanoshell group. However, the blood gold content for the gold-gold sulfide nanoparticle 
group was significantly higher than the gold-silica nanoshell group at 24 hours, indicating 
that the blood half life for gold-gold sulfide nanoparticles was greater than the blood half 
life of gold-silica nanoshells. This supports the gold-gold sulfide nanoparticles having 
maximal tumor accumulation at a timepoint later than 24 hours. However, despite the 
gold-gold sulfide nanoparticles having a longer half life in circulation, the survival of the 
mice treated at 48 hours by gold-gold sulfide nanoparticles was not greater than the 
survival of mice treated at 24 hours by gold-silica nanoshells. 
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Another type of gold nanoparticle explored for potential cancer therapy is the 
hollow gold nanoshell (HAuNS). As the name implies, these particles consist of a hollow 
center with a thin gold shell and can have a total diameter on the order of 30 nm. Hollow 
gold nanoshells are fabricated by first creating cobalt or silver template nanoparticles. 
After the addition of chloroauric acid, the template material is oxidized while a thin shell 
of gold is reduced onto the template surface, resulting in a hollow shell of gold.[51, 52] 
The hollow core of these nanoshells can be used as a reservoir for drugs or enzymes, 
giving this nanoparticle a potential role as a dual drug delivery and photothermal 
agent.[53] The utility of these nanoparticles for photothermal therapy was tested in vitro 
and in vivo by Li and colleagues. They conjugated HAuNS to anti-EGFR antibodies and 
ablated EGFR-overexpressing cells in vitro.[7] They subsequently used HAuNS 
conjugated to a peptide targeting melanocyte-stimulating hormone to target xenografted 
subcutaneous murine melanoma tumors in vivo.[6] In contrast to the gold-gold sulfide 
nanoparticles, where the smaller size resulted in a longer half life in the blood, Li and 
colleagues elected to perform laser treatment 4 hours post injection. Blood levels of gold 
were still high at the 4 hour timepoint, suggesting that a later timepoint would have 
permitted additional gold accumulation in the tumor. 
The final group of small diameter NIR gold nanoparticles discussed here are gold 
nanocages. These particles are synthesized by first creating template silver nanoparticles 
and then replacing the silver with gold in a manner analogous to the HAuNS.[54] By 
adjusting the wall thickness of the nanocages, the absorption peak can be varied from 400 
to 1200 nm, with an edge length range of 30 to 200 nm. Gold nanocages have been 
tested as contrast agents for optical coherence tomography [55] and as photothermal 
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therapeutic agents against breast cancer cells in vitro.[56-58] Gold nanocages have been 
successful in ablating tumors in vivo as well; Chen eta/. performed a successful in vivo 
study using gold nanocages to ablate murine models with subcutaneous glioblastoma.[ 55] 
Tumors were treated 72 hours post injection with the NIR laser, and a 70% decrease in 
tumor metabolism in the nanocage treated group was observed using positron emission 
tomography (PET). 
Gold-gold sulfide nanoparticles, hollow gold nanoshells, and gold nanocages each 
are NIR-tunable nanoparticles that have longer blood half lives in vivo due to their 
smaller size. Although no survival benefit was seen in a study comparing gold-gold 
sulfide nanoparticle-mediated photothermal therapy to gold-silica nanoshell-mediated 
photothermal therapy in mice, these nanoparticles may be advantageous for larger animal 
models, including humans, due to their longer blood half life and potential for higher gold 
nanoparticle accumulation in the tumor. We will next discuss gold colloidal nanospheres. 
These nanoparticles are not tunable to the NIR individually, but can be aggregated to red 
shift the plasmon to the desirable NIR window. 
Gold Colloidal Nanospheres 
The final group of gold nanoparticles discussed for hyperthermia applications are 
gold colloidal nanospheres. Previously, these solid gold spheres were solely investigated 
for their use as imaging probes.[l2, 59, 60] However, the small size and relatively simple 
synthesis of these particles make them appealing for in vivo applications. El-Sayed and 
colleagues first reported on the use of gold colloidal nanospheres for the imaging and 
therapy of oral cancer cells in vitro using a continuous argon laser at 514 nm, which is 
closely coincident with the peak absorbance of the 40 nm particles.[61] Compared to 
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Figure 2-5. Transmission electron microscopy images of 40 nm gold colloidal nanospheres along breast 
cancer cell membrane. a) The cancer cell after a short incubation time with the nanoparticles (black 
arrows), while d) shows the breast cancer cells after a longer incubation with the nanoparticles. 
Nanoparticles can be seen grouping together on the cell surface. Scale bars= 500 nm . Adapted from [62]. 
normal, non-cancerous cells, it was demonstrated that cancerous cells targeted with 
nanoparticles were destroyed with 2-3 times less laser power. A key disadvantage to this 
study was the use of a visible wavelength laser. Although visible wavelengths can be 
used in vitro, in vivo applications of photothermal therapy prefer a NIR laser because of 
the decreased tissue attenuation ofthe light. 
To shift the absorbance of gold colloidal nanospheres into the NIR, the 
nanoparticles can be aggregated or clustered together in close proximity (Figure 2-5). 
The close proximity of the nanoparticles to each other red-shifts the plasmon to the NIR 
region. El-Sayed et a!. used a short-pulsed, NIR laser on small gold aggregates formed 
from 30 nm gold colloidal particles to selectively ablate oral cancer cells.[63] By 
operating in the NIR instead of the visible region, the laser power needed to kill the 
cancer cells was approximately 20 times less than that needed to destroy normal cells. 
Alternatively, a similar result has been achieved using gold nanoclusters and 
photothermal microbubbles (PTB). Here, non-aggregated gold colloid is incubated with 
cancer cells and subsequently internalized via endocytosis. The nanoparticles are at close 
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proximity to each other within the cell endosome, creating a resultant shift of the 
nanoparticle absorbance to the NIR.[62] Through the use of laser pulses in either the 
visible[64, 65] and NIR[62] regions, vapor bubbles ranging from 10"8 to 10·4 m[65] can 
be formed around the nanoclusters and irreversibly damage the cells. Moreover, these 
vapor bubbles are detectable throughout their lifespan with a photothermal microscope, 
presenting the ability to both image and treat the cancer simultaneously.[66] The 
potential of this unique photothermal bubble technique has been demonstrated for both 
leukemia[64, 65]and breast cancer cells.[62] It also illustrates that photothermal therapy 
can be achieved using nanoparticles that are not individually tunable to the NIR. This 
expands the number of possible gold nanoparticle solutions that can used for 
photothermal therapy. With the large number of possible solutions, one difficulty 
presented is how to select the best gold nanoparticle for a therapy application. The next 
section discusses important factors to consider when making this decision. 
Gold Nanoparticle Selection Considerations 
The first factors to consider are the innate properties of the selected gold 
nanoparticle variant. The efficiency with which a nanoparticle absorbs and scatters is an 
essential parameter to consider when choosing a particle for use in photothermal therapy, 
particularly if the particle needs to serve as both an imaging and treatment agent. From 
the perspective of photothermal therapy alone, the absorptive cross-section a key initial 
consideration. Calculating the absorption cross-section of gold-based nanoparticles can 
be achieved by using Mie-based theory or numerical methods such as discrete dipole 
approximation.[67-70] Particle design is optimized by maximizing the absorption 
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efficiency at a desired wavelength in a specific surrounding medium in order to achieve a 
maximum particle temperature and surface heat flux.[70, 71] Cole eta/. compared the 
photothermal efficiencies of gold-silica nanoshells, gold-gold sulfide nanoshells, and 
gold nanorods.[44] They found that the photothermal transduction efficiencies, defined 
as the portion of the incident light being converted to photothermal power by the 
nanoparticle, varied less than a factor of three between the different particles studied.[44] 
This finding suggests that no particular nanoparticle has significant therapeutic advantage 
over the others in terms of heating efficiency. 
With this in mind, considerations such as nanoparticle delivery become very 
important in selecting a gold nanoparticle variant. Maximal gold nanoparticle 
accumulation in the tumor with minimal accumulation of gold nanoparticles in non-target 
organs is highly desirable. When trying to optimize the tumor therapeutic response 
overall, however, another important consideration is the location of the tumor and the 
tissue penetration depth of the irradiating energy. Near-infrared laser light is limited to a 
depth of less than 1 centimeter in tissue, restricting photothermal therapy to superficial or 
easily accessible tumors. These two areas, NIR light penetration depth and nanoparticle 
delivery, are the current limiting factors for nanoparticle-mediated photothermal therapy. 
The remainder of the chapter will focus on discussing these issues and examining 
currently proposed solutions in the literature. 
Focus #1: Penetration Depth of Near-Infrared Li&ht 
The penetration depth of NIR light in tissue is a key limiting factor in the 
expansion of gold nanoparticle hyperthermia. The selection of irradiation modality for 
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gold nanoparticle hyperthermia is a balance of three factors: sufficient depth penetration 
to reach the nanoparticle-laden cancerous tissue, extraneous heating of healthy tissue due 
to absorption of energy by tissue chromophores and off-target nanoparticles, and the 
properties of the chosen therapeutic nanoparticles. NIR light is generally favored in gold 
nanoparticle hyperthermia studies due to its low absorbance by tissue chromophores, 
which prevents it from damaging healthy tissue. To achieve a successful cancer ablation 
with any irradiation modality, the tissue must be heated to a minimum temperature for a 
minimum duration of time to induce tumor cell death. The necessary duration of heating 
is dictated by the temperature. Cytotoxic effects have been demonstrated in cells 
maintained at 42°C for 1 hour, but this duration can be shortened to 3-4 minutes by using 
a higher temperature of 70-80°C.[22, 23, 72, 73] In addition to temperature distribution 
concerns, the irradiating energy must reach the depth of the nanoparticles at an adequate 
intensity, or cancerous tissue may be heated insufficiently and survive. Here, we discuss 
three possible options for irradiation: NIR photothermal therapy (PIT), radiofrequency 
ablation (RF A), and magnetic fluid hyperthermia (MFH). 
Near-Infrared (NIR) Photothermal Ablation 
NIR laser light is a good choice for in vivo hyperthermia applications because of 
its low absorption by tissue chromophores, hemoglobin, and water. The absorption 
coefficient of these tissue chromophores is as much as 2 orders of magnitude greater in 
the visible range (400-600 nm) of light as compared to the NIR range (650-900 nm).[74, 
75] Gold nanoparticle-mediated photothermal therapies are predominantly designed to 
operate in this window of wavelengths ("the NIR window") to minimize the attenuation 
of the energy resulting from undesired light-tissue interactions, and prevent undesirable 
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Figure 2-6. The NIR window. The wavelengths of light in the NIR window (pink box) are minimally 
absorbed by water, hemoglobin, and tissue pigments when compared to other wavelengths . Adapted from 
[74] . 
and damaging heating of healthy tissue (Figure 2-6). Upon tumor laser irradiation, NIR 
light is absorbed by the nanoparticles and heat dissipation is generated as a consequence 
of electron-phonon interactions. Hirsch et al. demonstrated a 4-6 mm depth of thermal 
damage in mice with subcutaneous tumors after intratumoral injection of gold-silica 
nanoshells and subsequent continuous wave NIR light exposure (A = 820 run, 4 W/cm2, 6 
min maximum time).[l4] 
The in vivo penetration depth of NIR light is dependent on a variety of factors, 
including the degree of light scattering and absorption within tissue.[l4, 76] The heating 
of tissue is dependent on the NIR light intensity at a given point, on the absorptive 
cross-section of the gold nanoparticle, on the distribution and concentration of 
nanoparticles within the tissue, and on the degree of NIR light absorption by the tissue 
chromophores. Accurately modeling the heating profile of nanoparticle-laden tissue will 
be very important for optimizing thermal ablation in solid tumors, particularly because 
so lid tumors are known to be highly inhomogeneous. The distribution of nanoparticles 
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within the tumor, placement and orientation ofNIR light, and any variation in the optical 
and thermal properties of the tumor tissue will affect tumor heating. To understand and 
predict the effect of these variable, simulations of nanoparticle-laden tissues can be 
constructed using a variety of analytical and numerical approaches, such as light and heat 
diffusion theory, computational electromagnetic methods, and stochastic ray tracing.[76-
79] 
The simplest models assume homogeneous nanoparticle distribution and tissue 
properties. Elliott et al. modeled the laser fluence and temperature distribution of tissue 
phantoms embedded with gold-silica nanoshells of various optical densities. They 
demonstrated a maximum temperature change of l6°C for an 0.55 OD phantom and of 
21 °C for an 0.65 OD phantom using a 3-min 1.5W laser irradiation.[79] A disadvantage 
to this model was its inaccuracy in profiling regions of high nanoparticle concentration. 
Modeling of higher concentrations of nanoparticles is important due to the nature of gold 
nanoparticle distribution within the tumor. NIR narrow band imaging has revealed that 
gold nanoparticles tend to accumulate in highly concentrated pockets within the tumor, 
and that the gold nanoparticle distribution is very non-uniform.[80] The lack of 
uniformity and the high concentration of nanoparticles in certain regions impairs even 
tumor heating and provides challenges to modeling the temperature distribution of tissue 
during hyperthermia. In a later paper, they described an analytical model that was able to 
more accurately model higher concentrations of nanoshells. Using Green's function to 
solve the heat diffusion equation, they calculated the spatiotemporal thermal profile for 
phantoms with higher concentrations of nanoshells using the optical diffusion 
approximation.[77, 78] 
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The in vitro models described provide the theoretical basis for developing in vivo 
simulations. A recent study by von Maltzahn et al. demonstrated the potential of using 
computational simulations to model in vivo photothermal therapy and evaluate the effect 
of nanoparticle concentration on heating in vivo. An x-ray CT scan was used to 
characterize the distribution of intratumorally and intravenously administered PEGylated 
nanorods in vivo.[46] The high absorption efficiency ofthe gold nanorods in both the x-
ray and NIR regions enabled real-time visualization and therapy, and demonstrates the 
utility of imaging and treating with the same nanoparticle.[46] This in vivo study was an 
initial step towards personalizing photothermal therapy to an individual tumor. By 
understanding how the nanoparticles are distributed, the temperature profile of the tumor 
can be simulated and evaluated to ensure adequate heating in all tumor regions. 
Although this model accounts for the inhomogeneity of nanoparticle distribution within 
the tumor, the models previously described do not account for variations in the tumor 
tissue optical properties. 
Simulations based on nanoparticles distributed in actual tissue instead of synthetic 
tissue phantoms extend models to a more realistic medium. Vera et al. investigated the 
effects of gold-silica nanoshell concentration, laser power and laser arrangement on the 
thermal profile of gold nanoshell-laden human tissue from different organs ex vivo.[76] 
For this analysis, the optical and thermal properties of the tissue were extrapolated from 
previous studies at room temperature and assumed to remain constant during heating. 
Through this analysis, they found that when using a single, externally placed laser for 
therapy undesired overheating in one region could occur while leaving the rear region 
under-heated. They hypothesized that this uneven heating could be mitigated by the use 
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of an opposing dual-laser heating configuration. Practically, this would mean the 
minimally invasive placement of a fiber optic probe within the tumor to conduct NIR 
light, similar to what was done by Schwartz et al. in their study of nanoshell-mediated 
therapy for tumors in the brain.[35] To further optimize probe placement, simulations 
could be used to select the region of probe placement where maximal heating could be 
achieved by modeling and accounting for variations in the optical and thermal properties 
of tissue. A combination of all of the models discussed would allow simulations of in 
vivo photothermal therapy that selected the optimal laser and laser probe placement to 
account for variations in nanoparticle concentration and the inhomogeneity of tissue. 
An additional modification that has been suggested for the enhancement of NIR 
therapy is the use of a pulse mode laser instead of a continuous wave laser. Pulsed lasers 
permit more efficient photothermal conversion because of lapses between the pulses, 
allowing additional time for electron-phonon relaxation. This translates to lower power 
usage with a pulsed laser than with a continuous mode laser. Tong et al demonstrated 
this using folate-conjugated gold nanorods. After nanorod binding to a folate-
overexpressing cell line, exposure to a femtosecond-pulsed NIR laser at a power as low 
as 0.75 mW resulted in membrane blebbing, while a continuous wave laser required a 
power of 6 m W for the same effect. [21] Although this has potential for reducing laser 
power requirements and further minimizing damage to healthy tissue, this does not have 
an impact on the difficulties of deeper tissue penetration. 
The limited penetration of NIR light in tissue confines gold-nanoparticle 
hyperthermia to solid tumors that are either directly accessible, such as skin cancer, or 
indirectly accessible via endoscopy or fiber optic placement. For cancers that cannot be 
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accessed via any of these methods, alternative irradiation methods may provide an 
avenue for gold nanoparticle hyperthermia treatment. We discuss two ofthese methods in 
the following subsection: radiofrequency ablation and magnetic fluid hyperthermia. 
Alternatives to NIR Light 
Radiofrequency ablation (RF A) was first established in the early 1900s as a 
method for cauterizing blood vessels during surgery. However, it was not explored for 
oncologic hyperthermia applications until the early 1990s. Conventional RF A treatments 
require an invasive procedure to place electrodes within the tumor, and tumor shrinkage 
is induced as a result of radiowave-induced vibrations of ions within tumor tissue, which 
give rise to friction and heat.[81] Radiowaves have significantly better penetration of 
tissue than NIR light, making RF A appealing for deeper solid tumors.[82] However, in 
exchange for the greater depth of penetration, there is greater attenuation of the energy by 
tissue. This attenuation can be mitigated by adding a mediating absorptive agent, such as 
gold nanoparticles, which increases the specificity of RF A treatments, protects normal 
tissue by lowering energy requirements, and decreases the need for invasive electrode 
placement.[l9] 
The addition of absorptive mediators such as gold nanoparticles[19, 83] or 
carbon nanotubes [84] to RFA enhances the creation of thermal lesions within liver 
tumors. In mice bearing subcutaneous tumors and treated with gold nanoparticle-
mediated RF A, the temperature increase within the gold nanoparticle-treated tumors 
averaged 10°C compared to 4°C among control tumors injected with sterile water.[83] 
Gannon et al. also studied nanoparticle-assisted radiofrequency ablation of liver tumors 
using single-walled carbon nanotubes in New Zealand white rabbits with successful 
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results.[84] Although this method increases tissue penetration, it also increases the risk 
of damaging non-target tissues. Magnetic fluid hyperthermia (MFH) presents the 
possibility of increasing penetration while protecting non-target tissues. 
MFH is another form of nanoparticle-assisted thermal therapy currently under 
investigation. This form of thermal therapy utilizes magnetically susceptible particles in 
suspension to emit heat in the presence of an alternating current (AC) magnetic field. 
The magnetic energy of the external alternating field is converted to internal energy 
within the nanoparticles and subsequently released as thermal energy through Brownian 
and Neel relaxations. Superparamagnetic particles are known to undergo this conversion 
at lower field strengths, and iron oxide nanoparticles are the most commonly used owing 
to their established biocompatibility and the availability of methods for chemical 
modification.[85] Since alternating magnetic fields do not tend to be susceptible to 
attenuation by tissue, the main advantage of MFH compared to other methods of heat 
delivery lies in its ability to treat deeply embedded tumors. In addition, nanoparticles 
used for MFH can also be used as contrast agents for. magnetic resonance imaging, 
presenting a clear theranostic advantage. 
Clinical trials using iron oxide nanoparticles for MFH of cancer are currently 
being performed by MagForce Nanotechnologies AG. Utilizing these particles with 
MFH has met with clinical success in a prostate cancer patient.[20] In this feasibility 
study, it was demonstrated that MFH could produce temperatures in the tumor sufficient 
to induce thermal insult following direct intratumoral delivery of iron oxide 
nanoparticles.[20] More recently, MFH has been applied to the treatment of 
glioblastoma.[86] The investigators delivered iron oxide nanoparticles directly to brain 
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tumors in 14 patients, who were then treated with a combination of radiation and MPH 
without any significant adverse responses to therapy.[86] These results are encouraging, 
and further development of MPH could yield an effective alternative to current treatment 
options for advanced cancers. One potential disadvantage for MPH could be the iron 
oxide nanoparticles typically used. One study incubating iron oxide nanoparticles with 
proliferating neurons found some cytotoxicity.[87] Because the toxicity of nanoparticles 
in general has not been thoroughly characterized, and these nanoparticles have not 
demonstrated acute toxicity in vivo, it is difficult to understand the ramifications of this 
finding. However, it does suggest that alternative magnetic nanoparticles of different 
materials should be pursued for biomedical applications pending a more complete 
understanding ofnanoparticle toxicology. 
Although MPH has not yet been applied using gold nanoparticles, a number of 
composite particles using gold and a magnetic material have been developed.[88-91] 
These composite particles present possibilities for either NIR photothermal ablation and 
optical imaging, or for MPH and MR imaging. Larson et al. synthesized y-Pez03-Au 
core-shell nanoparticles and demonstrated their use as magnetic resonance imaging 
(MRI) contrast enhancing agents and as NIR absorbing agents for the targeted 
photothermal ablation of cancer in vitro.[88] Although the absorbance spectra for these 
particles did not show a pronounced peak within the NIR region, clustering of anti-
EGPR-conjugated nanoparticles along cell surfaces allowed for sufficient heating to 
induce cancer cell death in vitro using a pulsed wave laser at 700 nm. Similarly, Kirui et 
al. demonstrated photothermal therapy and MR imaging potential with 25 nm dumbbell-
shaped gold-iron oxide aggregates,[92] and Shah et al. used gold-iron oxide nanoparticles 
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for ex vivo photoacoustic imaging contrast to guide photothermal cancer therapy.[93] In 
the study by Shah and colleagues, they incorporated a simple model to relate the pressure 
change to the temperature rise caused by the energy absorption of the gold nanoparticles. 
With further development, composite gold-magnetic particles may represent a versatile, 
clinically relevant nanoparticle with sufficient flexibility to permit either photonic- or 
magnetically-controlled tumor ablation and imaging. This nanoparticle may represent the 
future of gold nanoparticle photothermal therapy due to the nanoparticle's flexibility for 
therapy and imaging. 
The ability of gold nanoparticles to adapt to each of the three modalities discussed 
in this section (NIR PTT, RF A, and MFH) highlights their adaptability and potential for 
clinical cancer treatment. However, another key issue that impacts the efficacy of gold 
nanoparticle hyperthermia treatments in vivo is the delivery of sufficient gold 
nanoparticles to the tumor to attain a successful tumor ablation that eliminates all tumor 
cells. The next section addresses the issues of gold nanoparticle biodistribution and 
tumor delivery and discusses possible strategies for increasing the specificity of gold 
nanoparticle accumulation within the tumor. 
Focus #2: Increasin& in vivo Delivea of Gold Nanoparticles 
The delivery of gold nanoparticles to the tumor site is an important consideration 
for photothermal therapy. Initial in vivo studies used direct intratumoral injection of the 
gold nanoparticles.[14] While this method was very successful in the subcutaneous 
tumors studied, most solid tumors are not easily accessible for direct injection. The lack 
of solid tumor accessibility led to a rapid transition to the use of intravenous injection for 
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delivery. Intravenously injected nanoparticles rapidly disperse throughout the entire 
body and accumulate within the tumor by the enhanced permeability and retention (EPR) 
effect. The EPR effect is a phenomenon that is causes by the malformed and angiogenic 
vasculature of tumors. Tumor blood vessels have larger fenestrations than normal blood 
vessels, allowing nanoparticles to passively accumulate in the tumor. However, the 
passage of nanoparticles through these fenestrations is dependent on both the size of the 
particles and the stage of tumor development; early-stage tumors have smaller 
fenestrations and thus lower nanoparticle accumulation.[94] In addition, passive 
accumulation ofnanoparticles by the EPR effect is not very efficient for delivery. 
In fact, gold nanoparticle tumor accumulation is typically a small percentage of 
the total injected dose, and non-target organs such as the liver and spleen receive the 
majority of the injected nanoparticles. Despite the inefficiency of gold nanoparticle 
delivery, it seems the gold nanoparticle concentration is adequate for ablation. However, 
it is possible that the delivery has an effect on the completeness of ablation. Figure 2-7 
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Figure 2-7. Tumor volume change over time following NIR light treatment for mice receiving PBS (control), 
intratumoral injection of PEGylated gold nanorods (direct), and systemically injected PEGylated ~old 
nanorods (tail vein). Mice receiving treatment experienced less tumor growth than the control m1ce. 
However, mice receiving directly injected nanorods had improved survival beginning 11 days post-treatment, 
suggesting that mice injected by tail vein had a lower tumor concentration of gold nanorods. [38] 
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shows the change in tumor size following photothermal therapy using PEG-coated gold 
nanorods. Day 0 correlates with NIR laser treatment. The control group was treated with 
phosphate buffered saline (PBS), the tail vein group received an intravenous injection of 
gold nanorods prior to laser treatment, and the direct group received an intratumoral 
injection of gold nanorods prior to laser treatment. Mice treated using directly 
administered nanoparticles had smaller tumors at 11 days post-treatment than mice that 
received intravenously delivered nanoparticles, although this difference never achieved 
statistical significance at a 5% level.[38] When looking at the concentration of gold 
nanorods present in the tumors, NIR transmission images showed a measured extinction 
4.35 times higher than the saline control in the directly injected tumors (2 min post-
injection) and 2.00 times greater than the saline control than in the tail vein injected 
tumors (24 hours post-injection). This difference in nanoparticle concentration seems to 
have affected the totality of the ablation, and is suggestive that nanoparticle tumor 
accumulation is important for ensuring longer-term therapy success. With the goal of 
maximizing nanoparticle concentration in the tumor in mind, we will next discuss the 
biodistribution of gold nanoparticles within a mouse model and strategies to enhance gold 
nanoparticle tumor delivery. 
Gold Nanoparticle Biodistribution in Mice 
Nanoparticle biodistribution is influenced by the size and surface characteristics 
of the nanoparticle. Most nanoparticles developed for biomedical applications are coated 
with chains of polyethylene glycol (PEG) to prevent rapid clearance from the body by the 
reticuloendothelial system (RES). The addition of PEG to the nanoparticle surface 
increases the hydrodynamic diameter of the particle, which prevents filtration by 
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excretory organs, hinders nonspecific binding of proteins to the particle surface, and 
delays recognition of the particles by the reticuloendothelial system (RES).[95] The end 
result is increased nanoparticle blood half-life. However, the degree with which PEG 
coating increases the nanoparticle half-life is dependent on both the original nanoparticle 
size and the chain length of the PEG (Figure 2-8). 
Zhang et al. found that after intravenous administration to mice, 20 nm PEG-
coated (PEG molecular weight = 2000 g/mol) gold colloidal nanospheres had slower 
clearance, less uptake by RES cells, and higher accumulation in the tumor compared to 
40 and 80 nm particles also coated with 2000 MW PEG.[95] Zhang et al attributed the 
higher clearance of the 40 and 80 nm nanoparticles to increased recognition by the RES 
due to larger nanoparticle size and a lower PEG layer density on the larger particles. 
Similarly, Terentyuk et al. compared 15 and 50 nm PEG-coated gold colloidal 
nanospheres with 160 nm PEG-coated gold silica nanoshells in vivo and concurred with 
Zhang and colleagues that the highest blood concentrations of gold at 24 hours were 
Figure 2-8. Effect of polyethylene glycol (PEG) chain length and particle size on the blood half-life of gold 
colloidal nanospheres. Smaller gold nanoparticles demonstrate increased PEG surface density, which 
correlates with increased half-life in the blood . Adapted from [96]. 
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found for the smaller 15 nm particles.[97] Most recently, Perrault et a/. conducted a 
systematic study that evaluated the effect of nanoparticle size and PEG coatings on blood 
circulation time. They showed that the increase in nanoparticle blood half-life due to the 
addition of PEG was more prominent in smaller versus larger total diameter nanoparticles 
(Figure 2-8).[96] A study by Gobin et a/. comparing PEG-coated gold-gold sulfide 
nanoparticles (total diameter = 35-55 nm) to PEG-coated gold-silica nanoshells (total 
diameter= 120-160 nm) showed that gold-gold sulfide nanoparticles had a longer half 
life than the gold-silica nanoshells.[47] This would support the hypothesis that a smaller 
diameter NIR-tunable nanoparticle such as gold-gold sulfide nanoparticles would be 
advantageous for in vivo therapy. 
In addition to nanoparticle size influencing clearance from the blood, it also 
influences the distribution of nanoparticles within the tumor. As discussed in the 
previous section, intratumoral distribution of the nanoparticles influences the heating of 
the tumor. Ideally, the nanoparticle distribution would be homogeneous throughout the 
tumor. In reality, Perrault eta/. observed that nanoparticles in the 100 nm range stay in 
the perivascular regions of the tumor, while smaller particles (<60 nm) have more success 
dispersing throughout the tumor.[96] Tunnell et a/. also observed non-uniformity of 
nanoparticle distribution, and observed that the gold-silica nanoshells (> 100 nm 
diameter) remained in close proximity to the vasculature (Figure 2-9).[80] Based on 
these studies, small nanoparticles are not only more difficult for the body to clear, but 
also have better tumor distribution than larger nanoparticles. 
Small nanoparticles in the range also have an advantage in that they are in the 
optimal size range for cellular uptake.[98, 99] By endocytosing the nanoparticles into the 
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Figure 2-9. a) Gold-silica nanoshell distribution within a tumor in vivo. A two-photon confocal image was 
taken of an excised colon carcinoma tumor after accumulation of nanoshells. Tumor blood vessels labeled 
with fluorescein (red) and nanoshells (green) were imaged utilizing their two-photon characteristics. The 
perivascular relationship of silica-gold nanoshells (green) to the tumor vasculature (red) is clearly evident. 
Adapted from [26] . b) Gold colloidal nanosphere distribution with respect to distance from tumor blood 
vessels by densitometry analysis of tumor sections. Adapted from [96]. 
tumor cells, nanoparticle retention by the tumor could be increased, enhancing heating 
and therapy. Another influencing factor on nanoparticle endocytosis by the tumor is the 
nanoparticle surface charge. Kim et al. performed a study looking at positively and 
negatively charge gold nanoparticles in tumor cyl indroid models ex vivo, and found that 
positively charged nanoparticles were more efficiently endocytosed by tumor cells, but 
negatively charged nanoparticles rapidly spread throughout the bulk of the tumor.[l 00] 
However, though this result is interesting, the study does not account for the influence of 
nanoparticle surface charge on the clearance ofthe nanoparticles in vivo. Studies looking 
at polymeric nanoparticles have found that a positively charged surface increases the 
clearance of nanoparticles by the liver and spleen.[l 01] Thus, the addition of charge to 
the nanoparticle surface to increase tumor retention of the nanoparticles must be balanced 
with the effect of nanoparticle surface charge on clearance. The end goal of nanoparticle 
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modifications should be to maximize the nanoparticle concentration within the tumor to 
ensure a complete tumor ablation. 
Quantitative comparisons between nanoparticle variants reveal a very similar 
biodistribution, with the majority of the injected dose delivered to the spleen and liver. 
For example, James et al. studied gold-silica nanoshells (130 nm diameter) after 
intravenous administration to mice and noted a peak tumor accumulation of the 
nanoshells at 24 hours.[1 02] The concentration of gold reported in the liver and spleen at 
24 hours was 20-25x the gold concentration observed in the tumor, indicating that < 5% 
of the total measured gold was in the tumor (Figure 2-10).[1 02] Gold nanoparticle liver 
accumulation is observed irrespective of particle size.[ 102-1 09] De Jong et al. found that 
10, 50, 100 and 250 nm gold nanoparticles all accumulate in the liver, and suggested that 
this was caused by the high perfusion of blood through this organ.[1 05] However, both 
bare and PEG-coated gold nanoparticles can be found localized within Kupffer cells, 
phagocytic cells present in the liver, and this suggests that phagocytic uptake plays a 
significant role in the large gold accumulations seen in the liver.[l 04, 108, 11 0] 
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Figure 2-10. Biodistribution of silica-gold nanoshells in a mouse model following systemic administration via 
the ta!l vein . All organs show less accumulation than the tumor with the exception of the spleen, which has 
16.7 t1mes the gold of the tumor. [ 1 02] 
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The large amount of gold nanoparticles accumulating in non-target sites decreases 
the number of nanoparticles available for heating the tumor and presents difficulties when 
considering the use of gold nanoparticles for visualization and treatment of metastases. 
Redirecting nanoparticles from the liver and spleen to the tumor would improve the 
chance of therapeutic success, reduce the risk of undesired side effects, and permit 
improved differentiation between metastases and healthy tissue during imaging. The next 
subsection focuses on strategies designed to improve gold nanoparticle tumor 
accumulation, tumor retention, and biodistribution. The first group of these strategies 
focuses on the addition of molecules to the nanoparticle surface to increase nanoparticle 
retention by the tumor and decrease nanoparticle accumulation in non-target sites. The 
second group of strategies utilizes inorganic and cellular vehicles to transport 
nanoparticles to their destinations. 
Strategies to Enhance Tumor Accumulation of Gold Nanoparticles 
To optimize the delivery of gold nanoparticles and enhance ablative therapy, two 
types of strategy have been reported in the literature. The first strategy utilizes the 
addition of markers to the nanoparticle surface to increase the nanoparticle specificity for 
a particular cancer and to bind the nanoparticle directly to the cancer cell surface. The 
second strategy utilizes larger particles or cells to target the tumor with the rationale that 
these larger vehicles may not accumulate at such a high rate in non-target sites such as 
the liver. These vehicles carry the therapeutic nanoparticles to the tumor site where they 
then diffuse from the tumor vasculature into the tumor body. We begin the discussion 
with gold nanoparticle surface modifications. 
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Nanoparticle Surface Modifications 
Conjugation to gold nanoparticle surfaces is simply accomplished using thiol or 
amine chemistry. By adding an antibody or other small molecule to the nanoparticle 
surface that targets the desired cancer, the specificity of tumor accumulation and tumor 
cell binding may be increased. In vitro studies using gold nanoparticles support this 
hypothesis. Loo et al. were the first to demonstrate the increased specificity of anti-
HER2 modified nanoshells for HER2 overexpressing breast cancer in both in vitro 
darkfield imaging and in vitro photothermal therapy applications.[24, 28] TheEl-Sayed 
group subsequently demonstrated in vitro cancer ablation using anti-EGFR-conjugated 
gold nanorods,[36, 73] and other groups had similar findings antibodies for acute 
lymphoblastic leukemia, Pseudomonas aeroginosa, and medulloblastoma.[25, 65, 111] 
Similarly, small molecules specific for cancer cells have also been added to the surface of 
gold nanoparticles to increase specificity. It is hypothesized that these molecules will 
diffuse through tissue more efficiently than antibodies in vivo because of their smaller 
size. Black et al demonstrated using gold nanorods conjugated to modified deltorphin 
peptide that the nanorods specifically bound delta opium receptor expressing colon 
cancer cells.[112] This specificity was also demonstrated using a conjugation to 
bombesin, which was targeted breast and prostate cancer.[113] 
An additional advantage of conjugating cancer-targeting moieties to gold 
nanoparticles is the ability to internalize nanoparticles into cancer cells. Jiang et al 
demonstrated that gold colloid conjugated to anti-HER2 were internalized into HER2-
expressing breast cancer cells in a size dependent manner,[99] and Tong et a/. used 
folate-conjugated nanorods to target folate-overexpressing KB cells for photothermal 
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therapy.[21] Other groups have used arginine-rich peptides to promote nanoparticle 
intemalization.[l14] However, Tong et al found that more laser power was required to 
kill cells with internalized nanorods versus cells with surface-bound nanorods.[21] This 
may prove a disadvantage for cancer therapy, particularly in vivo where it is desirable to 
minimize laser power. Moreover, the specificity of conjugated nanoparticles in vitro has 
not been duplicated in vivo. 
In fact, in vivo studies using nanoparticles with surface targeting modifications 
have not shown widespread success in enhancing delivery. Eghtedari et a/. compared 
PEG- and anti-HER2-PEG-coated nanorods administered to tumor-bearing mice.[115] 
While they presented qualitative histology data that seemed to show improved tumor 
accumulation using anti-HER2 nanorods, they did not present quantitative data indicating 
a delivery enhancement. Similarly, Li eta/. used gold nanorods conjugated to antibodies 
for either the HER2 or EGFR receptor, and saw enhanced photoacoustic imaging contrast 
of squamous cell carcinoma tumors in mice with the targeted nanorods.[116] However, 
they presented quantitative data showing that 6.1% of the non-targeted nanorod injected 
dose and 8.88% of the anti-HER2 nanorod injected dose accumulated within the tumor. 
It is unclear if this was a statistically significant difference or not. 
Similar studies have been performed with in vivo targeting of hollow gold 
nanoshells, which are ~30 nm in diameter before surface modification. Melancon eta/. 
modified hollow gold nanoshells with anti-EGFR and presented qualitative evidence via 
histology showing that the antibody-coated surface increased the delivery of 
nanoparticles to the tumor when compared to nonspecifically targeted nanoparticles.[7] 
However, when quantitatively comparing in vivo anti-EGFR hollow gold nanoshell tumor 
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uptake to anti-JgG hollow gold nanoshell tumor uptake using radiolabeling, the uptake 
difference was not statistically significant. In addition, the radiolabeling showed 
increased accumulation of the anti-EGFR gold nanoparticles in the liver when compared 
to the anti-IgG gold nanoparticles. 
In contrast, another study using melanocyte-stimulating hormone (MSH) analog-
modified hollow gold nanoshells to target murine melanomas showed a statistically 
significant enhancement of tumor delivery by targeted hollow gold nanoshells (12.6± 
3.1% of the injected dose per gram oflyophilized tissue for the MSH-modified versus 4.3 
± 1.2% of the injected dose per gram of lyophilized tissue) 4 hours post-injection.[6] 
These results are promising, but the choice of a 4 hour timepoint is surprising. The blood 
concentration of hollow gold nanoshells at 4 hours is between 11 and 13% of the injected 
dose per gram of blood for both the targeted and non-targeted nanoshells. Based on 
studies previously discussed that used gold-gold sulfide nanoparticles, which are of 
similar size to the hollow gold nanoshells, the timepoint of maximal tumor accumulation 
for hollow gold nanoshells should be much later. The perceived enhancement due to 
MSH targeting may in fact be due to selection of such an early timepoint, and only 
establishes that the MSH-conjugated nanoparticles more rapidly localize to the tumor 
than the non-targeted nanoparticles. The fundamental problem of using surface 
molecules to modulate nanoparticle tumor delivery is that nanoparticle delivery remains 
dependent on the EPR effect. 
Vehicle-based strategies have an advantage over simple surface modifications in 
that they can be dependent or independent of the EPR effect. The next section discusses 
two of these methods for nanoparticle transport. 
40 
Vehicles for Nanoparticle Delivery 
The first method proposed by Ferrari et al. uses a 3-4 J.!m porous silicon 
microparticle as a nanoparticle carrier. This method is dependent on the EPR effect, and 
has multiple steps (Figure 2-11).[93] First, nanoparticles would be loaded into the 
carrier particles. Next, the loaded carrier particles would be intravenously injected, 
would localize to the tumor vasculature, and would bind to the tumor blood vessel wall. 
Finally, the smaller therapeutic nanoparticles diffuse into the tumor. Targeting of the 
si I icon particles would be achieved using a phage coating on the outside of the particle. 
Bacteriophage (phage) display libraries have been used to identify peptide ligands that 
specifically bind the integrins, proteoglycans, and other features unique to blood vessels 
undergoing angiogenesis.[ll7] Tumor blood vessels are by nature angiogenic, and by 
coating the primary particles with phages specific to angiogenic blood vessels, the 
a) 
b) 
Figure 2-11. Vehicle delivery strategies for gold nanoparticles. a) Scanning electron microscope images of 
porous silicon microparticle carriers. Microparticles would be loaded with therapeutic nanop~rticles and 
targeted to the tumor vasculature. Once in the tumor vicinity, the nanoparticl~s wou_ld locally d1~use out of 
the microparticle via the nanoscale pores. Adapted from [118]. b) Hematoxylin/eosin (H&E)-sta1ned tumor 
tissue slices demonstrating the delivery of nanoparticle-laden macrophages (black cells) to the tumor. 
Adapted from [119]. 
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primary particles could be targeted to the tumor vasculature for margination, adhesion, 
and, ultimately, delivery of therapeutic particles. Tasciotti et a/. performed initial studies 
with the silicon microparticle carriers delivered quantum dots and single-walled carbon 
nanotubes (SWNTs) to a cell's cytosol in vitro.[118] This demonstration was 
encouraging for establishing the ability of this method to deliver particles in vivo. To 
date, no in vivo studies for tumor delivery with this technique have been published. 
Another vehicular strategy that has been used in the literature is the aptly named 
"Trojan Horse" method, which is independent of the EPR effect (Figure 23).[ 119] Choi 
and colleagues hypothesized that macrophages could be used to actively deliver gold 
nanoparticles to a tumor. Gold-silica nanoshells were incubated with macrophages for 24 
hours and internalized via phagocytosis. These nanoshell-loaded macrophages infiltrated 
tumor spheroids in vitro after 3 days of incubation and accumulated at the rim of the 
spheroid's core hypoxic region. Although this was not a significant enhancement of 
tumor core penetration, there was a marginal increase in gold nanoparticles reaching the 
hypoxic core. Their study demonstrates the possibility of using active carriers such as 
macrophages to delivery gold nanoparticles to the tumor site independent of the EPR 
effect. 
Conclusions 
NIR-absorbing gold nanoparticles, such as gold-silica nanoshells,[l4, 34] gold 
nanorods,[36] and gold nanocages,[55, 58] have shown great promise as light absorbers 
for cancer therapy, demonstrating an ability to destroy cancerous lesions both in vitro and 
in vivo. As the design of gold nanoparticle-based thermal therapies continues to mature, 
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efforts towards clinical translation should focus on the need for: (1) improved methods 
for reaching deeper, hard to access tumors both through alternative irradiation modalities 
that possess low attenuation in tissue and improved fiber optic technologies for internal 
delivery ofNIR light; (2) continuing progress towards modeling light-nanoparticle-tissue 
interactions during therapy and integration of these algorithms together with real-time 
imaging technologies to permit therapy optimization; and (3) improved delivery methods 
that will allow accumulation of a larger number of particles to the tumor site, which will 
enhance therapeutic efficacy. This thesis will seek to address the third of these three 
aims, improving gold nanoparticle delivery to the tumor, using T cells as a gold 
nanoparticle delivery vehicle that is independent of the EPR effect. 
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CHAPTER3 
T CELL-MEDIATED IMMUNE RESPONSE AGAINST TUMORS 
Introduction 
As highlighted in Chapter 2, gold nanoparticle photothermal therapy (PTT) has 
demonstrated efficacy against localized tumors in mice and would benefit from 
improvements in gold nanoparticle delivery. In this thesis, we demonstrate the use ofT 
lymphocytes, a type of white blood cell that is important for immunity and tumor-tropic, 
as a delivery agent for gold nanoparticles in Chapters 5 and 6. We further expand the use 
of gold nanoparticles with T cells by using PTT as an adjuvant for adoptive T cell 
transfer immunotherapy of metastatic melanoma in Chapter 7. The combination of PTT 
and immunotherapy extends the scope of gold nanoparticle PTT to include distant and 
metastatic cancers that are not easily accessible or too extensive for ablation to be 
effective. Because immunotherapy is rooted in the physiology of the immune system and 
the immune system's response to malignancy, this chapter will explain the role ofT cells 
in the immune system, the response ofT cells to malignancy, and the effect of the tumor 
microenvironment on T cell immune response. 
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Mechanisms of the T Cell Immune Response 
A fully functional immune system is critical for preventing and combating 
infection and malignancy. It is well known that patients with an impaired immune 
system are subject to a number of opportunistic infections and cancers that are not 
typically seen in the immunocompetent population. To protect its host from potentially 
lethal infections, the immune system uses a series of complex cell-cell and cell-receptor 
interactions that are designed to prevent and eliminate existing infections and to preserve 
healthy tissues and cells. 
The immune system has two major mechanisms --- innate immunity and adaptive 
immunity (Figure 3-1). Innate immunity rapidly responds to microbe-specific molecular 
patterns not present on host cells, such as bacterial lipopolysaccharide (LPS), terminal 
mannose residues on glycoproteins, double-stranded RNA, and unmethylated CpG 
nucleotides.[120] This type of response is geared to rapidly respond to bacteria or other 
foreign invaders. Adaptive immunity permits a more specialized response to the invader 
(Figure 3-2). This type of immunity is slower, but targets specific molecules produced 
by the invading microbe. In addition, adaptive immunity has memory, or the ability to 
recognize a previously encountered antigen and generate a more rapid response upon 
repeat exposure. The specificity of the adaptive immunity arm also permits the 
generation of a large population of immune cells that narrowly target a particular 
molecule. This property is utilized in adoptive T cell transfer approaches, as discussed 
later in Chapter 6. 
There are three groups of cells important for inducing an adaptive immune 
response: the naive T and B lymphocytes, the antigen presenting cells (APCs), and the 
1 
Time after i r ec on 
Figure 3-1 . Cells of innate and adaptive immunity.[120] 
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Figure 3-2. Immune response by the adaptive immune system.[120] 
45 
46 
effector T and B cells. T cells are responsible for a cell-mediated response against 
pathogens; these cells recognize foreign antigens, then mature and differentiate into cells 
capable of directly killing the microbe or infected cell. B cells are responsbile for the 
humoral immune response; these cells recognize foreign antigens, then differentiate into 
cells that secrete antibodies for those antigens. In the remainder of the chapter, T 
lymphocytes will be the primary focus because of their importance in generating an 
immune response against tumor cells. First, however, we shall discuss the basic 
mechanism of the T cell immune response against pathogens. 
T Cell Activation 
The key receptor that allows T cells to recognize antigens is the T cell receptor 
(TCR). Individual T lymphocytes or T cells each possess their own unique TCR. This 
receptor is made up of two protein chains, typically an a. and a f3 chain. Each chain of the 
heterodimer receptor has a unique variable region that facilitates T cell recognition of a 
wide variety of peptide antigens. This TCR diversity is achieved using random gene 
recombination during naive T lymphocyte development in the thymus. In the thymus, T 
cells are also selected for their ability to weakly bind to the host's major 
histocompatability (MHC)b molecules. T cells that do not bind the host's MHC 
molecules or bind too strongly are marked for apoptosis. In this way, T cells are 
developed that will be able to recognize antigens in the context of a professional APC but 
will not react to self-antigens that would lead to an immune response against healthy 
tissues. Mature naive T cells leaving the thymus express a TCR and either CD8 or CD4 
bIn humans, these molecules are called human leukocyte antigens (HLA).[l] 
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on their cell surface. These nai've T cells will circulate in the blood and through lymph 
nodes until they are activated. 
In order for T cell activation to occur, the T cell must not only recognize an 
antigen with its TCR, but the antigen must also be presented by a professional antigen 
presenting cell (APC) in the context of the appropriate MHC molecule and co-stimulatory 
molecules. This multi-step process reduces the possibility of a T cell responding against 
a self-antigen. In addition, there is a process for the processing of an antigen and the 
activation of an APC that further ensures that the immune system is responding to non-
self antigens. Antigen processing by the APC is the first step in generating an immune 
response and ultimately inducing T cell activation. Although there are many different 
types of cells (e.g. dendritic cells, macrophages, and B cells) that can present antigens to 
T cells, dendritic cells are considered the most potent APCs for activating nai've T cells, 
and I shall focus my discussion on them. 
Dendritic cells (DCs) are present in the epithelia of the skin, gut, and lungs. 
These DCs are immature and are not yet ready to stimulate T cell activation. Immature 
dendritic cells express surface receptors that recognize conserved microbial features 
called pathogen-associated molecular patterns (P AMPs), allowing the 
DC to internalize encountered microbes. Microbes further facilitate DC activation by 
binding specialized toll-like receptors (TLR) on the DCs, macrophages, and parenchymal 
cells present in the tissue. TLRs are able to stimulate an innate immune response in the 
form of inflammatory cytokines such as interleukin-1 (IL-l) and tumor necrosis factor 
(TNF). The combination of microbe endocytosis, TLR activation, and cytokine secretion 
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results in DC activation. The activated dendritic cell detaches from the epithelium and 
migrates to the tissue-draining lymph nodes. As the DC migrates, the DC matures by 
increasing its expression ofMHC and other costimulatory molecules such as CDSO (B7-
1) and CDS6 (B7-2).[121] The mature DC arrives at the lymph node prepared to activate 
na'ive T cells against the encountered microbial antigen. 
In order for T cells to recognize and respond to an antigen, it must be presented in 
the context of an MHC molecule on the surface of the DC. MHC molecules consist of 
two peptide chains that are non-covalently associated on the cell surface, and are only 
stably expressed on the APC surface when they are displaying a peptide antigen. There 
are two classes of MHC associated with antigen presentation. The two classes have 
slightly different protein crystal structures: class I MHC molecules have one a chain and 
a smaller l32 microglobulin peptide, while class II MHC molecules have an a and a 13 
chain. The tissue distribution of these molecules is also different by class. Class I MHC 
molecules are found on all nucleated cells and platelets in the host organism, while class 
II MHC molecules are only found on APCs, although their expression can be induced on 
endothelial cells and fibroblasts by interaction with interferon-y (IFN-y).[121] 
This difference in the tissue distribution of MHC molecules also correlates with 
the type of antigens presented by each class (Table 3-1). Class I MHC molecules display 
protein antigens from intracellular microbes (e.g. viruses that live inside host cells). 
Because every nucleated cell in the host expresses MHC class I molecules, infected 
parenchymal cells or APCs are able to display intracellular antigens on MHC class I 
molecules for recognition by CDS+ T cells. Class I MHC molecules can only be 
recognized by CDS+ T cells, which is important because only CDS+ T cells are able to 
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Table 3-1. Major histocompatibility complex properties. Adapted from [120]. 
MHC Class Distribution of Type of Antigen Responding T Cell 
II 
MHC Displayed 
All nucleated cells 
and platelets 
Antigen presenting 
cells 
Intracellular microbe 
proteins; viral 
proteins; self 
proteins 
Extracellular 
microbial proteins 
CDS+ cytotoxic T 
cells 
CD4+ helper T cells 
mount an effective cytotoxic response against infected host cells. Class II MHC 
molecules display extracellular protein antigens on APCs. Class II MHC molecules can 
only be recognized by CD4+ or helper T cells, which secrete cytokines to induce the 
proper effector response to the extracellular microbes. This class restriction ensures that 
the proper effector response is induced for the antigen-producing microbe. 
Because the two different MHC molecule classes display microbes from different 
origins, i.e. class I displays intracellular microbial antigens while class II displays 
extracellular microbial antigens, the process of preparing an antigen for MHC 
presentation is different for the two classes. For class I MHC display, the antigen 
proteins are first unfolded, ubiquinated, and then digested in the proteasome of the cell. 
This process is performed on any cytoplasmic protein in the cell, including abnormal 
proteins produced by tumors and normal, aged proteins of the cell. After digestion in the 
proteasome, the peptide fragments are transported into the endoplasmic reticulum by the 
transporter associated with antigen processing (TAP).[l20] The peptides bind with 
newly translated MHC I molecules, and are then transported from endoplasmic reticulum 
to golgi apparatus to the cell surface. 
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For MHC II antigen loading, the antigen must first be endocytosed or pinocytosed 
into the APC. The endosome or phagosome containing the internalized antigen then 
merges with a lysosome, where the proteins are enzymatically digested into fragments. 
Meanwhile, class II MHC molecules are being synthesized in the endoplasmic reticulum. 
However, these synthesized molecules have a peptide known as class II invariant chain 
peptide (CLIP) that blocks the antigen-binding site of the class II MHC. This prevents 
the class II MHC molecules from binding peptides destined for the MHC class I 
molecules in the ER. Once the MHC class II molecule leaves the ER in an exocytic 
vesicle, it merges with the endosome bearing lysosome-digested extracellular peptides. 
The endosome bearing the digested peptides also contains a protein that removes CLIP 
from the MHC II molecule, permitting binding of the peptides. This CLIP-removing 
protein is called HLA-DM in humans, H-2M in mice.[120] If the MHC molecule is able 
to bind, it becomes stable and is transported to the APC surface for presentation. If the 
MHC molecule does not bind a peptide, it is ultimately degraded. Once the APC or 
parenchymal is displaying an antigen on a MHC, it is possible for a T cell to recognize 
the antigen and become activated. 
The T cell requires a minimum of two signals for activation and effector response 
(Figure 3-3). First, the T cell must recognize the cognate antigen via its TCR in the 
context ofMHC presentation (Signal 1). However, recognition ofthe antigen alone is not 
sufficient for activation. The antigen must also be presented in the context of 
Dendritic 
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Siqnal2 
Co-stimulation 
Signal1 
Antigen 
recognition 
Signal3 
Cytokine I Secretion 
A 
CD4+ T Cell 
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Figure 3-3. Activation ofT lymphocyte by a mature dendritic cell. Antigen is processed by the dendritic cell 
and presented in the context of MHC molecules (Signal 1 ). The T cell receptor recognizes the antigen on 
the MHC, as well as the co-stimulatory signals (Signal 2), such as 87 -CD28 interaction. These interactions 
can result in T cell activation, leading to clonal proliferation and differentiation. However, a third signal in the 
form of helper T cell cytokine secretion can be required for an effector response (Signal 3) in the case of 
tumor cells and some viral infections. 
co-stimulatory signals such as CD80 (B7 -1) or CD86 (B7 -2) costimulatory molecule 
expression on the APC (Signal 2), which bind CD28 on T cells. Other co-stimulatory 
signals include high affinity binding of leukocyte function-associated antigen-! (LFA-1) 
on the T cell to intercellular adhesion molecule-1 (ICAM-1) on the APC and the binding 
of CD40L on the T cell to CD40 on APCs. The binding of LF A -1 to ICAM-1 allows the 
T cell to bind to the APC long enough to accomplish activation via an intracellular 
signaling cascade. The binding of CD40L to CD40 results in the APCs producing the 
chemokines and cytokines necessary to convert LF A-1 on the T cell from the low affinity 
to high affinity binding state and to induce increased expression of B7 proteins and other 
co-stimulatory molecules, both of which are essential forT cell activation. 
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The two-signal requirement for activation prevents the lymphocyte from 
responding to harmless stimuli or the organism's own normal proteins or cells. T cells 
that encounter a cognate antigen for their TCR but insufficient additional co-stimulation 
will become anergic or unresponsive to the antigen. This requirement for co-stimulation 
explains why adminstering a protein antigen alone fails to generate a vaccine response. 
Without co-administration with molecules or compounds that are able to induce an innate 
immune response, there is insufficient cytokine secretion to induce co-stimulation. 
However, when peptide antigens are injected with adjuvant compounds that can induce 
an innate immune response, T cells will be activated and will produce a clonal population 
that recognizes the peptide antigen. 
In the case of some viral infections or malignancy that infect parenchymal cells, 
not APCs, three, not two, events are required for CD8+ T cell response. First, the 
presentation ofthe antigen on class I MHC molecules by an APC (signal 1). Second, co-
stimulation of the T cell by the APC (signal 2). Finally, additional cytokine stimulation 
from CD4+ T cells (signal 3). Without these 3 signals, CD8+ T cells will not be 
sufficiently activated to generate an effective response against these intracellular 
antigens. In order for these three signals to occur, the intracellular antigens must be 
presented on both class I and class II MHC molecules. Parenchymal cells do not express 
class II MHC molecules --- these are only present on APCs. It is hypothesized that APCs 
phagocytose infected or malignant host cells to allow the antigens of these cells to be 
presented by the APC[l20], or that the APC internalizes intracellular microbes that are 
transiently in the extracellular space and transfers them to class I MHC molecules[l22]. 
The process of the APC presenting the infected or malignant cells' antigens on both its 
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MHC I and II receptors as well as the appropriate co-stimulatory molecules is known as 
cross-presentation or cross-priming. The cross-presentation process is thought to involve 
autophagy, reverse trafficking of proteins from the ER into the cytosol, phagolysosomal 
rupture, and/or the loading of class I MHC molecules in the cytosol.[l22] Cross-
presentation activates both CD4+ and CD8+ T cells, allowing the production of the 
cytokines necessary for a CD8+ T cell-derived CTL response to intracellular pathogens 
that do not directly affect APCs. The occurence of cross-presentation is also key to 
inducing an effective anti-tumor response from T cells. 
After the T cells are sufficiently activated through recognition of the cognate 
antigen and adequate co-stimulation, the T cell begins secreting IL-2 to promote T cell 
clone proliferation. NaYve T cells only weakly bind IL-2, but activated T cells strongly 
bind IL-2 due to the production of a third chain for the IL-2 receptor that increases IL-2 
binding affinity. Autocrine stimulation by IL-2 results in the proliferation ofthe antigen-
specific T cell clones. These clones begin to differentiate into effector cells that produce 
the countering immune response to the antigen-generating microbe or cell. After 
differentiation, a fraction of these effector cells remain in the lymph nodes and another 
small fraction of the activated T cells become memory cells, and do not differentiate into 
effector cells. The memory cells remain in the body, dormant, prepared to stimulate a 
rapid response in the event the antigen is re-experienced by the host. The majority of the 
activated T cells migrate from the lymph nodes into the blood to the infection site and 
address the infection through their effector response. 
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T Cell Effector Response 
After leaving the lymph nodes and entering the bloodstream, the T cells must first 
localize or home to the location of the infection or malignancy. Within the infected 
tissue, the innate immune cells produce inflammatory cytokines and chemokines that 
signal the local endothelial cells to upregulate the expression of E-selectin, P-selectin, 
and integrin ligand on the blood vessel surface (Figure 3-4). Passing T cells in the blood 
will weakly bind to the selectins on the endothelial cell surface by surface carbohydrates, 
and begin to "roll" along the blood vessel surface. Activated T cells express a high 
affinity integrin on their cell surface, allowing them to halt the rolling by binding to 
integrin ligand on the endothelial cell surface. In contrast, naive T cells express a low 
affinity integrin on their cell surface. After binding to the endothelial cell's integrin 
ligand, the T cell reorganizes its cytoskeleton and uses PECAM-1 (also known as CD31) 
to extravasate into the infected tissue. This homing process from the lymph node to the 
site of infection takes approximately 24 to 48 hours . Once the effector T cell encounters 
its cognate antigen in the tissues, the T cell increases expression ofvery late activation 
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Figure 3-4. Migration of neutrophils into tumor site. This is the same mechanism that is used by T 
lymphocytes to extravasate to the tumor site . Adapted from [123]. 
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(VLA) integrins that binds to extracellular matrix components such as hyaluronic acid 
and fibronectin.[l20] In this way, effector T cells that recognize their cognate antigen 
remain in infected tissue longer to perform their effector response. 
The effector response of the T cell is dictated by the type of T cell (CD8+ or 
CD4+). While cytoplasmic antigens induce a CD8+ T cell response, extracellular 
antigens induce a CD4+ T cell response. CD8+ T cells differentiate into cytolytic T cells 
(CTLs), and are able to kill infected or malignant host cells. When a CTL encounters an 
infected cell presenting its cognate antigen on a class I MHC molecule, the CTL firmly 
binds to that cell. The CTL then releases granzymes and perforins into the targeted cell, 
and the cell subsequently undergoes apoptosis. CD8+ CTLs also secrete IFN-y, a 
powerful activator of macrophages. IFN -y signals the macro phages to phagocytose and 
destroy microbes, while also signaling the macrophages, which can function as APCs, to 
increase the expression of class II MHC molecules and B7 co-stimulatory molecules. In 
this way, the CTLs destroy cytoplasmic microbes and lead to the activation of CD4+ 
helper T cells against the microbes as well. Whereas CD8+ CTLs are able to directly 
destroy microbes, CD4+ helper T cells serve primarily as signaling intermediaries. 
There are two primary types of CD4+ T cell responses: the THl response or the 
T H2 response. The cytokine and chemokine environment of the infected tissue controls 
which response is given by the helper T cells. If IL-12 is present and being produced by 
the local APCs, the production of a T H 1 cell response is favored. IfiL-12 is not present, 
then the autosecretion ofiL-4 by the helper T cells favors a TH2 response. THl CD4+ T 
cells are strong secretors of IFN-y, which, as discussed in the previous paragraph, 
activates macrophages. T Hl cells also activate macrophages by stimulating them through 
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the CD40L-CD40 interaction. The signals given by T H 1 cells induce the macrophages to 
produce increased amounts of reactive oxygen species and nitric oxide that are used to 
kill phagocytosed microbes. T H2 cells secrete IL-4 and IL-5, and are important mediators 
of the humoral or antibody-mediated immune response against certain types of parasites 
via eosinophils. The T H2 cells also produce Il-l 0 and IL-13, which inhibit macrophage 
activation. Although CD8+ CTLs are able to directly attack malignant cells, the profile 
of the effector CD4+ helper T cells is thought to influence the efficacy of the CTL 
response. Melanoma patients that respond well to immunotherapies tend to have a 
predominantly T H 1 helper T cell profile, while patients that do not respond seem to have 
a predominantly T H2 helper T cell profile. [ 124] This supports the importance of both 
CD8+ and CD4+ T cells in the immune response to cancer. 
Now that the basic mechanism of T cell immunity has been established, I shall 
tum my attention to the role of the immune system in responding to malignancy. Based 
on the discussion thus far, the immune system has the ability to identify malignant cells 
and destroy them, yet sometimes fails to accomplish this end goal. The next section will 
discuss the role of the immune system in tumor development and the mechanisms used 
by the tumor to evade immune detection and response. 
The Role of the Immune System in Tumor Pro&ression 
The response of the immune system to tumor development has three theoretical 
phases: elimination, equilibrium, and escape (Figure 3-5). In the first phase, 
elimination, a combination of CD8+ T lymphocytes, intraepithelial lymphocytes (y8 T 
cells), macrophages, and natural killer (NK) cells are able to attack and destroy the 
malignant cells. If the immune system fails to eliminate the tumor cells, the tumor 
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continues to evolve genetically, altering its antigen expression and developing other 
resistance mechanisms that permit the malignant cells to survive (Table 3-2). The 
immune system assists in the selection of these genetic changes by destroying vulnerable 
tumor cells, leaving behind the resistant tumor cells. When the proliferation of the tumor 
cells overtakes the rate at which the immune cells can destroy tumor cells, the tumor has 
reached the escape phase. At this stage, the tumor is producing immunosuppressive 
cytokines and molecules, preventing an effective immune response by the host. 
Tumor suppression of the immune response is not well understood and is an area 
currently under study. One difficulty seems to be that CTLs have impaired killing of 
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Figure 3-5. Host immune response to cancer. DR5 = death receptor 5, IDO = indoleamine 2,3-
dioxygenase, MICA/8 = MHC class I chain-related antigens A and 8, RAE1 = retinoic acid early transcript 1, 
sMICA/8 =soluble MICA/8, UL8P = UL 16-binding protein .[125] 
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Table 3-2. Mechanisms orchestrated by the tumor that contribute to its escape from 
the host immune system (adapted from [126]) 
A. Interference with the induction of anti- 1. Decreased expression of 
tumor immune responses costimulatory molecules on the tumor 
orAPC 
2. Alterations in TCR signaling in TIL 
3. Death receptor/ligand signaling and 
'tumor counterattack' 
4. Dysfunction of DC and inadequate 
cross-presentation of TAA to T cells 
5. DC apoptosis m the tumor 
microenvironment 
B. Inadequate effector cell function in the 1. Suppression of T -cell responses by 
tumor microenvironment Treg 
C. Insufficient recognition signals 
2. Suppression of immune cells by 
myeloid suppressor cells (MSC) 
3. Apoptosis of effector T cells in the 
tumor and in the periphery 
4. Microvesicles (MV, exosomes) 
secreted by human tumors and inducing 
apoptosis of CD8+ effector T cells 
1. Downregulation of surface 
expression of HLA molecules on tumor 
cells 
2. Downregulation of surface T AA 
displayed by tumor cells: antigen loss 
variants 
3. Alterations in APM component 
expression in tumor cells or APC 
4. Suppression of NK activity in the 
tumor microenvironment 
D. Development of immunoresistance by the 1. Lack of susceptibility to immune 
tumor effector cells 
2. Immunoselection of resistant 
variants 
3. Tumor stem cells 
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tumor cells in the tumor microenvironment. An in vivo study performed using tumor-
antigen specific T cells demonstrated that the CTLs took an average time of 6 hours to 
kill a tumor cell, while a normal T cell can kill a cell in about 25 minutes.[I27] Part of 
the mechanism behind this CTL impairment may be the tumor antigen itself. Tumor 
antigens are a mutant form of a self-protein, a normal protein that is overexpressed in 
tumor cells, or a normal protein that is being expressed at the wrong stage of 
development.[I20] The fact that these antigens were previously self-molecules ignored 
by the immune system may prevent CTLs from generating an effective response against 
them after malignant transformation; in fact, this similarity to self-antigens is likely to 
induce T cell anergy (failure of the T cell to react to the antigen).[I28] The lack of co-
stimulatory molecules on tumor cells also prevents T cell activation, even when the tumor 
cell is presenting tumor antigens on its MHC class I molecules.[I20] Moreover, to 
induce a truly effective response, the tumor antigen must be cross-presented on both 
MHC class I and MHC class II molecules by an APC. A lack of cross-presentation 
impairs the T cell immune response to the tumor.[I26] 
However, the lack of aT cell response to the tumor is not simply due to a lack of 
effective T cell activation. Zippelius et al collected T cells from the blood of Stage III/IV 
melanoma patients and found that the CD8+ T cells targeting MART-I, a marker of 
melanocytes, could destroy melanoma cells in vitro, but in vivo the same MART-I T cells 
were anergic.[I29] This suggests that the tumor microenvironment possesses additional 
factors that suppress T cell effector response and induce T cell anergy. Research into this 
area thus far has revealed that tumor-produced cytokines, immunosuppressive cells, and 
other factors are part of the myriad of tumor-induced defense mechanisms that prevent an 
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effective immune system offense. These mechanisms are summarized in Table 3-2. We 
will next briefly discuss the key immunosuppressive players in the tumor 
microenvironment as we may influence the prevalence and effectiveness ofthese players 
using our combination ofnanoparticle photothermal therapy and immunotherapy. 
There are several cell types that serve an inhibitory role in the tumor 
microenvironment. Important examples include T regulatory cells, tumor-associated 
macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs).[130] The first 
cell type mentioned, T regulatory cells (CD4+ CD25high Foxp3+), are designed to prevent 
the response of CTLs and helper T cells against normal self-antigens. Regulatory T cells 
induce anergy in autoimmune-responding T cells by a combination of TGF -13 and IL-l 0 
secretion as well as contact-dependent mechanisms.[120] In the tumor 
microenvironment, T regulatory cells are found to be enriched (5-15% of tumor 
infiltrating lymphocytes) compared to their presence in the peripheral blood, and are able 
to suppress the ability of CTLs to release cytotoxic granules and kill malignant 
cells. [ 126] 
Within the tumor, dendritic cells contribute to regulatory T cell activation through 
the binding of CTLA-4. The coupling of CTLA-4 on the regulatory T cell with CD80 and 
CD86 on the dendritic cells results in a high level of indoleamine 2,3-dioxygenase (IDO) 
expression, which impairs T cell proliferation, induces T cell anergy, and enhances a T 
cell's vulnerability to apoptosis.[128] The enriched regulatory T cell population in the 
tumor prevents tumor-antigen recognizing T cells from generating a cytotoxic response 
against the tumor cells. The role ofT regulatory cells is not limited to influencing other 
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T cells, however. T regulatory cells also drive the macrophages present in the tumor 
(tumor associated macrophages or TAMs) to favor immunosuppressive functions.[131] 
As discussed earlier in the chapter, macrophages can serve as innate immune 
defenders and antigen presenting cells. However, like helper T cells, macrophages can be 
polarized to favor one type of immune response over the other. In tumors, Ml 
macrophages are produced in the presence ofiFN-y and are able to eradicate tumor cells, 
while M2 macrophages are produced in response to IL-l 0 and are thought to be 
immunosuppressive.[l32] These M2 macrophages promote immunosuppression by 
releasing reactive oxygen species (ROS) and peroxynitrite, decreasing TCR binding 
affinity for professionally presented antigens by adding nitrates to tyrosine residues on 
the T cell receptor complex of CTLs.[130] M2 macrophages also secrete IL-10 and 
prostaglandins, which also can inhibit T cell function.[l26] Moreover, M2 macrophages 
are thought to have a role in promoting tumor growth and expansion through the 
secretion of proangiogenic factors such as VEGF, TNF -a, IL-8, and extracellular matrix 
proteases,[l33] and it has been observed that tumor cells are more motile when within 
close proximity of M2 macrophages.[ 130] Like regulatory T cells, M2 TAMs protect the 
tumor from immune surveillance, but in addition they also promote tumor expansion. 
Myeloid-derived suppressor cells (MDSCs) also create a tumor environment that 
favors immunosuppression and metastasis. MDSCs (CD11b+ Grl+ in mice) are immature 
cells of bone marrow origin that occur in cancer patients and accumulate at the tumor site 
due to tumor secretion of IL-10, VEGF, and GM-CSF.[l26] They enhance 
immunosuppression within the tumor through the increased secretion and production of 
inhibitory cytokines, nitric oxide, ROS, and arginase.[l33] MDSCs also migrate to 
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tumor-draining lymph nodes and interfere with DC priming of T cells. MDSCs are 
believed to promote tumor angiogenesis independent of VEGF, thus contributing to 
tumor progression and proliferation.[133] 
The combination of these three immunosuppressive cell types as well as the tumor 
cells producing their own immunosuppressive cytokines prevents the endogenous 
immune system from successfully combating tumor growth. Despite these challenges, 
recent immunotherapy clinical trials have demonstrated that collecting, expanding, and 
reinjecting tumor antigen-specific T cells into patients has clinical benefits for cancer 
treatment. The final section of this chapter will discuss adoptive T cell immunotherapy, 
its preliminary successes in clinical trials, and areas where combining gold nanoparticle 
photothermal therapy with adoptive T cell transfer may present some treatment benefits. 
Adoptive T Cell Immunotherapy 
Immunotherapy is a very broad term that can refer to many different types of 
immune system derived treatments. Commonly used immunotherapy-based cancer 
therapies include trastuzumab (Herceptin®), an antibody used for the treatment of 
advanced HER2+ breast cancer (see Chapter 4), Bacille Calmette-Guerin (BCG), a 
mycobacteria used to treat early bladder cancer, and the human papillomavirus (HPV) 
vaccine, a non-infectious virus-like particle mixture used to prevent cervical cancer. 
More active immunotherapy treatments, such as dendritic cell and T cell vaccines, are 
currently under development. Because CD8+ T cells can directly target and destroy 
cancer cells, they are considered the gold standard cell for cancer immunotherapies. 
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Adoptive T cell immunotherapy uses T cells derived from either a tumor biopsy 
sample or the peripheral blood of the patient and expands them in vitro for reinjection.[8] 
Patients receiving transferred T cells may also receive a lymphodepleting regimen using 
radiation and/or chemotherapy in addition to high doses of interleukin-2 (IL-2). These 
adjuvant treatments have been demonstrated to enhance the clinical response of the tumor 
toT cell therapy.[l34, 135] A disadvantage to both the lymphodepletion regimen and the 
high dose IL-2, however, is that both of these regimens are known to have potentially 
serious side effects, including infection, capillary leak syndrome, hypotension, fever, 
cardiac arrhythmias, and allergic reactions.[l36] Adding an adjuvant regimen, such as 
gold nanoparticle photothermal therapy, that obviates the need for these drugs would 
reduce the morbidity of i cell immunotherapy treatment. 
To date, T cell-based immunotherapy has been most successful against metastatic 
melanoma, but have been used against other metastatic cancers with some degree of 
success.[8-l 0] Most recently, a clinical trial with melanoma patients receiving adoptive 
T cell transfer with lymphodepleting chemotherapy +/- whole body radiation 
demonstrated success against brain metastases, with 15 of 26 patients attaining a 
complete or partial response of the brain metastases to therapy.[l37] One difficulty with 
using the patient's own unmodified T cells from a tumor biopsy sample or peripheral 
blood is the difficulty in isolating T cells that are specific for tumor antigens. One 
solution that has been proposed is using T cells that are genetically modified to target 
specific tumor antigens. This was first demonstrated using T cells targeted against 
MART-I, a melanoma tumor antigen.[l38] Using retrovirus, the antigen-specific 
portions of the MART-1-specific T cell receptor were inserted into autologous T cells 
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isolated from the peripheral blood. Two patients from this trial demonstrated a shrinking 
of their cancerous lesions and persistence of the engineered T cells for I year in the 
peripheral circulation, demonstrating the viability of this approach for generating large 
numbers of tumor antigen-specific T cells. 
Genetic modification of the T cell receptor to produce large numbers of antigen-
specific T cells has also seen some success. In two different clinical trials, T cells were 
retrovirally modified with T cell receptors (TCRs) specific for tumor antigens. In the 
first trial, autologous T cells were modified with a TCR specific for NY -ES0-1, an 
antigen commonly expressed in I 0-50% of metastatic melanomas and 80% of synovial 
cell sarcomas.[l39] This trial demonstrated an overall response rate of 45% for 
metastatic melanoma and 67% for synovial cell sarcoma. Another trial retrovirally 
modified T cells to target carcinoembryonic antigen (CEA), which is commonly 
expressed in metastatic colon cancer. In this trial using 3 patients with metastatic colon 
cancer, a sharp drop in CEA blood levels was seen in all three patients.[l40] One out of 
three patients had a clinical partial response to treatment, but all patients experienced 
moderate to severe colitis beginning I week after treatment and resolving over 4-6 weeks 
as well as progressing cancer after 6 months. Despite the lack of long term success with 
the TCR-modified T cells, the increase in T cell function seen was encouraging. 
One potential risk with this genetic engineering strategy is the development of 
hybrid T cell receptors. Native T cell receptors in the recipient T cell can trade portions 
of the donor T cell receptor with portions of the native T cell receptor, resulting in 
possible loss of T cell specificity for the tumor or in possible self-recognition and life-
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threatening graft vs. host disease.[141] Because of this risk, an alternative strategy has 
been proposed using chimeric antigen receptors (CARs). 
To create a CAR, the antigen-specific chain of a monoclonal antibody is 
engineered into aT cell and linked to the intracellular signaling within the T cell needed 
for immune response. Antibodies have an advantage over native TCRs because of their 
ability to respond to carbohydrates and lipid antigens in addition to peptide antigens. The 
engineering of the CAR into the T cell permits T cell response to non-protein tumor 
antigens, as well as eliminating the requirement for the MHC complex recognition.[IO] 
It does not, however, remove the requirement for co-stimulation, which is required to 
permit full T cell activation. Because co-stimulation within the tumor tends to reduced, it 
may be necessary to provide co-stimulation through additional cloning of co-stimulatory 
molecules, such as CD28, into the CAR.[lO] Di Stasi and colleagues recently 
demonstrated that the genetic modification of T cells with a CAR targeted to CD30 and 
constitutive expression of chemokine receptor 4 (CCR4) increased T cell migration and 
anti-tumor response to Hodgkin lymphoma in mice and reduced the development of 
regulatory T cells from these CAR+ CCR4+ T cells (Figure 3-6).[142] Alternatively, the 
T cells genetically modified with CARs could be stimulated through their native TCR by 
vaccinating the T cells against a virus that is present in the host.[lO] This would ensure 
consistent T cell activation and co-stimulation. 
Although T cell adoptive transfer has demonstrated some successes in clinical 
trials, the challenges of the immunosuppressive tumor microenvironment have prevented 
a high percentage of complete and durable clinical responses. The addition of an 
adjuvant treatment such as gold nanoparticle photothermal therapy may benefit T cell 
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Figure 3-6. Bioluminescent imaging performed using firefly-luciferase modified T cells and SCID mice with 
subcutaneously xenografted Hodgkin's Lymphoma (right flank). Top row shows unmodified T cells while 
bottom row shows T cells genetically modified with a CAR targeting CD30 and the CCR4 receptor. DO 
correlates with the day of injection, 0+3 with 3 days post-injection, 0+6 with 6 days post-injection, and 0+9 
with 9 days post-injection. At day 9 post-injection, the genetically modified T cells are seen to persist in the 
tumor while non-modified T cells do not persist. Adapted from [142]. 
immunotherapy by providing increased tumor antigen presentation and co-stimulation, 
ultimately leading to an improved CTL anti-tumor response. In addition to this benefit, 
the use of PTT as an adjuvant may reduce the need for the high-dose IL-2 regimen that is 
commonly used in patients receiving T cell transfer. In the remaining chapters of this 
thesis, I will demonstrate the combination of immunotherapy with gold nanoparticle PTT 
to enhance gold nanoparticle delivery to the tumor for PTT, as well as demonstrate the 
additive effects of PTT on immunotherapy. 
CHAPTER4c 
NANOSHELL THERAPY OF TRASTUZUMAB-RESISTANT BREAST 
CANCER CELL LINES 
Introduction 
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In Chapter 2 of this thesis, the advantages of gold nanoparticle photothermal 
therapy (PIT) for cancer treatment were outlined. One application of PTT has that has 
been very lightly explored is the use of PTT against chemotherapy resistant cancers. To 
date, gold nanoparticle-mediated treatment has only been applied to chemotherapy-
sensitive cell lines. Many cancers rapidly adapt to chemotherapeutics and develop 
resistance mechanisms that ultimately evade treatment. Because PTT ablates tumors with 
heat, we hypothesize that treating a chemotherapy-resistant cancer with PIT will evade 
any innate resistance and result in cancer cell death. 
For our initial testing of this hypothesis, we chose to focus on trastuzumab-
resistant breast cancer in vitro. In 2006, a therapeutic antibody against HER2 receptor, 
known as trastuzumab (Herceptin®), was brought to market as the first of the molecular 
therapeutic drugs for breast cancer. It is a commonly used adjuvant treatment for 
metastatic HER2+ breast cancers, which are known to be aggressive and to have a 
tendency to recur.[143, 144] Trastuzumab binds to the HER2 receptor and halts tumor 
cell growth through suppressing HER2 signaling and elevating the levels of p27KIPI 
c Adapted from: Carpin LB, Bickford LR, Agollah G, Yu TK, SchiffR, Li Y, Drezek RA, 
"Immunoconjugated Gold Nanoshell-Mediated Photothermal Ablation ofTrastuzumab-Resistant Breast 
Cancer Cells";Breast Cancer Research and Treatment, 125(1):27-34 (2011). 
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protein.[l43] Initial clinical trial results against metastatic breast cancer were positive, 
and trastuzumab was subsequently approved for use.[145, 146] 
Despite the initial successes of trastuzumab, the trastuzumab resistance has 
presented a major barrier. The majority of patients are intrinsically resistant to 
trastuzumab prior to starting therapy,[147] and most initially responsive patients develop 
resistance to treatment within a year.[l43] The development of trastuzumab resistance 
has been attributed to a variety of mechanisms, including overexpression of glycoprotein 
MUC4,[148] overexpression of insulin-like growth factor I (IGF-1),[149] and 
constitutive P13K/Akt activity.[150] In addition, although a mutation of the extracellular 
component of the HER2 receptor that results in trastuzumab resistance is theoretically 
possible, in most cases of resistance this does not occur.[143] This presents the 
possibility of using an antibody generated against the HER2 receptor as a targeting 
modality for nanoshell-mediated therapy. Gold nanoshell photothermal therapy could 
potentially be used to ablate these treatment-resistant breast cancers, presenting a new 
possibility for treating difficult cancers. 
By adding surface-conjugated ligands to gold nanoparticles, such as antibodies, 
polymers, or DNA, the nanoshells demonstrate increased target specificity in vitro.[14, 
151, 152] In the case of HER2+ breast cancer, Loo et al demonstrated that gold-silica 
nanoshells conjugated to anti-HER2 can be successfully used to target and ablate 
chemotherapy-sensitive breast cancer cells in culture.[24] Here, we will demonstrate that 
antiHER2-conjugated silica-gold nanoshells can mediate effective targeting and 
photothermal ablation of cultured two antiHER2-resistant breast cancer cell lines - JIMT-
1 has a lower level of anti-HER2 binding due to overexpression of MUC4,[148] and 
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BT474 AZ LR is resistant to both trastuzumab and lapatinib, an second generation agent 
developed for use against trastuzumab-resistant breast cancers. 
Materials and Methods 
Breast Cancer Cell Lines 
Three HER2-overexpressing breast cancer cell lines were chosen for this study: 
SK-BR-3, JIMT-1, and BT474 AZ LR. The SK-BR-3 cell line is trastuzumab sensitive, 
while the JIMT-1 cell line and BT474 AZ LR cell line are both trastuzumab resistant. 
The BT474 AZ LR cell line is also resistant to lapatinib, a second line agent developed 
for trastuzumab-resistant breast cancers. The MCF10A cell line, which is an 
immortalized, HER2 negative breast epithelial cell line, was used as a control. The SK-
BR-3 and JIMT-1 cell lines were both cultured in McCoy's SA and Dulbecco's Modified 
Essential Medium, respectively, supplemented with 10% fetal bovine serum (FBS) and 
1% penicillin-streptomycin. The BT474 AZ LR cell line was cultured in Dulbecco's 
Modified Essential Medium High Glucose supplemented with 10% FBS and 1% 
penicillin-streptomycin-glutamine and with 0.1 f.!g/mL of lapatinib to maintain HER2 
therapy resistance. The MCF10A cells were cultured in Mammary Epithelial Basal 
Medium (MEBM) supplemented with a BulletKit (Clonetics). All cells were maintained 
at 37°C in a 5% C02 atmosphere. 
Quantification of HER2 Receptor Antigens on Cell Surface 
Quantification of HER2 surface receptors was performed as described by 
Bickford et al.[27] Cells were grown to confluence, trypsinized, counted, and incubated 
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with either media alone, PE anti-human CD340 (erbB2/HER-2) antibody, or PE mouse 
IgG 1 isotype control antibody for 30 minutes on ice in the dark. The IgG 1 isotype serves 
a background signal correction. The cells were then washed in 1x PBS, resuspended in 
500 f.d of cell staining buffer, and stored on ice until analysis. Immunofluorescence 
intensity was determined by flow cytometry at The University of Texas M.D. Anderson 
Cancer Center (MDACC) flow cytometry core. To correlate the immunofluorescence 
intensity with the quantity of HER2 antigens available for binding on each cell, a 
Quantum Simply Cellular anti-Mouse IgG kit was used. This kit has 4 different sets of 
microbeads possessing a known number of antigen binding sites, which permits the 
development of a calibration curve correlating immunofluorescence intensity with the 
quantity of antigen binding sites. The curve is then used to calculate the number of 
antigen binding sites per cell. 
Silica-Gold Nanoshells and Antibody Conjugation 
The silica-gold nanoshells were synthesized using previously described 
methods.[24, 28, 32] In brief, silica cores were created using the StOber method,[153] 
and the silica core surface was functionalized with amine groups. These amine groups 
were then used to seed 4-7 nm gold colloid onto the silica surface. The size of the silica 
cores was determined to be 120 nm by scanning electron microscopy (SEM) prior to gold 
seeding. The gold shell was then completed by adding additional gold solution, 
potassium carbonate, and formaldehyde. After synthesis, the UV-Vis spectrum ofthe 
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Figure 4-1. Absorbance spectrum of the silica-gold nanoshells (silica core radius= 60 nm, total radius= 75 
nm). Inset shows SEM image of the nanoshells; scale bar is 300 nm. 
nanoshells was correlated with Mie Theory to determine the absorption, extinction, and 
scattering coefficients of the nanoshells, and subsequently the approximate concentration. 
The average nanoshell diameter was confirmed to be 150 ± 10 nm by SEM. The 
nanoshell extinction peak was determined to be 780 nm with a concentration of 3.85 x 
109 nanoparticles/mL (Figure 4-1). 
To modify the surfaces of the nanoshells with anti-HER2 antibody, the methods 
of Loo et al were employed.[24] The anti-HER2 antibody (C-erbB-2/HER-2/neu Ab-4, 
Lab Vision Corporation) was incubated with a custom orthopyridyl-disulfide-
polyethylene glycol-N-hydroxysuccinimide ester (OPSS-PEG-NHS, MW = 2kD, 
CreativeBiochem Laboratories) linker at a molar ratio of 3:1 in sodium bicarbonate (100 
mM, pH 8.5) overnight on ice at 4°C. Aliquots were then stored at -80°C until use, when 
they were thawed on ice. The antibody binds to the OPSS-PEG-NHS linker via the 
amide group, and adsorbs to the gold surface of the nanoshell via the thiols of the OPSS 
group. To attach the antibody-linker to the gold nanoshells, nanoshells were incubated 
with the antibody-linker at 4°C for 2 hours, then 1 mM polyethylene glycol-thiol (PEG-
SH, MW = 5kD, Nektar) was added and the nanoshells were incubated overnight at 4°C 
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for further stabilization. After nanoshell conjugation, the unreacted PEG-linker and 
PEG-SH were removed by centrifugation of the nanoshell solution and removal of the 
supernatant. The anti-HER2 nanoshells were then resuspended in cell-line appropriate 
media prior to use in cell studies. 
Two-Photon Laser Scanning Microscopy to Confirm Binding Efficiency 
For in vitro two photon nanoshell binding studies, -5 x 105 cells in suspension 
from each cell line (MCFlOA, SK-BR-3, JIMT-1, and BT474 AZ LR) were incubated 
with 1. 73 x I 09 nanoshells in 1 mL of media for 1 hour at 3 7°C with rotation in a 
hybridization oven. Cell incubated with media alone were used as a control. After the 
incubation, the cell lines were washed three times with 1 mL of 1 x phosphate-buffered 
saline (PBS) to remove unbound nanoshells, and resuspended in 0.5 mL of cell line 
appropriate media. Each treatment and control group was then seeded onto an inverted 
covers! ip and allowed to attach overnight. A Zeiss Laser Scanning Microscope 510 
MET A multi photon system was used in combination with a Coherent Chameleon 
femtosecond mode locked Ti :sapphire laser for imaging. 
Nanoshell-Mediated Photothermal Therapy 
For in vitro photothermal ablation studies, -5 x 105 cells in suspension from each 
cell line (MCFIOA, SK-BR-3, JIMT-1, and BT474 AZ LR) were incubated with 1.71 x 
1010 nanoshells as described above. Media alone was again used as a control. Cells were 
washed with PBS and seeded in coverslips as described above. 
Laser irradiation of the cells was performed in a similar manner to previous 
photothermal therapy studies.[24, 30, 32] After the cells were attached, each well was 
uncovered, placed on top of a glass microscope slide, and exposed to an 808 nm NIR 
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diode laser at 80 W/cm2 with a 1.5 mm spot size for 5 minutes. Following laser 
irradiation, the cells were returned to the 37°C incubator with 5% C02 for several hours. 
Live/dead viability staining was then performed using an Invitrogen Live/Dead 
viability/cytotoxicity kit and cells were imaged using a Zeiss Axiovert 135 Fluorescence 
microscope. To confirm nanoshell binding, silver staining was performed using Sigma 
Aldrich Silver Enhancement solutions, followed by brightfield imaging. 
Results 
Quantification of Antigen Binding 
Using flow cytometry, the number of antigen binding sites for each cell line was 
determined, as displayed in Figure 4-2. Data for the MCF10A, SK-BR3, and JIMT-1 
cell lines are being reused with permission from [27]. A one-factor ANOVA test 
indicated significant differences between cell lines in the number of binding sites (p < 
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Figure 4-2. Anti-HER2 binding capacity of each breast cancer cell line, determined by flow cytometry. The 
HER2+ cell lines (SK-BR-3, JIMT-1, BT474 AZ LR) show a significantly higher binding capacity than the 
HER2- cell line (MCF10A). MCF10A, SKBR3, and JIMT-1 data adapted from [27 , 154]. 
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0.01 ). Each of the HER2+ breast cancer lines used in this study had a larger number of 
anti-HER2 binding sites than the normal epithelial cell line, MCF10A (2.43 x 104 ± 3.77 
x 103 receptors), by the Tukey comparison test (p<0.01). The BT474 AZ LR cell line had 
the greatest anti-HER2 binding capacity (2.19 x 106 ± 3.25 x 105 receptors), followed by 
the SK-BR-3 (1.68 x 106 ± 6.78 x 104 receptors) and then the JIMT-1 (3.82 x 105 ± 1.47 x 
104 receptors) cell lines. Notably, the JIMT-1 cell line has a significantly lower HER2 
binding site expression when compared to the SK-BR-3 and BT474 AZ LR cell lines (p < 
0.01). 
Two Photon Microscopy ofNanoshell-Cell Binding 
Nanoshell binding is evaluated through two-photon laser scanning microscopy in 
Figure 4-3. The figure shows phase contrast images overlaid with the two photon 
images. The cells incubated with media only demonstrate no nanoshell signal. The 
Media 
Anti - HER2 
Nanoshells 
MCFlOA SKBR3 JIMT-1 BT4741 L 
300 ~U11 
Figure 4-3. Verification of nanoshell binding using two-photon laser scanning microscopy. Images depicted 
are phase contrast images overlaid with two photon images, where red is nanoshell signal. SK-BR-3, JIMT-
1, and BT474 AZ LR cell lines, all HER2+, show greater binding of the anti-HER2 nanoshells than the 
MCF10A normal epithelial cell line. 
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HER2+ cell lines incubated with nanoshells each show nanoshell signal, while the HER2-
cell line shows significantly less. The SK-BR-3 and BT474 AZ LR cell lines show the 
most nanoshell binding. The JIMT -1 cell line demonstrates less nanoshell binding than 
the SK-BR-3 and BT474 AZ LR cell lines, but greater nanoshell binding than the 
MCF 1 OA cell line. There is some degree of binding seen with the MCF 1 OA cell line, but 
this binding is still significantly less than the HER2+ breast cancer cells. 
Nanoshell-Mediated Cell Destruction ofTrastuzumab-Resistant Cell Lines 
Figure 4-4 shows the live/dead imaging and silver staining for the treatment and 
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Figure 4-4. Photothermal therapy results . Live/dead imaging demonstrates cell ablation in HER2+ cell lines 
(SK-BR-3, JIMT-1 , BT474 AZ LR) treated with anti-HER2 nanoshells and NIR laser irradiation (red ethidium 
homodimer stain= dead cells , green calcein stain= live cells) . Silver staining shows nanoshell binding for 
each of the HER2+ cell lines. 
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media control group of each cell line. None of the media alone groups show evidence of 
cell death on the live/dead images or evidence of nanoshell binding on the silver stain. 
The silver staining confirms that nanoshells are bound to each of the HER2+ cell lines 
(SK-BR-3, BT474 AZ LR, JIMT-1), with minimal nanoshell binding to the HER2-
MCFIOA cell line. The MCFIOA-nanoshell group does not demonstrate localized area 
of cell death, while each of the HER2+ breast cancer-nanoshell groups show a clearly 
defined region of dead cells (red) corresponding to the laser spot surrounded by non-
irradiated, nanoshell-bound live cells (green). 
Discussion 
Anti-HER2 resistance continues to be a challenge for clinicians treating advanced 
cancers. Gold nanoparticle-mediated photothermal therapy could present new 
possibilities for cancers that are currently resistant to conventional chemotherapy and 
radiation treatments. The objective of this study was to demonstrate that 
immunoconjugated silica-gold nanoshells can effectively destroy both chemotherapy-
sensitive and chemotherapy-resistant breast cancer cell lines. Two trastuzumab-resistant 
breast cancer cell lines were selected for testing, JIMT-1 and BT474 AZ LR. A 
trastuzumab-sensitive breast cancer cell line, SK-BR-3, and a HER2 negative normal 
epithelial cell line, MCF 1 OA, were also chosen as positive and negative binding controls. 
Each of the HER2+ breast cancer cell lines selected were effectively ablated using 
nanoshell-mediated photothermal therapy. These results suggest gold nanoparticle-
mediated photothermal therapy may have potential to be employed against chemotherapy 
resistant breast cancers in vivo. 
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As the first step of this study, we evaluated nanoshell binding efficiency using 
two-photon laser scanning microscopy. Silica-gold nanoshells have demonstrated two-
photon properties, and can be used to label HER2+ breast cancer cells in vitro.[25, 26] 
Nanoshell binding has also been demonstrated using darkfield microscopy [28] and 
optical coherence tomography,[15] which depend on the enhanced scattering of the 
nanoshells for contrast. However, for future in vivo studies, two-photon luminescence 
may prove superior in bulk tissue to these scatter-based techniques. This is due to the 
improved signal to noise ratio of two photon microscopy, as well as its demonstrated 
ability to more effectively investigate the nanoshell distribution within the tumor with the 
assistance of software.[26] In Figure 4-3, we observe that the antiHER2 conjugated 
silica-gold nanoshells bind specifically to trastuzumab-resistant HER2+ breast cancer cell 
lines, with very little binding to the normal breast epithelial cell line, MCF10A (Figure 
4-3 and Figure 4-4). The degree of nanoshell binding shown by both the two-photon and 
silver stain images seems to correlate with the HER2 antigen binding capacity of the 
breast cancer cell lines. The JIMT -1 cell line has the lowest anti-HER2 binding capacity 
of the three breast cancer lines studied. Nagy et al found that only 20% of HER2 
receptors are available for trastuzumab binding due to obstruction of the extracellular 
component of the HER2 receptor by MUC4.[148] Despite this, anti-HER2 nanoshell 
binding is still clearly seen in both the two-photon and silver stain images, though to a 
lesser degree than the other two HER2+ lines. Importantly, this lesser degree of binding 
is still sufficient for the photothermal destruction of the JIMT -1 cells, while the action of 
trastuzumab is impaired against these cells.[148] In the case of the BT474 AZ LR cell 
line, the nanoshell binding is more than adequate to ensure cell death upon NIR laser 
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irradiation. Photothermal therapy is also effective against the BT474 AZ LR cell line, 
while the action of both trastuzumab and lapatinib, a second generation agent, are 
impaired against these cells. 
Using silica-gold nanoshells as a mediating absorptive agent for photothermal 
therapy has advantages over conventional hyperthermia treatments. In Figure 4-4, the 
ablated areas (red) are surrounded by living, healthy cells (green), and cell lines with 
minimal or no nanoshell binding show no regions of cell death. Only HER2+ cells with 
bound nanoshells in the region of the laser spot are ablated. Targeting the gold 
nanoparticles with an antibody or peptide permits single cell specificity in vitro.[21, 112] 
This specificity is important during in vivo studies, when healthy tissues such as skin will 
be in between the laser and the cancerous tissue. Because nanoshells efficiently absorb 
the irradiating laser energy and convert it to heat, the laser power requirements to induce 
cell death are lowered. In conventional hyperthermia treatments, this specificity is 
lacking, as the power of the irradiating energy source must be high enough to kill cells 
without the assistance of a mediating agent. Thus, using nanoshells as part of 
photothermal therapy in vitro lowers the power requirements of the irradiating energy, as 
well as increasing the specificity of therapy for malignant cells. 
Figure 4-4 does demonstrate some variation in the size of the ablated regions. 
This variation was seen consistently among several replicate experiments. These 
differences are likely due to variations in the laser intensity distribution, the degree of cell 
confluence, and density of HER2 receptors on the cell surfaces. In order for cell death to 
occur, a temperature of 70-80° C must be achieved for approximately 4 minutes.[36] The 
net temperature increase of the cells within the laser spot is dependent on a combination 
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of variables, including: the absorptive cross-section of the silica-gold nanoshells, the 
physical distribution of the nanoshells among the cells, the intensity and duration of the 
laser illumination, and the heat transfer and dissipation properties of the cells and 
media.[155] Non-uniform laser intensity could lead to cells at the periphery of the spot 
receiving less laser power,[156] resulting in the minimum temperature and duration 
needed for cell death not being achieved. However, the laser spot size, power, and 
duration were held consistent throughout each of the treatment groups and experiments, 
so it is unlikely that in this case it is a large contributor to the variation seen in ablation. 
The nanoshell binding density could also be playing a significant role, and, based on the 
information in Figure 4-2 and Figure 4-3, is a likely contributor to the variation in 
ablated area size. 
The low anti-HER2 binding capacity of the JIMT-1 cell line versus the higher 
binding capacities of the SK-BR-3 and BT474 AZ LR cell lines correlates with the small 
ablated area for the JIMT-1 cells and the larger ablated areas for the SK-BR-3 and BT474 
AZ LR cells. This supports the nanoshell binding density being a major contributor to 
the variation in ablation size. However, although the SK-BR-3 cell line has a lower anti-
HER2 binding capacity than the BT474 AZ LR cell line, the size of the ablated area for 
this cell line is larger. This could be due to several factors. Some of this variation may be 
due to the differences in how the SK-BR-3 and BT474 AZ LR cell lines tend to grow. 
The SK-BR-3 cells grow in a monolayer, while the BT474 AZ LR cell line tends to grow 
in conglomerates. These growth differences may have resulted in different heating 
profiles between the two cell lines, affecting the sizes of the ablated regions. Another 
possible contributing factor is differences in thermal sensitivity between the SK-BR-3 
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and BT474 AZ LR cell lines, which has been seen in response to conventional 
hyperthermia treatments in tumors resected from breast cancer patients.[! 57] Regardless 
of variation in the size of the ablated regions, each of the HER2+ breast cancer cell lines 
was successfully ablated using nanoshell-mediated photothermal therapy. Each of these 
variables (laser intensity profile, nanoshell binding density, the tumor cell density/ tumor 
shape, the thermal sensitivity of the tumor) will need to be considered in applying and 
optimizing nanoshell-mediated therapy to trastuzumab-resistant cancers in vivo. 
Conclusions 
The successful application of gold nanoshell-mediated photothermal therapy to 
trastuzumab-resistant breast cancer cells in vitro suggests a promising new approach for 
the treatment of advanced HER2+ breast cancers. By virtue of its physical means of 
destroying cancer, nanoshell-mediated thermal ablation of these types of cancer has an 
innate advantage over trastuzumab, lapatinib and other antibody or small molecule-based 
therapies. Gold nanoparticle-mediated photothermal therapies also have demonstrated 
synergistic cell killing in combination with chemotherapy in vitro and radiation in 
vivo,[l52, 158] suggesting that the combination of conventional treatments and this 
technology could also be beneficial for cancer therapy. 
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CHAPTER5d 
T CELLS AS IN VIVO GOLD NANOPARTICLE DELIVERY VEHICLES 
Introduction 
As discussed in detail in Chapter 2, attempts at augmenting gold nanoparticle 
tumor delivery have included a variety of nanoparticle surface modifications, including 
conjugation with antibodies[?] and other tumor targeting molecules [6]; however, 
inclusion of targeting ligands has only modestly improved tumor accumulation and 
specificity. This is likely due to the reliance of these nanoparticles on passive 
accumulation through EPR, which is highly dependent on adequate blood flow to the 
tumor. Therefore, tumors or tumor regions that exhibit poor vasculature and hypoxia are 
less likely to be effectively targeted using nanoparticles, ultimately limiting their 
therapeutic use. 
Choi et al. recently demonstrated that macrophages could be used as a cellular 
delivery vehicle to deposit AuNPs in tumors and hypoxic tumor tissues, facilitating 
delivery through active cellular migration and extravasation in response to chemotactic 
factors produced by malignant cells. [ 119] These encouraging results suggested that other 
immune cells might be used as cellular delivery vehicles. In this study, we assessed the 
capacity of activated T cells to function as chaperones for AuNPs. Unlike macrophage, T 
cells are readily isolated and expanded in vitro, and upon infusion, circulate throughout 
the body and migrate into tumors in response to tumor-associated chemokines. This 
d Adapted from: Kennedy LC*, Bear AS*, Young JK, Lewinski NA, Kim J, Foster AE, Drezek RA, "T 
Cells Enhance Gold Nanoparticle Delivery to Tumors in vivo"; Nanoscale Research Letters, 6:283 (2011). 
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tumor-tropic property permits their use as cellular vehicles for the delivery of molecular 
therapeutics. [ 159-162] 
Combining the advantages of T cells with nanotechnology has the potential to 
generate innovative new approaches to cancer therapy. Several studies have 
demonstrated that T cells may serve as efficient drug delivery vehicles for the treatment 
of cancer, including transport of magnetic particles bearing doxorubicin and for use in 
boron neutron capture therapy.[163, 164] Here we have explored whether T cells can be 
used as AuNP carriers to increase delivery to tumor sites in vivo using gold colloidal 
nanospheres ( 40-45 nm), comparable in size to hollow gold nanoshells and gold-gold 
sulfide nanoparticles used for PTT. Although gold colloid in this size range has maximal 
absorbance in the visible wavelengths, there are several variants of AuNPs that are of 
similar size (25-60 nm) and absorb optimally in the NIR region, permitting translation of 
this delivery method for PTT. These gold nanoparticle variants include gold-gold sulfide 
nanoparticles, hollow gold nanoshells, and gold nanocubes, all of which have 
demonstrated efficacy as PTT-mediating agents in mouse studies.[l65] Additionally, 
there have been studies demonstrating photothermal therapy using gold colloid that has 
been strategically aggregated to red-shift the peak absorbance into the NIR.[62, 63] 
The possible applications of a AuNP-T cell delivery system could further be 
extended to imaging and drug delivery applications, as gold nanoparticles also have 
demonstrated potential as scatter- and absorption-based imaging contrast agents[l5, 26, 
36, 60] and drug delivery agents[166]. In this study, we demonstrate that gold colloid is 
readily taken up by activated human T cells without impairing their viability or cellular 
83 
functions, and that following intravenous infusion into tumor bearing micecan more 
efficiently deliver AuNPs to distant tumor sites. 
Methods 
In vitro Characterization Studies 
AuNP Synthesis and PEGylation 
Gold(III) chloride trihydrate (HAuC14·3H20 99%) and potassium carbonate 
anhydrous (K2C03 99%) were purchased from Sigma-Aldrich (St. Louis, MO). 
Deionized water was provided by a Milli-Q system. In this synthesis method, Au3+ is 
reduced to Au0 using CO as a reducing agent. A 0.38 mM HAuCl4 solution was prepared 
and aged in an amber bottle at 4°C for a minimum of 72 h prior to use. After aging the 
chloroauric acid solution, the temperature was allowed to gradually rise to l6°C. A 
1.8 mM K2C03 solution was then prepared by adding 75 mg of K2C03 to the aged 
200 mL HAuCl4 solution. This solution was aged for 30 min prior to aeration with CO 
gas. A 40 mL volume of the aged solution was added to the beaker and stirred 
continuously prior to aeration. CO gas (Matheson-Trigas) was injected into the 
continuously stirring solution at a flow rate of 30.5 mL/min. The CO flow was controlled 
via a flow rate control valve. A visible color change from clear to dark purple to red is 
observed during synthesis, indicating formation of AuNPs. TEM images were taken to 
confirm size and monodispersity. Particles were sterilized by filtration through a 0.22 Jlm 
polyethersulfone filter. To stabilize the particles in preparation for mouse injection, 
0.5 mM polyethylene glycol-thiol (PEG-SH, MW = 5 kD, Nektar) was added to the 
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particles. After a 24-h incubation, excess PEG-SH was removed by centrifugation and 
PEGylated particle stability was confirmed by increasing solution tonicity with 1 M 
NaCl. Dynamic light scattering measurements were taken to assess the hydrodynamic 
diameter of the PEGylated gold colloid. 
T Cell/solation and Preparation 
Peripheral blood was obtained with informed consent from willing healthy donors 
using a Baylor College of Medicine Institutional Review Board approved protocol. 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll gradient 
centrifugation (Lymphoprep, Nycomed, Oslow, Norway). PBMC were used to generate 
EBV-transformed B cells lines (LCL) and T cell lines. LCL and T cells were maintained 
in RPMI 1640 supplemented with 10% fetal calf serum (FCS; Hyclone, Logan, UT) and 
2 mM GlutaMAX (Invitrogen, Carlsbad, CA). ForT cell expansion, non-tissue culture 
treated 24-well plates were coated with OKT3 (1 J..Lg/mL; Ortho Pharmaceuticals, Raritan, 
NJ) and anti-CD28 antibody (1 J..Lg/mL; BD Biosciences, San Diego, CA) overnight at 
4°C. Plates were washed and 2 x 106 PBMC were plated per well in complete RPMI 
supplemented with 100 U/mL recombinant human interleukin-2 (IL-2). On day 3, T cell 
blasts were harvested and further expanded or transduced in IL-2 supplemented media. 
T Cell Internalization of AuNPs 
Day 7 OKT3 blasts were harvested and suspended in complete RPMI 
supplemented with IL-2 and 0, 0.05, 0.1, 0.25, 0.5, or 1 nM of AuNPs for 24 h (1 
mole= 6.022 x 1023 nanoparticles). Cells were harvested and washed a minimum of three 
times using 1x phosphate-buffered saline (PBS) prior to subsequent experiments. To 
confirm loading, T cells were imaged using darkfield microscopy. To quantitatively 
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characterize loading, 2 x 106 T cells per sample were prepared for ICP-OES analysis by 
digesting the cells in three parts trace metal grade hydrochloric acid (Fisher Scientific, 
Pittsburgh, PA) and one part trace metal grade nitric acid (EMD Chemicals, Gibbstown, 
NJ) overnight. Samples were then diluted to 10 mL in distilled water and filtered. T cells 
incubated with media alone were used as a control. 
T Cell Viability and Functionality after AuNP Loading 
To determine the effect of AuNP loading on T cell phenotype, we used the 
following monoclonal antibodies conjugated to FITC, PE, PerCP, or APC (BD 
Biosciences): CD3, CD4, CDS, CD45RA, CD45RO, CD56, CD62L, CCR5, and CCR7. 
An Annexin V apoptosis detection kit (BD Biosciences) was used to determine T cell 
viability post-AuNP loading. Cells were analyzed using a F ACSCalibur flow cytometer 
(BD Biosciences) and FCSExpress software (De Novo Software, Los Angeles, CA). A 
eH] thymidine incorporation assay was used to assess the effects of AuNP loading on T 
cell proliferation. Following AuNP loading, T cells were seeded in triplicate into 96-well 
round bottom plates at 1 x 105 cells per well in complete RPMI containing 100 U/mL IL-
2 for 24 h. T cells were then pulsed with 5 f.lCi eH] thymidine (Amersham Pharmacia 
Biotech, Piscataway, NJ) overnight. Cells were then harvested onto glass filter strips and 
analyzed using a TriCarb 2500 RT ~-counter (Packard Biosciences, Downers Grove, IL). 
To determine if AuNP-loaded T cells retain the ability to migrate in vitro, we used 
a transwell migration assay. T cells were labeled with 50 f.lCi Chromium51 (Cr51 ; MP 
Biomedicals, Solon, OH) and 1.5 x 105 cells were placed in the upper chamber of 24-well 
6.5 mm diameter, 5 f.tm pore size transwell chambers (Costar Transwell, Coming, NY). 
Media alone or LCL tumor supernatant was placed in the bottom chamber. Plates were 
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then incubated for 3 h at 37°C. Cells in the bottom chamber were then harvested and 
analyzed using a y-counter (Cobra Quantum, Perkin Elmer, Shelton, CT). Specific 
migration was calculated usmg the following equation: Specific Migration 
(%)=(Experimental [LCL supernatant]- Spontaneous [media alone])/(Maximum 
[1.5 x 105 cells]- Spontaneous [media alone]) x 100. To measure the ability of AuNP-
loaded T cells to secrete IFN-y following mitogenic stimulation, 2 x 105 T cells were 
seeded into 96-well round bottom plates for 24 h. T cells were then stimulated with 25 
ng/mL phorbol myristate acetate (PMA; Sigma-Aldrich, St. Louis, MO) and 1 J.tg/mL 
Ionomycin (I; Sigma-Aldrich). Following 2 h ofPMA-I stimulation, Brefeldin A (Sigma) 
was added to allow for intracellular cytokine retention. Four hours later, cells were 
permeabilized using 1% Saponin (Sigma) and IFN-y expression was detected by 
intracellular cytokine staining using PE-conjugated anti-IFN-y monoclonal antibody (BD 
Biosciences ). 
In vivo Delivery Studies 
SCID Xenograft Model 
In vivo migration, AuNP delivery, and biodistribution studies were performed 
using severe combined immune deficient mice (SCID [strain ICR-Prkdc(scid)]; Taconic, 
Hudson, NY). All mouse experiments were performed under a Baylor College of 
Medicine Institutional Animal Care and Use Committee (IACUC) approved protocol. 
1 x 107 LCL tumor cells were resuspended in Matrigel (BD Biosciences) and injected 
subcutaneously (s.c.) into the shaved right flanks of mice. Tumors were allowed to 
establish and grow to at least 0.5 mm x 0.5 mm in size (2-3 weeks) before use. 
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Mouse Injections and Sample Collection 
To prepare AuNP-T cell injections, T cells were prepared as above and incubated 
with 0.5 nM AuNPs for 24 hours. Cells were harvested and washed extensively using 1 x 
PBS prior to injection. For delivery studies, mice received either PBS, I x I 07 AuNP-T 
cells, or 1 x 1011 PEGylated AuNPs via the tail vein in a 200 JlL bolus. These dosages 
were selected based on previous in vivo studies using AuNPs and adoptively transferred 
T cells. To determine optimal time points for delivery analysis, tumors were resected at 
either 4, 8, 24, or 48 hours for the PEGylated AuNP group and 24 or 48 hours for the 
AuNP-T cell group. In addition, plasma as well as portions of the liver, spleen, kidneys, 
small intestine, muscle, heart, lung, bone, and brain were also collected for analysis at 4, 
8, or 24 hours for the PEGylated AuNP group and 24 or 48 hours for the AuNP-T cell 
group. All tissues, including tumors, were flash frozen with liquid nitrogen after 
collection and stored at -80°C until analysis. 
Bioluminescent Imaging 
To determine if AuNP-loaded T cells can migrate to tumors in vivo and thereby 
deliver AuNP to the tumor site, T cells were transduced with retrovirus encoding GFP luc 
as previously described by our group [167]. Transduced cells were then loaded with 
AuNPs for 24 h then injected intravenously (i.v.) via the tail vein (1 x 107 T cells per 
mouse). Forty-eight hours post-T cell infusion, the biodistribution of T cells was 
visualized using the In Vivo Imaging System (IVIS; Xenogen) following intraperitoneal 
(i.p.) injection of 150 mg/kg D-luciferin (Xenogen, Alameda, CA). 
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Ex vivo Tissue Analysis and Imaging 
To image AuNP-T cells within the tumor, tumors were thawed in a 37°C water 
bath and embedded in optimal cutting temperature (O.C.T.) compound (Sakura Finetek 
USA, Inc., Torrence, CA) using dry ice. The embedded tissue was then sectioned into 8 
J.lm slices using a cryostat, dried overnight at room temperature, and stored at -80°C. 
Tissue sections were then fixed with acetone and stained for CD3 using anti-CD3 
(Abeam ab5690, Cambridge, MA) as the primary antibody and the Invitrogen Histostain® 
Plus Broad Spectrum (AEC) kit. Slides were coverslipped with immunomount (Thermo 
Scientific, Pittsburgh, PA) and imaged by bright field and dark field microscopy. 
Resected mouse tissues were prepared and analyzed for gold content using ICP-MS and 
ICP-OES. Samples were lyophilized and weighed, then digested and prepared as 
previously described. Samples of the AuNP-T cell and AuNP boluses were also analyzed 
to confirm the amount of gold systemically administered. 
Statistical Methods 
For the biodistribution analysis, we performed a one-way ANOVA followed by 
Tukey's method. Each organ was examined individually at various time points for each 
treatment group (n = 3 for all time points and treatment groups). Significance was set at 
P < 0.05. An asterisk indicates significant differences between every possible 
AuNP:AuNP-T cell comparison pair at all time points for each organ. For the tumor 
delivery analysis, we used a Student's t-test to compare AuNP systemic administration to 
AuNP-T cell delivery. For this study, n = 8 for the AuNP group, while n = 11 for the 
AuNP-T cell group. 
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Results 
Loading of Activated Human T Cells with AuNPs 
Synthesized gold colloid was determined to be 40-45 nm in diameter by 
transmission electron microscopy (TEM) (Figure 5-l). Activated and expanded human 
T cells were cultured in the presence of AuNPs for a period of 1 to 24 h to permit AuNP 
internalization. AuNP loading was confirmed using bright field and dark field 
microscopy demonstrating that T cells co-localize with AuNPs (Figure 5-2). We further 
optimized loading conditions by altering AuNP concentration To determine the number 
of nanoparticles present per T cell, an inductively coupled plasma optical emission 
spectrometry (ICP-OES) analysis was used. T cells from three different human donors 
were first cultured with concentrations of AuNPs ranging from 0.05 to 0.5 nM for a 
period of 24 h to evaluate for variability in gold nanoparticle loading due to differences in 
T cells from different donors (Figure 1 c). A maximum of 14,900 ± 2,400 AuNPs was 
internalized perT cell using a AuNP loading concentration of 0.5 nM (Figure 5-3). 
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Figure 5-1. Gold nanoparticle characterization. a) TEM imaging of gold colloid (diameter= 40-45 nm). b) 
Gold colloid size distribution. Particle sizes were determined using TEM. A total of 585 particles were 
examined over multiple images to generate the histogram. 
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Figure 5-2. Brightfield (upper) and darkfield (lower) images of human T cells demonstrate gold nanoparticle 
uptake by the increased light scattering seen in the AuNP-T cell group compared toT cells alone. 
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Each point is a composite of data acquired from three different T cell donors. b) Time course data forT cells from a 
single donor loaded with different concentrations of go ld nanoparticles. Optimal loading occurred after 24 h at a 
concentration between 0.5 and 1.0 nM. 
We then performed a time course study using T cells from a single donor to 
determine the minimum amount of time required to load the T cells with the maximum 
number of AuNPs (Figure 5-3). For this study, we incubated T cells with nanoparticle 
concentrations ranging from 0.05 to 1 nM. At 24 h, the 0.5 and 1 nM groups have similar 
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gold content, suggesting that there is a maximum amount of AuNPs that can be 
internalized by T cells. These results demonstrate that maximal AuNP loading ofT cells 
can be achieved using a concentration of 0.5 nM AuNP and an incubation period of 24 h. 
AuNP-Loading Does Not Affect T cell Viability or Function 
We next measured T cell viability and function post-AuNP loading to assess 
potential toxicity that may inhibit T cell performance as an in vivo delivery vehicle. 
Loading T cells with AuNPs had no immediate effect on T cell viability as determined by 
Annexin-V/7-AAD staining (Figure 5-4) and did not alter the phenotype of the cells 
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Figure 5-4. AuNP loading has no significant effect on T cell viability or function . T cells were loaded in the 
presence of 0.5 nM AuNPs for 24 h or cultured in medium alone and then measured for viability using 
Annexin-V/PI staining, b) proliferation using thymidine incorporation, c) migration through a transwell 
membrane in response to tumor (LCL) produced supernatant, and d) intracellular analysis of IFN-y cytokine 
production following mitogen stimulation . 
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(Figure 5-5). Furthermore, there were no prolonged effects on T cell proliferation as 
measured by thymidine incorporation (Figure 5-4). Importantly, AuNPs did not affect 
migration when tested in a transwell chemotaxis assay against supernatant produced from 
human LCL tumors, suggesting that T cells retain their migratory behavior post-AuNP 
loading (Figure 5-4). Finally, production of IFN-y following mitogen activation (PMA-I) 
was not impaired by AuNPs (Figure 5-4). These results show that AuNPs have no 
detrimental effects on T cell viability and function in vitro and indicate that T cell 
migration in vivo will likely be retained following loading. 
T Cells Migrate and Transport AuNPs to Tumors in vivo 
In vivo AuNP-T cell migration to tumor sites was first examined using 
bioluminescent imaging and histology. T cells were first genetically modified to express 
100 
0 T cells 
90 
• .!!J. AuNP-T cells 80 
Q) 
u 
+ 70 M 
c 60 (.) 
en 50 c 
·u; 
t/'J 40 Q) 
... Q. 
30 )( 
w 
~ Q 20 
10 
0 
9'0 9"" <P ~co Q-0 ~«:'J' ~«:'J' X" ¢- ¢-(j (j cP 0() t;..<8 91;;. 9'0 0v 0v 0() 91;;. (j ~ (j o\v 9'0 ~<:<:= (j 91;;. 
(j 
Figure 5-5. AuNP-loading does not affect T cell phenotype. T cells were loaded in the presence of 0.5 nM AuNP for 
24 hand subsequently stained with a panel of antibodies and analyzed by flow cytometry. 
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firefly luciferase and then subsequently loaded with AuNPs. Bioluminescent imaging 
48 h post-intravenous injection of AuNP-T cells demonstrate specific migration of the T 
cells to subcutaneous LCL tumors in immune deficient SCID mice (Figure 5-6). This 
timepoint was selected based on previous studies that have demonstrated T cell 
localization to tumor sites 48 h post-infusion.[l68, 169] We next resected the tumors and 
performed histology to determine if AuNPs and T cells co-localized within the tumor. 
Immunohistochemical staining using CD3 antibody (a pan-T cell marker) demonstrated 
infiltration ofT cells into the tumor (Figure 5-6). In addition, areas of increased scatter in 
the clarkfield images correlated well with areas of CD3+ staining. This observation 
demonstrates that the T cells maintain internalized AuNPs during in vivo migration to the 
tumor site. 
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Figure 5-6. AuNP-Ioaded T cells migrate to tumors in vivo. a) T cells were retrovirally modified to express 
firefly luciferase then loaded in the presence of 0.5 nM AuNP for 24 h. Cells were subsequently injected 
intravenously into SCID mice bearing subcutaneous xenografted LCL tumors. Bioluminescent imaging of 
AuNP-T cell biodistribution at 48 h post-injection showing AuNP-T cell localization at the tumor site (red 
circle) and within the spleen. b) Resected tumors were analyzed by bright field imaging (top row) and 
immunohistochemistry for human CD3 expression and dark field imaging (bottom row) to indicate the 
presence of AuNPs. Red arrows indicate the colocalization of CD3+ T cells and AuNPs within the tumor. 
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Delivery of AuNPs by T Cells Alters Nanoparticle Biodistribution 
We next performed a comprehensive in vivo biodistribution study usmg 
inductively coupled plasma mass spectrometry (ICP-MS) and ICP-OES to map the 
location of free PEGylated AuNPs ( 40-45 nm gold colloid coated with 5000 MW PEG) 
and AuNPs delivered by T cells. Prior to injection, ICP-OES was performed to determine 
the absolute gold dose for PEG-AuNPs and AuNP-T cells. Following intravenous 
injection with PEG-AuNPs or AuNP-T cells, tumors, and organs (bone, brain, heart, 
intestine, kidney, liver, lungs, muscle, plasma, and spleen) were harvested and analyzed 
for gold levels using ICP-MS. For PEG-AuNP treated mice, organs were harvested at 4, 
8, 24, and 48 h post-injection, while for AuNP-T cell treated mice, organs were harvested 
at 24 and 48 h (Figure 5-7). Predictably, the biodistribution of AuNP-T cells is altered 
when compared to that of the PEG-AuNPs. As observed in previous studies,[107, 170] 
the highest percentages of AuNPs using PEG coating were delivered to the liver and 
spleen (5.65 and 17.03% of the injected dose, respectively, at 48 h, Figure 5-7). In 
comparison, T cells delivered AuNPs to the lung, liver, and spleen, which received 4.76, 
33.5, and 2.69% of the injected dose at 48 h, respectively (Figure 5-7). The plasma half-
life of the PEG-AuNPs was calculated to be 6.05 h, and no gold was detected in the 
plasma for the AuNP-T cell group, suggesting no significant AuNP leakage from the T 
cells during in vivo migration. The AuNP-T cell biodistribution over time correlates with 
the normal biodistribution of human T cells, suggesting that the presence of internalized 
AuNPs does not significantly change the T cell biodistribution.[l68] These data suggest 
that cellular delivery of AuNP will result in a unique biodistribution pattern that is 
dependent on the cell type used for delivery. 
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Figure 5-7. Biodistribution comparison of AuNPs and AuNP-T cells in mice. Mice were injected with PEG-
AuNPs (60-65 nm hydrodynamic diameter), AuNP-T cells, or PBS and subsequently sacrificed at various 
time points to determine biodistribution. PBS gold levels were negligible in comparison to AuNP and AuNP-T 
cell groups for all organs. Values are percentage of the injected gold dose (%10) were calculated from ICP-
MS and are normalized for dry weight differences. The AuNP-T cell group exhibited significantly higher gold 
delivery to the lungs, liver, and bone, while the AuNP group demonstrated higher gold levels within the small 
intestine. No significant differences were seen in the spleen, kidney, muscle, or brain . An asterisk indicates 
statistically significant (P < 0.05) differences. 
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T Cell Delivery Increases Tumor Accumulation of AuNPs 
Closer examination of LCL tumors following treatment with either PEG-AuNPs 
or AuNP-T cells showed an increase in AuNP delivery to tumors following cellular 
transport. For PEG-AuNPs, the highest level of accumulation in tumors was observed at 
24 h post-injection, while peak tumor gold accumulation following T cell delivery was 
seen at 48 h. Using PEG-AuNP, ICP-MS analysis of gold content of excised tumor tissue 
showed that 0.39 ± 0.33% of the injected dose reached the tumor at 24 h. Whereas, using 
AuNP-T cells, 1.55 ± 0.72% of the injected dose localized to the tumor at 48 h 
(P < 0.01) (Figure 5-8). This represents a four-fold increase in the efficiency of AuNP 
delivery to the tumor site using T cells as vehicles. 
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Figure 5-8. AuNP-T cells enhance the delivery of gold nanoparticles to the tumor site in vivo. !umo.r-beari~g mice 
were injected i.v . with PEG-AuNPs or AuNP-T cells. Tumors were subsequently resecte? ~t vartous ttme po~nts and 
measured for AuNP content using ICP-MS. Values displayed represent the percentage of tnjected gold normalized for 
tumor dry weight differences (mean± SEM). The percentage of gold delivered by the AuNP-T cells at 48 h represents 
a significant, four-fold increase over the PEG-AuNP group at 24 h (P < 0.01). 
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Discussion 
One of the greatest challenges of translating nanotechnologies to the clinical 
realm is optimizing in vivo delivery. Maximizing AuNP accumulation at the tumor site 
has the potential to enhance photothermal cancer therapy, as well as other applications 
such as optical imaging. In this study, we show that human T cells can be used to 
transport AuNPs to distant tumor sites following intravenous administration. Following 
short term incubation with AuNPs, T cells can be efficiently loaded with over 14,000 
AuNPs per cell without affecting cell viability, proliferation, and cytokine production. 
Importantly, T cells loaded with AuNPs retain their ability to migrate in vitro, and 
demonstrate tumor-specific homing in mice. Using T cells as a vehicle to deliver AuNPs 
resulted in a four-fold increase in the efficiency of AuNP tumor accumulation, 
demonstrating that active transport of AuNPs by cellular chaperones is superior to that of 
passive accumulation through the EPR effect. 
Stephan et al. recently demonstrated that synthetic drug-carrier nanoparticles 
could be stably conjugated to the surface of immune cells, including T cells, for delivery 
of therapeutic molecules.[l69] In these studies, T cells efficiently carried surface-
tethered nanoparticles to tumors in mice, and when loaded with cytokines to support T 
cell growth, dramatically increased antitumor efficacy. However, our study conclusively 
demonstrates in vivo that internal loading of AuNPs in T cells can improve tumor 
localization, and thus may be a useful technology for a variety of nanoparticle based 
therapies. 
In this study, we elect to use AuNPs. AuNPs are known to have low cytotoxicity, 
and gold has been used in humans for the treatment of arthritis for over 50 years,[l71] 
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which makes AuNPs a logical choice in the pursuit of clinical applications. For this 
study, 40-45 nm gold colloidal nanospheres were selected for internalization by activated 
human T cells. The internalization of nanoparticles by cells is believed to be 
accomplished predominantly by receptor-mediated endocytosis, and particle size is an 
important variable in determining the kinetics of cellular uptake, with maximal uptake in 
a size range of 40-50 nm.[98, 172] We selected the size of our AuNPs for this proof-of-
concept delivery study to optimize nanoparticle cellular uptake. We modulated the degree 
of nanoparticle internalization by altering the concentration of nanoparticles incubated 
with the T cells (Figure 5-3). We also evaluated nanoparticle uptake using T cells 
isolated from three different human donors (Figure 5-3) and saw only small variation, 
suggesting that this technique could be extrapolated to the T cells of any patient. 
The internalized gold colloid used in this study also had no detrimental impact on 
the viability or function of activated human T cells in vitro (Figure 5-4 and Figure 5-5), 
and the T cells were able to migrate to tumors in vivo while maintaining their AuNP 
payload (Figure 5-6). In addition to their ability to carry AuNPs to tumors, T cells can be 
selected for tumor-specificity for adoptive immunotherapy studies.[9, 173, 174] 
Furthermore, T cells may be genetically engineered to improve their function [10, 175] 
or enhance their ability to migrate to tumors in vivo[142, 176]. It has been demonstrated 
that systemically administered AuNPs tend to accumulate mainly in the perivascular 
regions of the tumor,[96] limiting passive accumulation of nanoparticles by the EPR 
effect to well-vascularized regions of the tumor. T cells may naturally localize to tumors, 
and tumor-specific T cell clones have been demonstrated to penetrate into the hypoxic 
cores of the tumors in vivo.[177] The more extensive infiltration of tumor sites by 
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antigen-specific T cells may permit enhanced penetration of the tumor when compared to 
freely-injected nanoparticles, potentially augmenting therapeutic efficacy. 
The use of T cell vehicles also significantly affects nanoparticle biodistribution 
(Figure 5-7). Freely injected nanoparticles (40-45 nm gold colloidal nanospheres coated 
with 5000 MW PEG) accumulate most significantly in well-vascularized organs such as 
the liver, spleen, kidney, and gut (Figure 5-7). Maximal AuNP tumor accumulation for 
the freely injected PEG-AuNP group is seen at 24 h (Figure 5-8). After 24 h, increased 
gold content for the PEG-AuNP group is seen in the spleen, liver, and kidney with a 
corresponding decrease in gold content within the tumor and other organs, which 
represents a shift towards AuNP clearance. 
AuNP-T cells present a much different biodistribution from the systemically 
administered nanoparticles that correlates with the expected biodistribution of T cells. 
After adoptive transfer of AuNP-T cells, a large percentage of the ID is seen within the 
liver and lungs at 24 h. T cells are known to accumulate within the liver and lungs after 
administration due to the vascularity and number of adhesion molecules present in these 
organs.[178] This pattern ofT cell migration is consistent with the biodistribution of 
adoptively transferred T cells seen in previous studies.[169, 178] AuNP-T cells are also 
seen accumulating in the spleen and bone of the mice; these locations are also normal 
reservoirs ofT cells.[179] The large number of AuNP-T cells seen in the liver likely 
represents apoptotic T cells. This large accumulation is not observed by bioluminescence 
imaging in Figure 3, and the liver is a known site where apoptotic T cells are 
entrapped.[180] Tumor accumulation of AuNP-T cells increases from 24 to 48 h as T 
cells escape from the lungs and migrate to the tumor (Figure 5-8). The biodistribution of 
100 
AuNP-T cells matches the expected biodistribution of normal activated T cells, 
suggesting that AuNP biodistribution can be modulated based on the selection of the 
cellular vehicle. In the case ofT cells, it is possible that the biodistribution may be altered 
to to further favor tumor accumulation and persistence by manipulating cell culture 
conditions [178] or by genetic modification ofT cells.[142] 
Using T cells as cellular vehicles for AuNP delivery, we achieve a four-fold 
increase in tumor delivery efficiency at 48 h when compared to freely injected PEG-
coated AuNPs at 24 h (Figure S-8). This represents a significant increase in delivery 
efficiency (P < 0.01, Student's t-test) using T cells. These results demonstrate for the first 
time that T cells can be used to enhance AuNP delivery to a tumor in vivo. The use of 
AuNPs and T cells together combines the photothermal therapy and imaging advantages 
of AuNPs with the immunotherapy and biodistribution advantages of T cells. Future 
directions will focus on utilizing the AuNP-T cell system for cancer therapy by 
modifying the T cells to further enrich AuNP tumor accumulation and enhance anti-
tumor effects. 
Conclusions 
In this study we demonstrate the internalization of AuNPs into activated human T 
cells for the delivery of nanoparticles in vivo. AuNP uptake has no negative impact on T 
cell viability, proliferation, or immune function, and T cells are able to transport the 
AuNP payload to tumor sites in vivo. Furthermore, the use ofT cells as a AuNP vehicle 
enhances in vivo delivery efficiency by four-fold. This delivery method alters the 
biodistribution of gold compared to freely injected AuNPs, and demonstrates that the 
selection of a particular cellular vehicle may dictate AuNP biodistribution. 
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CHAPTER6 
TUMOR-SPECIFIC DELIVERY OF HOLLOW GOLD NANOSHELLS FOR 
PHOTOTHERMAL THERAPY USING ANTIGEN-SPECIFIC T CELLS 
Introduction 
In Chapter 5, we demonstrated the ability of human T cells to bear gold colloidal 
nanospheres to a xenografted lymphoblastoid cell line (LCL) tumor in an 
immunocomproomised mouse model. This proof of principle study opened up a range of 
opportunities for the combination of gold nanoparticles and immunotherapy for disease 
treatment and imaging. However, the Chapter 5 study was also limited in that a) the 
gold nanoparticles used did not have near-infrared (NIR) resonance and b) the T cells 
tested were xenogeneic to the host. The next steps towards developing this delivery 
system for photothermal therapy include using NIR-resonant gold nanoparticles and 
allogeneic T cells. 
With this in mind, we elected to use the B16F10 melanoma tumor model. These 
tumors express the mouse homologue of gp100, a known human melanoma antigen. A 
transgenic mouse line, strain B6.Cg-Thyr!Cy Tg(TcraTcrb)8Rest/J, has been developed 
to express CDS+ T cells with T cell receptors specific to the mouse homologue of gp 100. 
We hypothesized the use of antigen-specific T cells would increase gold nanoparticle 
delivery and penetration into the tumor. The use of these T cells has an added benefit in 
that they are murine T cells, not human T cells, which should reduce liver sequestration 
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ofthe T cells. These transgenic mice and their gplOO-targeting T cells will subsequently 
be referred to as pmel mice and pmel T cells respectively. 
There are many choices for NIR-resonant gold nanoparticles that can be used for 
photothermal therapy. For the initial testing of the AuNP-T cell delivery system, gold 
colloidal nanospheres around 45 nm in diameter were chosen because of their similarity 
in size to the second generation of NIR-resonant gold nanoparticles, which range from 
25-60 nm in diameter. This size range has also been shown to be within the ideal range 
for the uptake of gold nanoparticles by cells.[98] Although gold-gold sulfide 
nanoparticles (GGS NPs), hollow gold nanoshells (HAuNS), and gold nanocages were all 
possible choices for this study, I chose to use hollow gold nanoshells because these 
nanoparticles have been previously used in the literature to ablate melanoma tumors. [ 6] 
In fact, these nanoparticles to date have the best tumor accumulation in the literature of 
-12.6% of the injected dose per gram of tissue at the 4 hour timepoint post-injection.[6] 
They are also very close in size to the gold colloid used in Chapter 5 ( -40-45 nm 
diameter) when tuned to the NIR. 
There are two methods used to synthesize HAuNS. Although mechanistically 
similar because both methods use a core template nanoparticle that is oxidized while the 
gold shell is forming, one method uses a silver-template nanoparticle while the other uses 
a cobalt-template nanoparticle. Both of these methods have previously synthesized 
hollow gold nanoshells with NIR resonance.[52, 181] However, in the experience of my 
lab, the cobalt-template method does not easily produce NIR-resonant HAuNS. For this 
reason, I chose the silver-template HAuNS for these experiments. 
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One challenge in the choice of these silver-based gold nanoparticles is the risk of 
cytotoxicity. Although the template core nanoparticle is oxidized during the reduction of 
the gold shell, leaving a hollow spherical nanoparticle, this does not mean that the 
template materials are removed from the nanoparticle solution. In the case of silver-
nanoparticle based hollow gold nanoshells, the likely source of toxicity would be residual 
silver salt remaining from the synthesis. Silver salts are known to be toxic and have been 
employed in the past as antiseptics due to their ability to inhibit microbial growth. [ 182] 
Because hollow gold nanoshells tend to be porous,[53] any residual silver salt in the 
hollow core could leach and kill surrounding cells. To circumvent this toxicity for T cell 
loading, a heating and salting step was added after HAuNS synthesis to remove the 
remaining silver salt from the solution. 
In this chapter, we will demonstrate the loading and in vivo delivery of silver-
based HAuNS to gp 1 00-expressing melanoma tumors using transgenic pmel T cells. We 
will compare the pmel T cell delivery of HAuNS to the HAuNS delivery of wild type T 
cells that have no antigen-specificity. These experiments will evaluate the translation of 
the AuNP-T cell delivery system to a more realistic tumor and T cell model, and will 
allow us to determine if the gold nanoparticle biodistribution and tumor delivery is 
enhanced by the use of allogeneic and antigen-specific T cells. 
Methods 
Silver-Based Hollow Gold Nanoshell Synthesis 
Silver Nanoparticle Synthesis 
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Silver nanoparticles (AgNPs) were prepared at 60°C in a well-stirred solution of 
0.2mM silver nitrate solution (50mL, AgN03) in the presence of sodium citrate (0.5mM) 
following an injection of 100 sodium borohydride solution (1 mL, NaBH4), which 
produces a yellow color. The silver colloid was allowed to stir at 60°C for a minimum of 
two hours. 
Increasing Core Size 
The Ag core solutions were then allowed to cool to room temperature. AgNP 
growth was initiated by adding a 200mM hydroxylamine hydrochloride solution (lmL, 
NH20H-HCL) to the silver colloid, followed by stirring for a minimum of 5 minutes. An 
additional 200)-lL AgN03 (O.IM) solution was injected, and the solution was allowed to 
age for a minimum of 24 hours with stirring. Growth was confirmed by the solution 
changing to a dark yellow or orange color based on the amount of AgN03 added. 
Gold Shell Growth 
The aged silver core solutions were then heated to 80°C and stirred at a rate of 
900 RPM. A 1 mL HAuC14 (25mM) solution bolus was injected into the silver core 
solution. The solution immediately changed color from the yellow-orange of the cores to 
a dark blue-black. The blue-black solution was allowed to stir for an additional 10 
minutes. Each 50mL Ag core solution with 1 mL 25mM HAuCl4 addition generated a 
final HAuNS solution with an OD between -2.5 to 3. 
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Removal of Excess Ag and AgCl 
During the formation of the gold shell, each Au atom that reduces to the surface 
of the core particle oxidizes 3 Ag atoms. These Ag atoms bind with free cr ions in the 
solution to form AgCl, which is insoluble in water at room temperature. To remove as 
much silver as possible from the HAuNS solution, the solubility of the AgCl must be 
increased by heating and the AgCl adsorbed to the surfaces of the HAuNS must be 
released. 
To achieve these goals, 3 grams ofNaCl crystals and I mL of 1% tween solution 
were added to every 50mL of HAuNS solution. The 1% tween solution was added to 
help stabilize the HAuNS during the salting steps. After the addition of the NaCl and 
Tween, the solutions were heated to 80°C, probe sonicated, and pelleted using 
centrifugation at 2500g for 5 minutes. The supernatant was removed, the pellets were 
combined, and the washed HAuNS concentrate was resuspended in 30mL of water. The 
addition of salt, tween, and heat was repeated as before, and the solution was once again 
probe sonicated. The solution was then split into 3 equal volumes of 1 OmL and diluted to 
30mL with water. The solutions were heated to 80°C and probe sonicated again. The 
solutions were then pelleted at 2500g for 5 minutes, the supernatant discarded, and the 
centrifugation step repeated twice more. After washing, the pellets were recombined into 
a single tube and 1 OOuL of 1% tween was added as a stabilizer for storage at 4 °C. 
Removal of Tween 
Prior to use with cell, the Tween stabilizer must be removed. The HAuNS were 
heated to 80°C and 3 grams of NaCl were added to the solution as before. After salting 
and heating, the solution was split into 3 tubes of equal volume and diluted to 30mL 
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using water. The solution was then washed 5 times at 2500g for 5 minutes, the pellets 
recombined, and 200!-LL of0.1mM citrate added as a stabilizing agent. The concentration 
of the nanoparticles was then determined using a combination of Mie Theory and the 
nanoparticle extinction spectra. 
PEGylation of Hollow Gold Nanoshells for Injection 
For free nanoparticle injection, hollow gold nanoshells prepared without the 
additional silver removal steps were used. The day prior to the mouse study, particles 
were coated with sterile polyethylene glycol (PEG MW 5000) by adding an optimized 
amount of 1 mM PEG solution. The optimized ratio of PEG molecules to gold 
nanoparticles was determined using a salt stability assay as described previously in 
Chapters 4 and 5. The nanoparticles and PEG were incubated overnight at 4°C. Excess 
PEG molecules were then removed by centrifuging the nanoparticles and removing the 
supernatant. The nanoparticles were then resuspended in sterile 1x PBS immediately 
prior to mouse injection. 
Cell Lines and Culture 
Both SK-BR-3, a breast cancer cell line, and B16F10, a melanoma cell line, were 
used for HAuNS toxicity testing. The SK-BR-3 was cultured in McCoy's 5A Medium 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. The 
B16F10 cells were cultured in Dulbecco's Modified Essential Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cells 
were incubated in a humidified 37°C incubator with 5% C02. 
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Isolation and Expansion of Mouse Splenocytes 
To isolate wild type and pmel splenocytes, a wild type or pmel mouse was 
sacrificed as per Baylor animal protocol and the spleen harvested. The spleen was then 
homogenized into a cell suspension using a cell strainer and phosphate buffered saline 
(PBS). The cells was then centrifuged at 400 rcffor 5 minutes and resuspended in 10 mL 
of PBS. Afterwards, the cell suspension was layered on top of 5 mL of Lympholyte 
FICOL buffer (2 tubes) and centrifuged at 1000 rcffor 20 minutes with acceleration= 3/9 
and brake = 0/9. The interphase was then transferred to separate tube and centrifuged at 
400 g for 5 minutes. The cell pellet was resuspended in 25 mL of splenocyte media 
(RPMI-1640 media supplemented with 10% fetal calf serum, 1% Glutamax, 1% HEPES, 
and 0.001% 2-B mercaptoethanol). The splenocyte mixture was then stimulated with 10 
ng/mL murine interleukin-2 (IL-2) and 5 J.lg/mL ConA and plated in a 24 well culture 
plate. The splenocytes were incubated at 3 7°C with 5% C02 and the media 
supplemented with 10 ng/mL of murine IL-2 at each feeding. 
Hollow Gold Nanoshell Toxicity Testing 
MTTAssay 
The cytotoxicity of HAuNS was initially evaluated using an MTT assay on SK-
BR-3 and B16F10 cells. Cells were seeded at 4000 cells per well in a 96 well plate and 
allowed to grow for 48-72 hours. B16F10 cells were exchanged into a phenol-free 
DMEM media for this experiment. For initial testing of the hollow gold nanoshells, 
B16F10 cells were incubated with 0.1 nM and 0.5 nM of both bare and PEG-coated 
hollow gold nanoshells synthesized with no additional cleaning steps. For testing of the 
HAuNS after additional silver removal steps, SK-BR-3 and B16F10 cells were incubated 
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with 0.1 nM, 0.25 nM, 0.5 nM, and 1.0 nM of cleaned HAuNS overnight. After an 
overnight nanoparticle incubation, the cells were washed 2-3 times with fresh media to 
remove the nanoparticles. A dead control was created by incubating some wells with 
0.1% Triton X in PBS for 10 minutes at room temperature. The 3-( 4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MIT) assay was then carried out as per Vybrant 
MIT Cell Proliferation Assay Kit protocol (Invitrogen V-13154). 
ICP-OES Testing of Hollow Gold Nanoshells for Silver 
The hollow gold nanoshells were tested for silver content using inductively 
coupled plasma optical emission spectroscopy (ICP-OES) analysis. For this experiment, 
hollow gold nanoshells were synthesized as described above without additional salting 
steps to remove excess silver. Approximately 1 x 1011 hollow gold nanoshells were 
concentrated into a <1 00 microliter volume and transferred to a glass scintillation vial. 
The nanoshells were digested in concentrated trace metal grade nitric acid for a minimum 
of 12 hours to leach any silver salt from the nanoshell core. The acid digests were then 
digested to 5 mL in Millipore-filtered water and analyzed on the ICP-OES for silver 
content. 
Loading and Analysis of Mouse Splenocytes with HAuNS 
Splenocyte Incubation with HAuNS 
On days 7-14, the splenocytes are incubated with the HAuNS at a loading 
concentration ranging from 0.25 nM to 1.0 nM in splenocyte media overnight. Prior to 
adding the nanoparticle mixture to the splenocytes, sonication was performed to disperse 
the nanoparticles evenly throughout the solution. After the overnight incubation at 37°C, 
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the loaded splenocytes were extensively washed using 1x PBS to remove excess 
nanoparticles. 
Propidium Iodide Staining 
Propidium iodide staining was performed using the FITC Annexin V Apoptosis 
Detection Kit I (BD Pharmingen #556547). Half a million washed T cells loaded with 
HAuNS were incubated with 5 mL of propidium iodide staining solution for 15 minutes 
at room temperature then analyzed by flow cytometry. 
Darkfield Microscopy and Hyperspectrallmaging of HAuNS-T Cells 
To confirm T cell loading with the HAuNS, the splenocytes were imaged using a 
Cytoviva® microscope and the Cytoviva® Hyperspectral Imaging System. After 
collecting the hyperspectral data for HAuNS-loaded and control T cells, the mean spectra 
of the entire cell was calculated using the ENVI software's region of interest tool. The 
spectral data was then normalized for a maximum intensity of 1 and divided by the lamp 
spectrum, also normalized for a maximum intensity of 1. The control cell spectrum was 
then subtracted from the HAuNS-loaded T cell spectra. 
ICP-OES Analysis of HAuNS-T Cells 
The number of gold nanoparticles per T cell was determined using inductively 
coupled plasma optical emission spectroscopy (ICP-OES). A minimum of2 x 106 T cells 
loaded with HAuNS was digested using trace metal grade hydrochloric acid and trace 
metal grade nitric acid at a ratio of 3:1 HCl:HN03 to form aqua regia overnight. Samples 
diluted to 1% aqua regia by volume using Millipore-filtered water, then filtered using a 
polyethersulfone syringe filter to remove undigestible debris. Samples were analyzed 
using ICP-OES. 
In vivo Delivery Analysis of HAuNS-T Cell 
B16F1 0 Xenograft Model 
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In vivo migration, AuNP delivery, and biodistribution studies were performed 
using albino and wild type C57BL/6 mice. All mouse experiments were performed under 
a Baylor College of Medicine Institutional Animal Care and Use Committee (IACUC) 
approved protocol. 5 x 105 B16F10 tumor cells were resuspended in PBS and injected 
subcutaneously (s.c.) into the shaved right flanks of mice. Tumors were allowed to 
establish and grow to at least 0.5 mm x 0.5 mm in size (7-10 days) before beginning 
experiments. 
Mouse Injections and Sample Collection 
To prepare AuNP-T cell injections, T cells were prepared as above and incubated 
with 0.25-1.0 nM HAuNS for 24 h. Cells were collected and washed extensively using 
1x PBS prior to injection. For delivery studies, mice received either PBS, 1 x 107 
HAuNS-T cells, or 1.2 x 1012 PEGylated HAuNS via the tail vein in a 200 JJL bolus. 
These dosages were selected based on previous in vivo studies using HAuNS and 
adoptively transferred T cells. 
To determine optimal time points for delivery analysis, tumors were resected at 
either 6, 24, or 48 hours for the PEGylated HAuNS group and 24 or 48 h for the HAuNS-
T cell group. In addition, whole blood, plasma, the spleen, left kidney, lungs, right tibia, 
tumor, and a portion of the liver were also collected for analysis at 6, 24, or 48 hours for 
the PEGylated AuNP group and 24 or 48 hours for the HAuNS-T cell group. All tissues, 
including tumors, were flash frozen with liquid nitrogen after collection and stored at 
-80°C until analysis. 
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Fluorescent Immunohistochemistry for CD3 and Thy1.1 
Tumors treated with PBS, wild type T cells, and pmel T cells were harvested 48 
hours post-injection and bisected. One half went to ICP analysis, while the other half 
went to immunohistochemistry analysis. To image HAuNS-T cells within the tumor, the 
tumors were thawed in a 37°C water bath and embedded in optimal cutting temperature 
(O.C.T.) compound (Sakura Finetek USA, Inc., Torrence, CA) using dry ice. The 
embedded tissue was then sectioned into 8 J..Lm slices using a cryostat, dried for 30 
minutes at room temperature, and stored at -80°C. When ready for staining, the slides 
were allowed to equilibrate with room temperature for 30 minutes prior to proceeding. 
Tissue sections were fixed with ice-cold acetone for 1 minute and subsequently 
washed with ice-cold PBS twice. Blocking was performed used 10% goat serum 
(Jackson ImmunoResearch Laboratories, 005-000-121) in PBS plus 0.5% saponin for 30 
minutes at room temperature followed by the blocking of endogenous mouse IgGs using 
Affinipure Fab fragment anti-mouse lgG (Jackson ImmunoResearch Laboratories, 115-
075-144) for 1 hour at room temperature. The primary antibodies, either anti-CD3 
(Abeam 19639) or anti-Thy1.1 (Abeam 65193), and anti-CD31 (Abeam 28364) were 
then applied to the tissue and allowed to bind overnight at 4°C in a humidified chamber. 
The tissue was then washed three times in PBS to remove unbound excess 
primary antibody and incubated with FITC-conjugated secondary Fab fragment or 
antibody {FITC-anti-syrian hamster for CD3, Jackson Immunoresearch Laboratories 107-
095-142, and FITC-anti-mouse Fab fragment for Thy1.1, Jackson Immunoresearch 
Laboratories 115-097-003) and Texas Red-anti-rabbit for CD31 (Jackson 
Immunoresearch Laboratories 111-075-144) for 30-60 minutes in the dark at room 
112 
temperature. The tissue was washed three times in PBS for 5 minutes after the secondary 
antibody incubation, then mounted with Fluoro-Gel II with Dapi mounting medium 
(Electron Microscopy Sciences # 17985-50), coverslipped, and allowed to harden 
overnight in the dark at 4°C. The coverslips were then sealed with nail polish prior to 
imaging. 
Preparation and Analysis of Tissue by ICP-MS and ICP-OES 
Resected mouse tissues were prepared and analyzed for gold content usmg 
inductively coupled plasma mass spectrometry (ICP-MS) and ICP-OES. Solid tissue 
samples were lyophilized and weighed, then digested for 48-72 hours with trace metal 
grade hydrochloric acid and trace metal grade nitric acid at a ratio of 3:1 HCl:HN03 to 
form aqua regia. Samples diluted to 1% aqua regia by volume using Millipore-filtered 
water, then filtered using a polyethersulfone syringe filter to remove undigestible debris. 
Blood and plasma samples were weighed but not lyophilized, then treated in the same 
manner as the solid tissue samples. All samples were then analyzed on either the ICP-
OES or ICP-MS for gold content. Samples of the AuNP-T cell boluses were also 
analyzed to confirm the amount of gold systemically administered. 
Results 
Hollow Gold Nanoshell Characterization 
Hollow gold nanoshells were synthesized as described above. The outer diameter 
of the nanoshells was 40 nm, and the shell thickness was 5-7 nm by transmission electron 
microscopy (TEM) imaging (Figure 6-1). The outer surfaces of the HAuNS show signs 
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of stress from the silver removal steps, but the inner surfaces of the nanoshells remain 
spherical and hollow. In addition, the peak resonance is in the near-infrared, and remains 
in the near-infrared after the removal of the Tween (Figure 6-2). 
100nm 
Figure 6-1 . Transmission electron microscopy images of hollow gold nanoshells after synthesis, silver 
removal , and Tween removal. 
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Figure 6-2. Extinction spectra of hollow gold nanoshells. Hollow gold nanoshells were stabilized with 
Tween and have undergone salting and heating to remove excess silver. 
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Hollow Gold Nanoshell Cytotoxicity Testing 
Initial Cytotoxicity Evaluation of Hollow Gold Nanoshells 
For initial testing, hollow gold nanoshells were synthesized as described above 
through the gold shell growth step, then washed using centrifugation twice. Preliminary 
toxicity testing was performed using an MIT assay on Bl6Fl0 cells. Both bare and 
PEG-coated hollow gold nanoshells were tested at two different concentrations (1 mole= 
6.022 x 1023 HAuNS). The uncoated hollow gold nanoshells demonstrated appreciable 
toxicity at both the 0.1 nM and 0.5 nM concentrations compared to the control cells 
incubated with media alone. The 0.1 nM concentration of the PEG-coated nanoshells had 
better cell viability, but still showed some toxicity. The 0.5 nM concentration of the 
PEG-coated nanoshells, like the uncoated nanoshells, demonstrated appreciable toxicity 
from nanoparticle exposure (Figure 6-3). 
ICP-OES analysis of the hollow gold nanoshells for silver revealed an average of 
0.016 moles of silver present per 1 x 1011 HAuNS. Table 6-1 shows the potential 
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Figure 6-3. MTT assay results for hollow gold nanoshells (HAuNS) synthesized with no additional silver 
removal steps. Both bare and polyethylene glycol (PEG) coated nanoshells caused a decrease in cell 
viability after a 12 hour incubation. 
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Table 6-1. Potential Silver Salt Concentration for Hollow Gold Nanoshell Loading Concentrations 
corresponding silver salt concentration for each concentration of the unwashed hollow 
gold nanoshells (Group A) tested in the MTT assay below. This concentration assumes 
that all silver associated with the hollow gold nanoshells leaches into the media to affect 
the cells. Silver-mediated cytotoxicity has been previously demonstrated at 
concentrations greater than 4. I ).!M after a 24 hour incubation of silver nitrate with 
fibroblasts.[182] 
The addition of the heating and salting steps described in the methods section 
significantly reduces cytotoxicity for all of the tested concentrations (Figure 6-4). This 
change confirms that the silver salt remaining from the synthesis causes cell death and 
that the removal of this silver abrogates toxicity. The lack of toxicity was further 
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Figure 6-4. MTT Assay Results for Hollow Gold Nanoshells with Additional Silver Removal Steps. A) 
HAuNS incubation at different concentrations with B16F10 cells. No appreciable toxicity is seen at any 
concentration tested. B) HAuNS incubation at different concentrations with SK-BR-3 cells. As with the 
B16F10 cells, no appreciable toxicity is seen. 
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confirmed by testing with a different cell line (SK-BR-3 cells). Based on these results, I 
proceeded with hollow gold nanoshellloading into mouse T cells. 
Internalization of Hollow Gold Nanoshells by Mouse T Cells 
Wild type and pmel mouse splenocytes were incubated with 0.25 nM, 0.5 nM, 
and 1 nM of HAuNS. Propidium iodide staining was performed to confirm that the 
splenocytes tolerated the nanoparticle incubation well with minimal effect on cell 
viability. The number of hollow gold nanoshells internalized per cell was estimated 
using ICP-OES. The wild type T cells internalized a maximum of 14500 ± 100 
nanoparticles per cell using the 1.0 nM HAuNS loading concentration, while the pmel T 
cells were calculated to have a maximum HAuNS of 33300 ± 300 nanoparticles per cell 
using the 1.0 nM HAuNS loading concentration (Figure 6-5). It is likely, however, that 
the pmel T cell gold content was artificially inflated due to the presence of visible gold 
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Figure 6-5. ICP-OES quantification of hollow gold nanoshell content per cell. A) Wild type T cells B) 
pmel Tcells. 
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Figure 6-6. Hyperspectral imaging results for pmel T cells loaded with 0.25 nM HAuNS. The average 
spectra of the entire cell was normalized for the lamp spectrum and a control cell's spectrum was 
subtracted. The presence of the HAuNS is confirmed by the scattering peak that peaks at 760 nm. 
The inset image is representative of the appearance of the HAuNS-Ioaded T cells. 
aggregates in the cell solution both during and after washing. The large size of these 
aggregates made separating them from the cells using centrifugation very difficult. 
The loaded splenocytes were further characterized using clarkfield imaging and 
the Hyperspectral Cytoviva® Imaging system. T cells incubated with hollow gold 
nanoshells exhibited a scattering spectrum that peaked around 760 nm (Figure 6-6). For 
hollow gold nanoshells tuned to the NIR, the scattering and the absorption spectra 
generally overlap fairly well,[ 183] so we assume that the HAuNS-loaded T cells will 
absorb well in the NIR. 
In vivo Delivery of Hollow Gold Nanoshells by Mouse T Cells 
After confirmation that the mouse T cells could be successfully loaded with 
HAuNS, in vivo testing was performed to confirm gold and T cell delivery to the tumor 
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CD3 Staining Thy1.1 Staining 
Figure 6-7. Immunohistochemistry of tumors harvested 48 hours after mice were intravenously 
injected with phosphate buffered saline (PBS), wild type T cells loaded with HAuNS (wt), or pmel T 
cells loaded with HAuNS (pmel). Left column shows staining CD3 (green) and DAPI. Right column 
shows staining for Thy1 .1 (green) , CD31 (red), and DAPI. CD3 staining shows endogenous and 
adoptively transferred T cell accumulation in all tumors. Thy 1.1 staining shows that the pmel treated 
group did have pmel T cell accumulation at the tumor site, while neither the PBS or wild type treatment 
groups stain for Thy1 .1. 
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and compare the performance of the wild type T cells to the pmel T cells for tumor 
delivery. Immunohistochemistry of tumors harvested 48 hours post-injections revealed 
the presence of endogenous and adoptively transferred T cells in the PBS-, wild type T 
cell-, and pmel T cell-treated tumors (Figure 6-7, left column) by staining for CD3, aT 
cell marker. The presence of pmel T cells was only found in the pmel treatment group as 
determined by staining for Thyl.l, a glycophosphatidylinositol (GPI) membrane protein 
found on the surface of some murine T cells (Figure 6-7, right column). The wild type T 
cells injected in the other treatment group and the endogenous T cells have Thyl.2, not 
Thy 1.1, and thus will not stain. Although all treatment groups show T cell accumulation, 
only a 3-4 T cells were seen per 8 micron tissue section. This is unlike the 
immunohistochemistry performed in Chapter 5, where many T cells were seen in each 
tissue section. 
The delivery of HAuNS by the T cells was confirmed by using ICP-MS and ICP-
OES analysis to quantify the delivered gold. Both the wild type and pmel T cells were 
able to deliver gold to the tumor. Surprisingly, the wild type T cells delivered more gold 
than the pmel T cells at the 48 hour timepoint (Figure 6-8). The T cell delivery was 
much lower than the freely injected nanoparticle delivery; intravenously administered 
PEGylated HAuNS had a tumor delivery of 27.0 ± 3.4 % of the injected dose per gram 
tissue (Figure 6-9). 
The T cell biodistribution results were more promising, however. As seen in 
Chapter 5, the gold biodistribution follows the expected biodistribution of the T cell 
carrier, with large accumulations seen in the lungs, spleen, liver, and bone. The pmel T 
cells had less accumulation than the wild type T cells in off-target sites such as the lungs, 
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liver, and spleen. In addition, the liver delivery at 48 hours seen with these murine T 
cells (wild type= 198 ± 23 % ID/gram tissue, pmel = 108 ± 24% ID/gram tissue) is less 
than the liver delivery seen with human T cells (248 ± 22 %1D/gram tissue) at 48 hours, 
supporting our hypothesis that the large liver accumulation seen in Chapter 5 was due to 
the use of human T cells in a mouse model. 
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Figure 6-8. Percentage of injected dose(% I D) per gram of tissue for mice receiving either 
wild type T cell loaded with 0.25 nM HAuNS or pmel T cells loaded with 0.25 nM HAuNS 48 
hour post-injection. 
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Figure 6-9. Percentage of injected dose (% ID) per gram of tissue for PEG-coated HAuNS injected via 
mouse tail vein at different timepoints. 
When directly comparing these results to the results seen in Chapter 5, it appears 
that the human T cells migrated more efficiently to the LCL tumors than the pmel or wild 
type T cells migrated to the melanoma tumors (Table 6-2). However, it is important to 
recognize that two different tumor and mouse models were used for these two studies, 
which could affect the biodistribution, tumor delivery, and the ability of the T cells to 
localize to the tumor. The human T cells also seemed to have less retention in the lungs, 
Table 6-2. Comparison of select organs from T cell and nanoparticle biodistribution studies. e 
e Human T cell and gold colloid values adapted from Kennedy et a/ (20 11) Nanoscale Research Letters 
6(1):283 been converted from percentage of injected dose to percentage of injected dose per gram oftissue. 
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spleen, and kidneys compared to the murine T cells. It is unclear if this is a result of 
differences in integrins on the human versus murine T cells, or if this is a reflection of the 
human T cells being healthier than the murine T cells prior to injection. 
Discussion 
Intravenously injected gold nanoparticles for cancer imaging and therapy 
accumulate within the tumor by the non-specific enhanced permeability and retention 
(EPR) effect. Although many studies have demonstrated that gold nanoparticle tumor 
accumulation is sufficient for therapy using intravenous injection,[6, 7, 47] maximizing 
tumor accumulation also maximizes the liklihood that the ablated tumor will not return. 
In addition, freely injected gold nanoparticles accumulate in high concentrations in 
organs such as the liver and spleen, which is undesirable. We hypothesized that the use 
of the T cell delivery system with antigen-specific murine T cells would increase gold 
nanoparticle tumor accumulation and decrease off-target delivery to organs such as the 
liver and spleen. In this study, we demonstrate the ability of gplOO-targeting murine T 
cells to carry hollow gold nanoshells to gplOO-positive melanoma tumors xenografted in 
immunocompetant mice. 
Although the hollow gold nanoshells loaded well into the murine T cells, the pmel 
T cells did not home well to the melanoma tumor. This is reflected in the 
immunohistochemistry and ICP-MS data. The wild type T cells actually accumulate in 
the tumor more efficiently based on the quantitative gold data. It is possible that this is a 
reflection of low level toxicity on the T cells from the hollow gold nanoshells. However, 
bioluminescent imaging done on unloaded wild type and pmel T cells shows that the wild 
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Figure 6-10. Bioluminescent imaging showing the migration of wild type and pmel T cells to B16F10 tumors 
seeded on the right flank. Signal is seen in both the spleen and tumor. The wild type T cells have stronger 
signal in the tumor and spleen than the pmel T cells. 
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type T cells accumulate at the tumor site better than the pmel T cells, and neither T cell 
has very high signal at the tumor site (Figure 6-10). In addition, it can be seen from the 
bioluminescent imaging data of the unloaded T cells that 72 hours has a stronger signal at 
the tumor for the wild type T cells. The pmel T cells do not have sufficient signal to 
make an evaluation of tumor accumulation at 72 hours. We based our timepoints on the 
previous study in Chapter 5, where 48 hours was the best timepoint, but perhaps a later 
timepoint for these T cells would yield better results. 
Regardless, the freely injected PEG-coated HAuNS demonstrate significantly 
better tumor accumulation than the T cell-based delivery. In fact, the delivery of the 
hollow gold nanoshells for this tumor model is better than the previously reported highest 
value for hollow gold nanoshells with melanoma tumors.[6] In that previous study, a 
timepoint of 4 hours was selected for the quantitation of gold in the tumor. Lu et al 
report a tumor concentration of 12.6 ± 3.1 % injected dose of gold per gram of tissue. 
However, it would seem that 24 hours is the optimal timepoint based on Figure 6-9, 
where we are able to deliver 26.9 ± 3.4% injected dose of gold per gram of tissue. 
The T cell-based delivery method may still have an advantage in terms of 
modulating biodistribution and targeting organs where gold nanoparticle do not 
accumulate well. Based on the biodistribution performed by Melancon et al, the majority 
of injected hollow gold nanoshells accumulate in the liver and spleen, while a smaller 
percentage goes to the tumor and other organs.[7] Using the murine T cells as delivery 
vectors, the distribution ofthe gold nanoparticles followed the expected biodistribution of 
the T cells, seen in Figure 6-10. The murine T cells also decreased the percentage of the 
injected dose being sequestered in the liver when compared to the percentage of the 
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injected dose in the liver with the human T cells. It is also notable that T cells 
accumulate well in bone compared to freely injected gold nanoparticles due to their 
affinity for the bone marrow space, and HAuNS-T cells could function as possible 
vectors for gold nanoparticle PTT of bone tumors. 
While the use of antigen-specific T cells did not increase gold nanoparticle tumor 
accumulation in this case, it is clear that the gold nanoparticle biodistribution can be 
altered by the selection of cellular vehicle. Although the lack of tumor delivery 
enhancement using pmel T cells was disappointing, it does not invalidate the previous 
success seen in Chapter 5. It is possible that the T cell delivery system would function 
more efficiently with a different tumor model that attracts T cells with higher avidity. 
Alternatively, perhaps a targeting a different melanoma tumor antigen, such as MART-I 
or Trp2, with the antigen-specific T cells would yield better results. The T cells could 
also be genetically engineered to increase tumor homing, retention, and persistence 
through the addition of chemokine receptors.[142, 184] There are many potential 
avenues that could be explored for augmenting gold nanoparticle delivery using antigen-
specific T cells. However, even if improved delivery is not possible, the ability to load 
gold nanoparticles into the T cell without detriment to viability or migration function 
opens a realm of possibilities for the combination of gold nanoparticles and 
immunotherapy. 
---------------------
CHAPTER 7 
HYPERTHERMIA-ENHANCED IMMUNOTHERAPY FOR THE 
TREATMENT OF DISTANT SECONDARY TUMORS 
Introduction 
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Gold nanopartic1e photothermal therapy (AuNP PTT) improves the survival and 
decreases the tumor progression of mice bearing a variety of subcutaneous xenografted 
tumors [6, 34, 38]. Although this treatment demonstrates efficacy against localized 
tumors, it does not address metastatic cancers, which continue to present a clinical 
challenge. The primary difficulty in using AuNP PTT against metastatic cancers is the 
source of irradiating energy, which is typically a near-infrared (NIR) laser. As discussed 
in Chapter 2, NIR light is advantageous for in vivo applications because of its low 
absorption by tissue chromophores, permitting maximum transmissivity of light. 
However, the penetration depth of NIR light into tissue is still limited to less than 1 em 
under ideal conditions. This limitation impairs the use of AuNP PTT against cancerous 
lesions in solid organs, such as the liver or lung, which are common locations of 
secondary cancer spread. Therefore, we must consider complementary therapies that will 
benefit from the use of AuNP PTT as an adjuvant. We hypothesize that the combination 
of AuNP PTT with adoptive T cell transfer, or hyperthermia-enhanced immunotherapy 
(HIT), has the potential to combat metastatic cancer by enhancing T cell expansion and 
infiltration into distant secondary tumors. 
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As discussed in Chapter 3, adoptive T cell transfer has previously demonstrated 
efficacy in patients with metastatic melanoma. Despite its successes, enhancing 
adoptively transferred cell expansion and tumor infiltration in vivo would most likely 
improve clinical tumor response. HIT could achieve these goals by inducing heat shock 
protein expression in the tumor, which has been associated with improved dendritic cell 
activation and cross-presentation. 
Heat shock proteins (HSPs) are a family of chaperone molecules that have been 
implicated in maintaining the progression of cancers and in promoting an inflammatory 
response by the adaptive immune system [ 185]. HSPs complex with tumor peptides and 
will couple with toll-like receptors (TLRs) and CD91 to activate dendritic cells [186-
188]. Activated dendritic cells then express higher levels of co-stimulatory molecules 
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Figure 7-1 . Heat shock protein-peptide (Hsp-peptide) complexes activate dendritic cells and ultimately T 
cells against the tumor. After hyperthermia, the tumor produces heat shock proteins that complex with 
peptides released by necrotic or apoptotic cells. These Hsp-peptide complexes are endocytosed and 
processed by professional antigen presenting cells such as dendritic cells (DCs). In addition, the Hsp-
peptide complexes provide the second signal needed for complete DC activation by activating toll-like 
receptors (TLRs) on the DC surface. The DC then travels to the tumor draining lymph nodes where it 
presents the tumor antigens to lymphocytes such as T cells. 
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and major histocompatibility complexes (MHC), becoming mature, and will ultimately 
present the processed tumor peptides on a MHC molecule to activate tumor-peptide 
specific T cells orB cells (Figure 7-1). Somersan et. al. demonstrated that dendritic cell 
(DC) maturation was proportional to the concentration of heat shock proteins present in 
tumor lysates [189]. HSP-peptide complexes also enhance cross-presentation [187, 188, 
190], which, as discussed in Chapter 3, is important for an effective immune response 
against tumor cells. The discovery of HSP-peptide complexes' role in triggering an 
immune response against tumors has spawned the development of HSP pharmaceuticals, 
including Vitespin®. 
Vitespin® (Oncophage, Antigenetics, Inc.) consists of autologous HSP gp-96-
peptide complexes extracted and purified from an individual patient's tumor. These 
complexes are reinjected into the patient subdermally and should bind CD91 on dendritic 
cells [187]. This approach has an advantage in that the tumor antigen does not have to be 
specifically selected, but may be tailored to the individual patient. Two disadvantages 
are the preparation of Vitespin®, which requires the patient's tumor to have sufficient 
non-necrotic tissue, and variations in the immunogenicity of an individual patient's gp96 
peptides, which may influence cancer response to treatment. In pilot studies, Vitespin® 
increased the number of T cells recognizing a tumor-specific antigen in metastatic 
melanoma patients [191], while a study with metastatic colon cancer patients saw a 
general increased T cell response to the cancer cells [192]. However, subsequent Phase 
II/III clinical trials in patients with metastatic renal clear cell carcinoma did not see 
appreciable clinical gains in time to progression or in survival with the use of Vitespin®, 
possibly due to insufficient immune response or continued suppression of the immune 
129 
response by the tumor microenvironment [193, 194]. An alternative means of producing 
hsp-complexes would be to use hyperthermia against an easily accessible tumor lesion. 
Hyperthermia, or raising the temperature of cells to trigger cell death, has been 
utilized previously in cancer therapy to sensitize malignant cells to chemotherapy and 
radiation [ 152, 15 8]. The relationship of HSPs with inducing dendritic cell maturation 
made the extension of hyperthermia as an adjuvant for immunotherapies natural. Shi and 
colleagues confirmed that melanoma cells heated to 42°C for a minimum of 2 hours had 
increased HSP70 expression compared to control cells, and demonstrated that heat-
treated melanoma cells excited a stronger melanoma-specific CTL response than the 
control [190]. In addition, Shi et. al. also discovered that melanoma cells treated with 
hyperthermia had increased expression of tumor antigens than the control cells, 
suggesting the possibility that the improved specific CTL response could also be due to 
enhanced antigen expression by the cancer cells [190]. 
Subsequent studies expanded on this idea by treating tumors with hyperthermia, 
then injecting immature dendritic cells cultured ex vivo directly into the tumor. 
Intratumoral dendritic cells are thought to modulate the tumor microenvironment by 
secreting immune response-amplifying cytokines and reducing the number of regulatory 
T cells [195]. Mukhopadhaya et. al. performed a study in mice bearing xenografted 
prostate adenocarcinoma [196]. Hyperthermia was performed by placing the tumor-
bearing extremity in a warm water bath at 43.7°C for 1 hour; control mice received no 
hyperthermia treatment. One day after hyperthermia treatment, mice received nothing, 
granulocyte-macrophage colony stimulating factor (GM-CSF), dendritic cells, or 
dendritic cells plus GM-CSF. GM-CSF is a cytokine known to stimulate dendritic cell 
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persistence. Hyperthermia-treated tumors demonstrated primarily apoptotic cell death in 
vivo and had increased levels of HSP70. The combination of hyperthermia, dendritic cell 
injection, and GM-CSF elevated the number of prostate cancer-specific effector T cells 
when compared to the other treatment groups and had the smallest amount of tumor 
volume growth over 22 days. Guo et. al. translated this to humans, performing a pilot 
study with 9 patients diagnosed with metastatic melanoma [197]. The hyperthermia 
treatment group received radiofrequency ablation of a single metastatic lesion plus direct 
injection of immature dendritic cells into the heated lesion, while the non-hyperthermia 
group received dendritic cell injection alone into a metastatic lesion. Patients treated with 
hyperthermia demonstrated expression of HSP70, HSP90, and gp96 in the heat-treated 
tumor lysates, greater expression of T Hl versus T H2 cytokines, decreased levels of 
regulatory T cells in the treated tumor, and migration of dendritic cells to the local lymph 
nodes. Both treatment groups saw increased levels of activated T cells. Clinically, 
hyperthermia treated patients had better local response than the control patients, but 
overall survival was the same. 
These studies show promising early results when hyperthermia is combined with 
the transfer of immune cells. However, the hyperthermia techniques employed above are 
disadvantaged because of concerns about damaging normal tissue. The addition of a 
mediating agent, such as gold nanoparticles, would permit localization of the thermal 
treatment, increase patient tolerance for the hyperthermia treatments, and minimize 
damage to normal tissues by reducing irradiation power requirements. Several groups 
have already begun to approach combined hyperthermia and immunotherapy this way. In 
a study on human metastatic breast cancer patients, Li et. al. administered indocyanine 
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green (ICG), a NIR-absorbing dye, into the tumor, then heat the tumor using a NIR laser, 
and finally inject glycated chitosan into the tumor to stimulate an immune response [198]. 
Kobayashi and colleagues have utilized magnetite liposomes and an alternating magnetic 
field to induce hyperthermia in rats and mice for their immunotherapy studies[199, 200]. 
The use of gold nanoparticles instead of a dye or other type of nanoparticle would 
enhance these types of therapies because of the low toxicity, enhanced NIR absorbance 
per particle, and simple conjugation of the gold nanoparticle surface to drugs or other 
molecules. 
We propose using AuNP PTT as our hyperthermia modality and adoptively 
transferring tumor-specific T cells post-ablation. To our knowledge, no previous studies 
have combined hyperthermia with adoptive T cell transfer. As opposed to using a 
dendritic cell-based vaccine, the use of adoptive T cell transfer in human patients with 
metastatic melanoma in clinical trials has shown greater objective clinical response [137, 
139], and we hypothesize that aT cell-based immunotherapy will have a greater effect 
when combined with photothermal ablation. The use of gold nanoparticles for tumor 
ablation has the added benefit of protecting healthy tissue from thermal damage. We will 
subcutaneously xenograft two opposing melanoma tumors in immunocompetent 
C57BL/6 mice. One tumor will serve as the primary tumor, which will be treated with 
PTT. The other tumor will serve as a secondary tumor and will be monitored for changes 
in growth secondary to immunotherapy (Figure 7-2). Hollow gold nanoshells will be 
injected intratumorally into the primary tumor and ablated using a NIR laser. One day 
post nanoparticle injection, tumor-specific T cells will be administered intravenously. 
The HSP-peptide complexes generated in the primary tumor by the PTT will activate 
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Figure 7-2. Schematic of basic experimental layout. C57BL/6 mice will be seeded with adjacent 
melanoma tumors. The primary tumor will be injected with HAuNS and treated with a NIR laser to 
ablate the tumor. One day post-ablation, T cells specific for melanoma will be injected via tail vein. 
We hypothesize that these cells will be activated and expand in the tumor draining lymph nodes of 
the primary tumor. The T cells will then suppress growth of the secondary, non-ablated tumor. 
132 
dendritic cells and stimulate cross-presentation of tumor antigens to the injected CD8+ T 
cells. We hypothesize that the tumor ablation will result in increased T cell proliferation, 
tumor infiltration, and decrease the growth rate of the secondary tumor. Ultimately, we 
hope that this method will enhance the objective clinical benefits of adoptive T cell 
transfer in metastatic melanoma and extend patient survival. 
Methods 
Hollow Gold Nanoshell Synthesis and PEGylation 
Silver Nanoparticle Synthesis 
Silver nanoparticles (AgNPs) were prepared at 60°C in a well-stirred solution of 
0.2mM silver nitrate solution (50mL, AgN03) in the presence of sodium citrate (0.5mM) 
133 
following an injection of 100 sodium borohydride solution (lmL, NaBH4), which 
produces a yellow color. The silver colloid was allowed to stir at 60°C for a minimum of 
two hours. 
Increasing Core Size 
The Ag core solutions were then allowed to cool to room temperature. AgNP 
growth was initiated by adding a 200mM hydroxylamine hydrochloride solution (1mL, 
NH20H-HCL) to the silver colloid, followed by stirring for a minimum of 5 minutes. An 
additional 200f..LL AgN03 (0.1M) solution was injected, and the solution was allowed to 
age for a minimum of 24 hours with stirring. Growth was confirmed by the solution 
changing to a dark yellow or orange color based on the amount of AgN03 added. 
Gold Shell Growth 
The aged silver core solutions were then heated to 80°C and stirred at a rate of 
900 RPM. A 1 mL HAuCl4 (25mM) solution bolus was injected into the silver core 
solution. The solution immediately changed color from the yellow-orange of the cores to 
a dark blue-black. The blue-black solution was allowed to stir for an additional 10 
minutes. Each 50mL Ag core solution with lmL 25mM HAuCl4 addition generated a 
final HAuNS solution with an OD between ~2.5 to 3. 
The gold nanoparticles were centrifuged at 2500 g for 30 minutes and the 
supernatant removed. The pelleted nanoparticles were resuspended in in MQ water. The 
washing step was repeated 2-3 times. Nanoparticles were sterilized by passing the 
solution through a 0.22 f..Lm polyethylsulfone syringe filter. The concentration of the 
nanoparticles was determined after sterilization using a combination of Mie Theory and 
the nanoparticle extinction spectra. 
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PEGylation of Hollow Gold Nanoshells for Injection 
The day prior to the mouse study, particles were coated with sterile polyethylene 
glycol (PEG MW 5000) by adding an optimized amount of 1 mM PEG solution. The 
optimized ratio of PEG molecules to gold nanoparticles was determined using a salt 
stability assay as described previously in Chapters 4 and 5. The nanoparticles and PEG 
were incubated overnight at 4 °C. Excess PEG molecules were then removed by 
centrifuging the nanoparticles and removing the supernatant. The nanoparticles were 
then resuspended in sterile 1x PBS immediately prior to mouse injection. 
Preparation ofT cells for Adoptive Transfer 
To acquire murine T cells for culture, a PMEL mouse was sacrificed and the 
spleen resected. Pmel T cells have a TCR specific for the mouse equivalent of gp1 00. A 
single cell suspension of splenocytes was created by placing the spleen in a cell strainer, 
homogenizing with the end of a syringe pluger, and washing with normal phosphate 
buffered saline (PBS). The strainer was washed with 15 additional milliliters of PBS. 
Cells were pelleted by centrifugation at 400 g for 5 minutes and the supernatant removed. 
Cells were resuspended in 10 milliliters of fresh PBS. Red blood cells were removed and 
white blood cells isolated using FICOL centrifugation. Isolated leukocytes were washed 
twice in fresh PBS. Leukocytes were respuspended in RPMI media supplemented with 
10% fetal calf serum, 1% glutamax, 1% HEPES buffer, and 0.001% 2-B 
mercaptoethanol. The T cells in the splenocyte resuspension were stimulated to 
proliferate by the addition of murine IL-2 (10 ng/mL) and ConA (5 J.lg/mL). The cells 
were seeded in a 24-well plate, placed in a 37°C incubator with 5% C02, and allowed to 
grow to confluency. 
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Photothermal Ablation of Tumors Using HAuNS 
Two tumor models were used for this study. The first model, B 16-0 VA, is a 
melanoma cell line that has been engineered to express chicken ovalbumin, which is an 
antigen with excellent immunogenicity. This mouse model will be used to evaluate the 
endogenous response ofthe mouse immune system to PTT. The second model, B16F10, 
is a melanoma cell line that expresses the murine equivalent of gp100, a known marker of 
human melanoma. This group will receive PTT followed by adoptive transfer therapy of 
pmel T cells. 
To xenograft the melanoma tumors, C57BL/6 mice were anesthetized with 
isoflurane and received two subcutaneous injections of 2.5 x 105 B 16F 10 or B 16-0V A 
melanoma cells, one in each flank. Tumors were allowed to grow to 5 x 5 mm over the 
course of7-10 days. To treat the primary tumor with PTT, mice were again anesthetized 
using isoflurane. The region around the tumor was shaved to remove excess hair, then 
injected with 10 microliters of PEG-coated hollow gold nanoshells (OD -40) in the 
primary tumor as shown in Figure 6.1. Nanoshells were allowed to disperse throughout 
the tumor for 5 minutes. The tumor was then irradiated with a near-infrared laser 
(Coherent diode array laser, /.., = 808 nm, 3 W /cm2) for 3 minutes. In the mice with 
B16Fl0 tumors, an intravenous injection of 10 x 106 PMEL T cells in a 100 microliter 
bolus was administered one day after PIT. Tumors were monitored for volume changes 
using digital calipers and mouse survival was recorded. 
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Bioluminescent Imaging forT Cell Expansion 
To visualize the T cell biodistribution and expansion, T cells were transduced with 
retrovirus encoding GFPluc as previously described [167]. Forty-eight hours post-T cell infusion, 
the biodistribution ofT cells was visualized using the In Vivo Imaging System (IVIS; Xenogen) 
following intraperitoneal (i.p.) injection of 150 mglkg D-luciferin (Xenogen, Alameda, CA). The 
biodistribution was evaluated at a minimum of three timepoints: 24 hours, 48 hours, and 96 
hours. 
Analysis of Immunological Response to Ablation 
Immune Cell Phenotyping 
One week post-ablation, mice were sacrificed and the tumor, tumor-draining 
lymph nodes, and spleen were resected. The tumor, lymph nodes, and spleen were 
homogenized through a cell strainer and washed using complete splenocyte media. To 
look at the phenotype of the immune cells present in each tissue, we used the following 
monoclonal antibodies conjugated to FITC, PE, PerCP, or APC (BD Biosciences): CD4, 
CD8, CD25, Thyl.l, CDllc, CD80, CD86, I-A/1-E, CDllb, GR-1, and Thyl.l. Cells 
were analyzed using a FACSCalibur flow cytometer (BD Biosciences) and FCSExpress 
software (De Novo Software, Los Angeles, CA). 
ELI SPOT 
ELISPOT was performed on the extracted spleen and lymph node cells to 
evaluate IFN-y expression of the T cells in response to melanoma tumor antigens OT -1, 
Trp-2, and gplOO. The ELISPOT plate was prepared with anti-IFN-y antibody and 
blocked with complete RPMI media to prevent non-specific binding. Cells were seeded 
into the wells (1 x 106 cells/well from the spleen and 2 x 105 cells/well for the lymph 
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nodes) and the tumor antigen peptides were added (final concentration in well = 5 J..LM). 
Cells were incubated with the peptide for 20 hours at 37°C. Cells are then decanted and 
the ELISPOT plate is washed using PBS and 0.05% Tween 20. A biotinylated secondary 
antibody is then added for 2 hours at 37°C and followed by a 1 hour room temperature 
incubation with Vectastain, an avidin-peroxidase complex. The ELISPOT plate is then 
thoroughly washed using 0.05% Tween 20 in PBS and developed by incubating each well 
with AEC chromogen for 4 minutes at room temperature. The color development is 
stopped by rinsing the plate thoroughly in tap water. After overnight drying of the plate 
in the dark, the membrane is removed and counted for IFN -y signal. 
32 plex Cytokine Kit 
Ablation study was performed on mice having a single tumor in the right flank. 
After ablation, peripheral blood was collected by retroorbital bleed at the 24 and 96 hour 
timepoint post-ablation. A 32-plex Milliplex MAP Mouse Cytokine/Chemokine panel kit 
(Millipore # MPXMCYT0-70K) was used to quantify cytokine and chemokine levels. 
Results 
Characterization of Hollow Gold Nanoshells 
Synthesized hollow gold nanoshells had a final outer diameter of 40-42 nm with a 
shell thickness of 5-7 nm. The extinction peak maximum was at 780 nm (Figure 7-3). 
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Figure 7-3. Extinction spectra of 
hollow gold nanoshells used for 
photothermal ablation. 
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Endogenous T Cell Response to Gold Nanoparticle PTT 
The first studies performed looked at endogenous T cell response after ablation of 
B 16-0V A primary tumors using hollow gold nanoshells. A B 16F 10 cell line with 
engineered expression of chicken ovalbumin (OVA) was used for these studies because 
the OVA protein is perceived as foreign and has excellent immunogenicity. These initial 
studies were designed to evaluate the immunological benefits of gold nanoparticle PTT 
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and the impact of PTT on T cell activation and tumor response. Mice were xenografted 
with bilateral B 16-0V A tumors, and one of the two tumors was treated using PTT on day 
14 post-primary tumor seeding. After ablation, tumor volume was monitored using 
digital calipers for 9 additional days (Figure 7-4). The ablated tumors collapse to a 
tumor volume of 0 mm3, and remain 0 mm3 for the remainder of the study. The 
secondary or distant tumor growth appears suppressed when compared to PBS-treated 
mice. 
To evaluate the immune system's role in the tumor suppression, a second study 
was performed where the secondary or distant tumors ofPTT-treated and PBS mice were 
resected 7-8 days post-ablation. The number of viable tumor cells was evaluated by 
using flow cytometry and looking at at the forward and side scattering of the cells 
(Figure 7-5). The secondary tumors in the PTT-treated mice trended towards having a 
smaller number of viable cells than the secondary tumors in the PBS-treated mice, but 
this difference was not statistically significant (p = 0.06). 
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Figure 7-5. B16-0VA distant tumor cell viability by flow cytometry after treatment with PBS (PBS) or PTT 
(NIR). The secondary tumor cells were less viable in the group where the primary tumor was treated with 
PTT versus PBS. 
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Figure 7-6. Flow cytometry analysis of tumor microenvironment. A) Percentage of cytotoxic T cells 
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myeloderived suppressor cells. 
Further evaluation of the tumor cell content reveals that the PTT -treated mice had a larger 
number of CD8+ T cells (p < 0.05) infiltrating the tumor (Figure 7-6). The PTT-treated 
mice did not have significantly larger macrophage population than the PBS-treated mice, 
but did have a significantly larger (p < 0.05) infiltrate of myeloderived suppressor cells 
(MDSCs). While macrophages are capable of suppressing tumor growth, MDSCs are 
cells that participate in the anti-immunity response of the tumor. The PTT-treated mice 
also have a higher concentration of activated T cells (CD8+/CD25+) (p < 0.05) than the 
PBS-treated mice. CD25 is a marker ofT cell activation. Activated CTLs secrete IFN-y, 
a cytokine that attracts macrophages, and the secondary tumors in the PTT -treated mice 
also show a higher tumor infiltration of macrophages. This result is highly promising for 
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PTT being able to stimulate adoptively transferred T cell effector function against the 
tumor. 
An ELISPOT for IFN-y expression was also performed on the tumor-draining 
lymph nodes extracted from the mice. Although changes in the T cell and macrophage 
populations of the secondary tumor were seen in the PTT -treated mice, no significant 
differences in IFN-y expression were seen between the PBS-treated and PTT-treated mice 
in response to ovalbumin, Trp-2, or gp 100. However, because no booster, i.e. second 
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Figure 7-7. Flow cytometry analysis of tumor microenvironment. A) Percentage of helper T cells present in 
the tumor. B) Ratio of regulatory to non-regulatory helper T cells. C) Percentage of tumor infiltrate that is 
regulatory helper T cells D) Percentage of the tumor infiltrate that is non-regulatory helper T cells. 
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ablation, was performed on these mice, that result was not surprising. 
The PTT-treated mice also had an increased percentage of helper T cells 
infiltrating the tumor compared to the control mice (Figure 7-7). Helper T cells are 
important for complete activation of CTLs against tumor cells. We also evaluated the 
ratio of FoxP3+ helper T cells to FoxP3- helper T cells. FoxP3 is a marker of regulatory 
T cells, which have a role in suppressing the immune response against the tumor. The 
ratio of regulatory T cells in the secondary tumor was lower in the PIT -treated mice than 
the PBS-treated mice. Although the percentage of regulatory T cells in both the PBS and 
PTT mice was about the same, the percentage of non-regulatory T cells in the PIT mice 
was significantly higher (p = 0.029). 
Based on these results, we have established that PTT does increase T cell 
activation and proliferation against distant tumors. Increased tumor infiltration by CD8+ 
and CD4+ T cells was seen in the secondary tumor of the PTT -treated mice with a 
corresponding increase in CD8+ T cell activation. The next experiments focus on 
treating melanoma tumors with PTT that are not engineered with an immunogenic 
foreign protein. For this set of experiments, we will use adoptively transferred pmel T 
cells that target gplOO, an endogenous melanoma antigen. 
Hyperthermia-Enhanced Immunotherapy of Melanoma 
The combination of PIT with pmel T cells is envisioned to combine the benefits 
of tumor de bulking given by PTT with the ability of pmel T cells to localize and destroy 
tumor cells in distant lesions. Based on the results in the previous section, we 
hypothesize that PIT will stimulate an augmented pmel T cell response to the secondary 
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melanoma tumor that has not been directly treated via ablation. The experimental set-up 
was the same bilateral tumor design described in Figure 7-2. Melanoma-bearing mice 
were treated with PBS or PTT in the primary tumor on day 10 post-tumor challenge. 
Mice then received either PBS or pmel T cells by tail vein injection 24 hours after 
ablation, giving a total of 5 treatment groups: PBS alone, PTT alone, pmel T cells alone, 
pmel T cells plus a direct injection of HAuNS with no laser irradiation, or combined PTT 
and pmel T cells. 
Tumor volume was monitored using digital calipers (Figure 7-8) for 
approximately a week after treatment. The two groups that received PTT had primary 
tumor volumes of 0 mm3 one day post-treatment. Primary tumors that did not receive 
PTT continued to grow. The secondary tumors that received pmel or pmel+PTT 
treatment seem to have a slower rate of growth when compared to the PBS, PTT, or 
pmel+HAuNS group secondary tumors. This supports our assertion that adding 
adoptively transferred T cells to therapy could have benefits for treating distant or 
metastatic lesions. 
We next looked at the overall tumor burden of each treatment group by adding the 
primary and secondary tumor volumes together (Figure 7-9). As expected, mice 
receiving PTT of the primary tumor had lower tumor burden than mice that did not 
receive PTT (p < 0.05, Tukey-Kramer comparison). The ablation of the primary tumor 
serves as a debulking agent. As established in the previous section, it also has effects on 
the tumor microenvironment that extend to the secondary, untreated tumor. Although 
there is no statistically significant difference between the total tumor burden of the PTT-
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treated and pmei+PTT -treated mice (p = 0.115, Tukey-Kramer comparison), there does 
seem to be a difference in the rate of secondary tumor growth between the two groups 
(Figure 7-10). The secondary tumors in the pmel+PTT group had a slower rate of 
growth than the secondary tumors of the PTT group (p < 0.05 , Tukey-Kramer 
comparison), strongly suggesting that the combination of PTT and adoptive transfer of 
pmel T cells may have some benefit in treating patients with distant lesions such as 
metastases. The reduced tumor burden provided by the PTT and the reduced distant 
lesion growth provided by the pmel T cells has the potential to prolong survival. 
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Figure 7-10. Detail from Figure 7-7 showing secondary tumor growth of the PTT treated group versus the 
pmei+PTT group. 
Based on the tumor growth data shown in Figure 7-8, Figure 7-9, and Figure 7-
10, we expect to see increased expansion and tumor infiltration of pmel T cells into the 
secondary, non-ablated tumor of the pmel+PTT mice. Bioluminescent imaging was used 
to evaluate T cell expansion in vivo by modifying the pmel T cells with firefly luciferase. 
Figure 7-11 shows the pmel and pmel+PTT treatment groups. The maximum T cell 
accumulation in the secondary tumor (left flank for this study) was seen at 72 hours. 
Stong signal can be seen within the spleen of some mice at both 24, 72, and 144 hours. 
The tumor draining lymph nodes of the mice did not show significant accumulation over 
the course of bioluminescent imaging (data not shown). Using the bioluminescent signal 
as a means for comparison and normalizing the signal to the 24 hour timepoint, the 
pmel+PTT group demonstrated a transient T cell expansion at 72 hours (p < 0.05), while 
the pmel only group does not demonstrate aT cell expansion (Figure 7-12). This 
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Figure 7-11. IVIS imaging data showing pmel T cell biodistribution. T cells are seen mostly in the lungs 
and the spleen at 24 hours, then gradually accumulate at the tumor sites over the course of the next 48 
hours. At the 144 hour timepoint, the T cells have been predominantly cleared from the tumors . 
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Figure 7-13. T cell phenotype in the spleen and tumor-draining lymph nodes 1 week after B16F10 ablation . 
No significant differences were seen in tumor-draining lymph node phenotype. 
expansion suggests that the addition of PTT may have stimulatory effects on adoptively 
transferred T cells. 
We next looked more closely at differences in cell phenotype in the spleen and 
tumor-draining lymph nodes between the treatment groups I week after ablative 
treatment using flow cytometry. No significant differences in T cell phenotype were seen 
between treatment groups in either the spleen or the tumor-draining lymph nodes (Figure 
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7-13). The lack ofT cell phenotype change in the spleen simply indicates that the effects 
from pmel+PTT treatment are not systemic. 
We next stained for Thyl.l, a pmel T cell marker. Endogenous T cells express 
Thy1.2, not Thyl.l, so this marker allows us to differentiate between adoptively 
transferred and native T cells. Using flow cytometry, pmel T cells were detected in both 
the spleen and the lymph nodes of mice in the pmel T cell-receiving groups (Figure 7-
14). There was no significant difference in pmel T cell accumulation between treatment 
groups in the spleen, but there were differences in pmel T cell accumulation in the tumor 
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Figure 7-14. A) Spleen pmel expression one week after B16F10 tumor ablation. No significant differences 
are seen between the pmel, pmei+NP, and pmei+PTT treatment groups in the spleen. B) pmel T cell 
accumulation in the lymph nodes one week after B16F10 ablation. Quantified average Thy1.1 expression 
for different treatment groups. The pmei+PTT treatment group has lower accumulation of pmel T cells in the 
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draining lymph nodes (Figure 7-14). While the pmel only treatment group had the most 
accumulation of pmel T cells in the tumor-draining lymph nodes, the pmel + PTT group 
had the least accumulation of pmel T cells in the tumor draining lymph nodes. 
Despite the pmel+PTT treatment group's lower pmel T cell lymph node 
accumulation, the ELISPOT performed on the tumor draining lymph nodes for IFN-y 
secretion shows that the pmel+PTT group has higher IFN-y secretion in response to 
gplOO than the pmel only treatment group (p < 0.05, Figure 7-15). This correlates to a 
higher IFN-y secretion per T cell in the pmel+PTT group than in the pmel only group. 
No difference is seen between the pmel and pmel+PTT treatment groups in the spleen 
ELISPOT for IFN-y production in response to gplOO. PTT seems to induce an enhanced 
T cell response in the local environment of the tumor. 
Despite these indications that the T cell response is restricted to the tumor 
draining lymph nodes and does not extend systemically, we did look at the peripheral 
blood cytokine profile mice with a single tumor receiving either PBS, PTT, pmel T cells, 
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Figure 7-15. IFN-y ELISPOT results for spleen and tumor draining lymph nodes one week after B16F10 
ablation. No differences in IFN-y response to gp100 are seen in the spleen, but in the lymph nodes the 
pmei+PTT treatment group has a greater IFN-y response than the pmel alone treatment group. 
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or combination pmel T cell and PTT. Peripheral blood was collected 24 and 96 hours 
after ablation and analyzed for cytokine levels. At the 24 hour timepoint. three cytokines 
had statistically significant differences between PTT-treated. PBS-treated, and tumor-free 
mice: interleukin-6. KC. and MIP-113 (Table 7-1). For each of these cytokines. there 
were no significant differences in expression between mice with tumors and mice without 
tumors. This suggests that the cytokine changes at this point are directly associated with 
the tissue damage or bum done by tumor ablation. Interleukin 6 is an early mediator the 
TH17 inflammatory response. which is associated with bums.[201] No difference 
between groups was seen for interleukin-7. another T H 17 early mediator. and 
Table 7-1. Significant (p < 0.05) Cytokine Profile Changes 24 hours After Ablation 
Cytokine/Chemokine PIT -treated vs PIT -treated vs PBS-treated vs 
PBS-treated Mice Tumor-Free Mice Tumor-Free Mice 
Interleukin-6 i i Equal 
KC i Equal Equal 
MIP-113 i i Equal 
Table 7-2. Significant cytokine profile differences 96 hours post-ablation 
Cytokine/Chemokine PTT -treated vs pmel+PTT -treated PBS-treated vs 
PBS-treated Mice vs PBS-treated Tumor-Free Mice 
Mice 
IL-113 i i Equal 
IP-10 ~ Equal i 
VEGF ~ ~ i 
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TGF -13 was not one an analyte on the cytoplex kit. A later mediator of the T H 17 
response, interleukin-17, also was not statistically different between treatment groups. 
Both elevated KC and elevated MIP-113 are also associated with bum injuries.[202] 
On day 4 post-ablation, three different cytokines have statistically significant 
differences between the PBS-treated, tumor-free, PIT-treated, pmel-treated, and 
pmel+PTT-treated mice: interleukin-113, IP-10, and VEGF (Table 7-2). Like IL-6, KC, 
and MIP-1 b at the 24 hour timepoint, the IL-113 increase in the mice treated with PTT is 
most likely associated with the burned tumor tissue, and has previously been shown to be 
increased in bum injuries.[202] However, the addition of pmel T cells to the PTT 
treatment seems to increase the amount of IL-113 present in the peripheral blood at 96 
hours when compared to PIT alone. This result is encouraging, as IL-l is produced by 
macrophages in response to IFN-y stimulation by T HI CD4+ T cells. 
IFN-y-inducible protein 10 (IP-10) secretion is also stimulated by the presence of 
IFN-y. The IP-10 level is higher in mice with tumors versus mice without tumors, 
indicating that this cytokine is affected by the presence of the tumor. IP-10 is a 
chemokine that has been associated with IL-12 mediated tumor growth suppression and 
the attraction ofT cells and NK cells to tumor sites.[203, 204] PTT reduces IP-10 levels 
below that ofthe PBS-treated control tumors to levels comparable with tumor-free mice. 
Because these mice only had one tumor instead of two, this could reflect complete 
ablation of the tumor. However, the pmel+PTT treated mice had levels of IP-1 0 that 
were comparable to the PBS control mice. The likely explanation is IFN -y secretion by 
the pmel T cells in response to tumor antigen found in the tumor-draining lymph nodes, 
which would result in increased levels of IP-10. IP-10 is also known to be a strong 
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inhibitor of angiogenesis in vivo, and tumor progression is associated with lowered levels 
of IP-10.[205, 206] Although PTT alone lowered IP-10 levels, a combination of 
PTT +pmel resulted in IP-1 0 levels that were on the same level as the PBS-treated mice. 
Another angiogenesis factor that had signficant changes after PTT was vascular 
endothelial growth factor (VEGF). While IP-10 functions as an anti-angiogenic factor, 
VEGF functions as a pro-angiogenic factor in the tumor. However, high levels of IP-1 0 
are associated with lower levels of VEGF.[205] In our study, the mice with tumors had 
higher levels of VEGF than the tumor-free controls (p < 0.05). Mice receiving either 
pmel T cells, PTT, or combination PTT and pmel T cells all had significantly lower 
levels of VEGF than the PBS control mice with tumors (p < 0.05). 
Discussion 
Metastatic cancer continues to be a leading cause of cancer death. 
Immunotherapy has emerged as an effective treatment of metastatic melanoma and is 
able to produce objective clinical responses in up to 60% of clinical trial patients. 
However, the lymphdepletion schemes used in these trials are a risk for the patient, and 
many patients fail to respond to adoptive T cell transfer. The combination of gold 
nanoparticle PTT and adoptive T cell transfer presents a possible enhancement of 
immunotherapy treatment for metastatic cancer. The use of PTT as an immune system 
stimulant may decrease the need for lymphodepletion prior to adoptive cell transfer and 
increase the number of responding patients. 
We have demonstrated that the combination of hollow gold nanoshell-mediated 
ablation and intravenous administration of T cells that specifically target gp 100, a 
melanoma antigen, can suppress the growth of distant tumors. We initially evaluated the 
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response of endogenous T cells to PTT using a B 16-0 VA tumor model. The engineered 
chicken ovalbumin antigen used in this study is considered foreign by the mouse immune 
system, and thus stimulates a strong immune response. Using this model, we 
demonstrated that treatment with PIT induces distant tumor suppression and superior 
CTL and helper T cell infiltration of the distant tumor compared to control tumors. 
We next evaluated the combination of PTT and immunotherapy using B16F10 
melanoma tumors in combination with pmel T cells, which are specific for the murine 
gp 100 that is expressed in B 16F 1 0 cells. This is a more realistic tumor model, as tumor 
antigens often have moderate to low immunogenicity due to their great similarity to 
molecules recognized as self by the immune system. In this study, we did see moderate 
suppression of distant tumor growth after PTT ablation and pmel T cell infusion 
compared to PTT ablation alone. In addition, the combination of PTT with pmel T cells 
resulted in a transient expansion of pmel T cells in vivo at the 72 hour timepoint and 
increased IFN-y secretion in response to gp100 in the tumor-draining lymph nodes. 
These T cell effects were seen without systemic injections of IL-2 or lymphodepletion 
prior to T cell administration, both of which have previously been required to get the 
clinical response seen recently in clinical trials. These results are encouraging for PIT 
being able to induce a T cell response against the tumor without IL-2 or lymphodepletion. 
The second study also demonstrates the additive effects of PTT and pmel T cells. 
When looking at the total tumor burden of the mice, mice treated with PTT had 
substantially lower tumor burden than non-PTT treated mice due to the ablative 
de bulking of one of the two tumor masses. Lower tumor burden has been demonstrated 
in previous PTT studies to correlate with longer survival times.[34, 47, 207] However, 
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PTT to date has not been able to address metastatic disease because of the difficulty in 
targeting the NIR laser to every metastatic lesion. We have shown that the addition of 
pmel T cells after PIT slows distant tumor growth when compared to PTT alone. In 
addition, the secondary tumors that we were using to model distant lesions were 
comparable in size to the primary tumors. In reality, metastases are usually much smaller 
than the primary lesion, and the T cells would most likely be more effective. We 
conclude, therefore, that the combination of PTT and adoptive T cell transfer may have 
utility against metastatic disease. 
Finally, the second study demonstrates that there may be some benefit for using 
combined PTT and adoptive T cell transfer in terms of chemokine profiling. Mice treated 
with photothermal therapy had decreased levels of VEGF when compared to the PBS-
treated mice. The addition of pmel T cells to photothermal therapy resulted in a low level 
of VEGF and a higher level of IP-1 0, which has angiostatic effects, compared to PTT-
alone. This profile has been shown to be favorable to preventing tumor progression and 
angiogenesis.[205] 
Future studies could begin to apply this treatment strategy to models of melanoma 
with lung metastases to evaluate the impact of PTT and pmel T cell transfer on metastase 
progression. Studies exploring the immunological mechanisms behind the PTT 
enhancement of T cell response could also be performed. Because dendritic cells have 
previously been implicated in hyperthermia-enhanced immune responses, it would be 
interesting to repeat these treatments in dendritic cell knock-out mice. Future 
experiments could also focus on increasing the T cell response by choosing different 
tumor antigens to target, or by using a population of T cells that target multiple tumor 
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antigens to maximize response. We have demonstrated that the combination of PTT with 
adoptive T cell transfer, or hyperthermia-enhanced immunotherapy (HIT), has potential 
for suppressing metastatic cancer growth and extending patient survival. 
Conclusions 
CHAPTERS 
CONCLUSIONS AND FUTURE WORK 
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Cancer research continues to be highly funded, with the NIH estimating it spent 
over $5 billion dollars in cancer research in 201 0.[208] This research funding reflects the 
impact that cancer has on the United States as one of the leading causes of death. 
Researchers continue to seek new ways to prevent, screen, diagnose, and treat cancer. 
Gold nanoparticle photothermal therapy (AuNP PTT) is one technology that has recently 
gone to clinical trials for the treatment of head and neck cancer. This technology has 
advantages in that it has high tumor specificity, low occurrence of side effects, and the 
ability to treat any tumor that is accessible to NIR light. This therapy is currently limited 
to localized tumors because of the < 1 em depth penetration of NIR light and because of 
concerns about shielding the liver and other healthy organs that tend to accumulate large 
quantities of nanoparticles. Metastatic disease, however, is one of the major causes of 
cancer death, and conventional treatments such as chemotherapy and radiation have been 
limited in their success against widespread cancers. In this thesis, we seek to expand the 
realm of gold nanoparticle photothermal therapies to treatment-resistant or metastatic 
cancers that continue to defy conventional treatments. 
In Chapter 4, we addressed a form of chemotherapy-resistant breast cancer with 
photothermal therapy. Using anti-HER2 conjugated gold-silica nanoshells, we 
demonstrated for the first time in vitro that HER2+ breast cancer cells that were resistant 
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to ther chemotherapy agents trastuzumab or lapatinib could be treated using PTT. 
Trastuzumab and lapatinib are both chemotherapy agents approved by the Food and Drug 
Administration (FDA) to treated patients with advanced or metastatic HER2+ breast 
cancer. A high percentage of patients' tumors are resistant to these drugs, leaving fewer 
potential treatment options for these patients. The success of photothermal therapy 
against these cancers could open another avenue for treatment of HER2+ metastatic 
breast cancer. 
In Chapter 5, we introduced a new gold nanoparticle delivery strategy using T 
cells as nanoparticle vectors. When performing in vivo PTT studies using nanoparticles, 
one major difficulty is optimizing gold nanoparticle tumor accumulation while 
minimizing off-target delivery to the liver and spleen. Freely injected nanoparticles use 
the EPR effect to accumulate at the tumor site, which is passive and non-targeted. We 
proposed a T cell-based delivery strategy that was active and more targeted. We 
internalized gold nanoparticles into human T cells with no adverse effects on the viability 
or functionality of the T cells, then injected these AuNP-T cells into mice bearing 
lymphoblastoid cell line (LCL) tumors. Using this stategy, we increased gold 
nanoparticle delivery efficiency by a factor of 4 compared to EPR effect delivered freely-
injected gold nanoparticles. We also demonstrated a shift in the biodistribution of gold; 
the T cell-delivered gold nanoparticles accumulated in areas that matched the normal 
biodistribution ofT cells. Because we were using a xenogeneic model (human T cells in 
a mouse), we did see significant liver sequestration of T cells. However, the tumor 
delivery that we were able to achieve of 36.5 ± 12.8% injected dose per gramf of tissue 
r This value has been converted from the % injected dose value reported in Chapter 5 forT cell delivery at 
48 hours 
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using human T cells in Chapter 5 ts 2.9 times higher than the highest tumor 
accumulation currently reported in the literature of 12.6 % of the injected dose per gram 
of tissue.[6] Therefore we have shown that the T cell delivery strategy has merits over 
EPR effect-based delivery and potentially could improve gold nanoparticle delivery for 
PTT. 
In Chapter 6, we turned to using gp 1 00-specific murine T cells to carry hollow 
gold nanoshells to melanoma tumors. We were able to demonstrate for the first time that 
NIR-resonant gold nanoparticles could be borne to the tumor by antigen-specific murine 
T cells. Unfortunately, the wild type T cells migrated to the tumor more efficiently than 
the pmel T cells, disproving our hypothesis that using antigen-specific T cells would 
further enhance tumor delivery. Because this was an allogeneic, not xenogeneic, model, 
the liver sequestration in this study was substantially improved. These negative results 
do not, however, disprove the overall concept ofT cell-based gold nanoparticle delivery. 
A different antigen-specific T cell or even a different tumor model with different antigen-
specific T cell may have better results. As was the case with the human T cells, the 
HAuNS-murine T cells followed the normal biodistribution of the murine T cells, 
establishing firmly that the biodistribution is decided by the cellular carrier. In addition, 
we found that freely injected hollow gold nanoshells had delivered 27.0 ± 3.4 % of the 
injected dose per gram of tissue to the tumor, which is the better than the value 
previously reported in the literature for hollow gold nanoshells and melanoma (12.6 ± 3.1 
%injected dose per gram oftissue).[6] 
In Chapter 7, we demonstrated the benefits of hyperthermia-enhanced 
immunotherapy (HIT) for treating distant tumors. We initally looked at the endogenous 
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immune effects on a secondary tumor that occurred after treating a separate primary 
tumor with photothermal therapy using a B16-0VA tumor model. We saw that the 
secondary tumor in the mouse treated with PTT had increased CD4+ T cell and CDS+ T 
cell infiltration compared to the secondary tumor in a mouse treated with PBS. In 
addition, the secondary tumors of a mice treated with PTT had slower growth than the 
secondary tumors of a mice treated with PBS. These results indicate that PTT has some 
immune system-boosting effects and could be used to enhance adoptive T cell transfer. 
We next tried the bilateral tumor study using PBS, PTT, pmel T cells, or 
combined pmel T cells and PTT with B 16F 1 0 tumors. While the previous study had the 
advantage of using a tumor with ovalbumin (OVA), a strongly immunogenic protein, this 
study targeted the mouse homologue of gp 100, a known melanoma antigen that is less 
immunogenic than OVA. Although no massive systemic T cell expansion or phenotype 
changes were seen, there was a transient T cell expansion seen at 72 hours in the 
combined PIT +pmel group and an increase in IFN -y secretion in the tumor-draining 
lymph nodes of the PTT +pmel group, suggesting a localized enhancement in T cell 
function. 
Although PTT did not significantly improve the performance of the adoptively 
transferred pmel T cells, the additive effects of PTT and pmel T cells on the total tumor 
burden were encouraging for applying this combinatorial therapy towards metastatic 
disease. We showed that mice receiving PTT had lower tumor burden than mice that did 
not receive PTT. We also showed that in mice receiving PTT alone versus PIT with 
pmel T cell transfer, the unablated tumor grew more slowly in the combined PTT +pmel 
treatment group versus PIT alone. The mice receiving PTT or PTT +pmel also had lower 
161 
vascular endothelial growth factor (VEGF) levels than mice treated with PBS, suggesting 
that PTT may have some angiostatic benefits. This gives hope that a mouse with a 
primary tumor and micrometastases could successfully be treated using HIT (combined 
PTT with pmel T cell transfer), ultimately giving longer survival than PTT alone or pmel 
T cell transfer alone. 
Future Work 
The combination of gold nanoparticles and T cells presents many exciting 
possible combinations that extend even beyond cancer. In terms of gold nanoparticle 
delivery, experimentation with different antigen-specific T cells and tumor models may 
yield certain cancers that attract T cells well and thus have improved gold nanoparticle 
delivery. T cells could also be genetically engineered with chemokine receptors or other 
factors that would improve tumor accumulation and retention. For hepatic tumors, the T 
cell delivery method may actually be preferable because of the altered biodistribution; 
there is reduced risk to healthy liver tissue. 
The next step in developing this technology will be to verify that the tumors can 
be ablated by HAuNS-T cells. Once this is demonstrated, it may be possible to use 
HAuNS-T cells for HIT, which would have several advantages. For one, one injection 
would adminster both gold nanoparticles and antigen-specific T cells. Once the primary 
tumor has been ablated, there is still a reservoir of HAuNS-T cells within the spleen and 
tumor-draining lymph nodes that would permit a second ablation if needed. These T 
cells could then home to micrometastases and provide an immune response. 
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The use of HIT as a vaccination regimen could also be expanded to diseases other 
than cancer. T cell vaccines are currently being tried against a variety of infectious 
diseases such as HIV,[209] tuberculosis,[210] and malaria[211]. Various drugs or 
peptides could also be loaded into hollow gold nanoshells or nanocages that would be 
released upon heating and augment the activation and effector response of the T cells or 
dendritic cells in the local area. 
This thesis had established the value of combining gold nanoparticles with T 
cells. We have demonstrated that T cells can function as efficient gold nanoparticle 
delivery vectors to tumors. We have also demonstrated that gold nanoparticle PTT can 
be an effective adjuvant for inducing T cell activation and effector response against 
distant tumors. The benefits of more efficient gold nanoparticle tumor delivery and the 
ability to treat distant tumor lesions using HIT have the potential to ultimately prolong 
cancer patient survival. 
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